+ Guide · Flow cytometry

Particle, signal, number.

How an instrument that lines particles up and reads their flashes of light tells one kind of cell from another, how small a particle it can see, how it is engineered and verified as a system, and what a cytometry test must show before its result is trusted.
+ The central question

A flow cytometer records flashes of light from particles that cross a laser one at a time. How can those flashes tell one kind of cell from another, how small a particle can they reveal, and when can their count be trusted as a test result?

Starts at:school biology and physics: cells, the colors of light, and what a lens does. No optics, statistics, immunology or regulatory background is assumed.Ends at:reading a cytometry plot, an instrument datasheet and a clinical immunophenotyping report critically, and knowing what a cytometer and an assay must show before a laboratory may report a result. Built around:one hard measurement, extracellular vesicles smaller than the wavelength of light, and one clinical use, leukemia immunophenotyping as the EuroFlow consortium standardized it.
+ Opening

Fifty thousand cells a minute.

In March 1969, four researchers at the Los Alamos Scientific Laboratory in New Mexico described an instrument built around a stream of water fifty micrometers wide. Their report filled two pages of Science. Hamster cells had been stained so that the DNA in their nuclei glowed green, and they flowed down the stream and across the beam of an argon-ion laser running at about one watt. Each cell took 15 to 20 microseconds to cross the beam and gave one flash of that length. A photomultiplier, a detector for very faint light, caught the flashes, and a pulse-height analyzer sorted them by brightness, typically 50,000 a minute.

The result was a histogram with two peaks. Cells that had not yet copied their DNA made the first. Cells that had copied it, before or during division, made the second, and its brightness was 1.97 times that of the first, against the 2.00 that a doubling of DNA predicts. The authors set their result beside one made on mouse cells with a scanning microscope: 594 cells, measured over many hours. Theirs held about 50,000 cells and took a minute.

The instrument used no microscope and, in the paper's words, "a minimum of optics." It made no image of any cell. It recorded flashes and their brightness, and the analyzers built since have kept that kind of record, with many detectors in place of one.

The 1969 histogram could be checked against a simple expectation, because DNA doubles exactly and one stain reported it. Most of what cytometry is asked today is harder: which of a dozen kinds of cell a particle belongs to, whether a particle a tenth of a micrometer across is there at all, and whether a count is good enough to decide a diagnosis.

+ Before we start

Before we start.

This guide gathers those harder questions into one and follows them to their answers. A flow cytometer records flashes of light from particles that cross a laser one at a time, so how can those flashes tell one kind of cell from another, how small a particle can they reveal, and when can their count be trusted as a test result?

The instrument never touches a cell and never sees one. A stream of fluid lines particles up so that they cross a focused laser one at a time, each in a few microseconds. Every crossing sends out two kinds of light: light scattered by the particle itself, and fluorescence from dye molecules that antibodies have carried to particular proteins on its surface. Cells are told apart because different kinds of cell carry different proteins, so they glow in different combinations of color, and because their size and inner structure change how they scatter. How small a particle can be seen is set by how many photons, the smallest units of light, it sends to the detectors. Cells also release vesicles, particles enclosed by a membrane and far smaller than any cell, into blood and other body fluids. For particles much smaller than the wavelength of light, scattered light falls roughly with the sixth power of the diameter, so halving the diameter of a vesicle from 100 to 50 nanometers cuts its scatter about fiftyfold. Below a size that depends on the instrument, the signal sinks into the background. A count can be trusted as a test result only when every step from particle to number has been made reproducible and checked: the instrument set up and standardized, the reagents and the analysis fixed, the whole assay validated for its purpose, and, for a product, the evidence shown to a regulator. Where a result needs physical units, such as a vesicle's diameter, the instrument must also be calibrated in them. An assay, in this guide, is the complete test procedure, from preparing the sample to reporting the result.

The 1969 histogram already holds the distinction the rest of the guide depends on. Every number in a cytometry file is a measurement of light, not of a particle. The particle, the signal it produced and the number written into the file are three different things. Most errors in cytometry, from a misplaced gate to a wrong count of vesicles, come from treating one of them as if it were another, and most of the engineering in a cytometer exists to keep the chain between them known.

The chapters take that chain apart one link at a time. Along the way they explain why forward scatter is not a measure of size and why two dyes that look different to the eye are hard to tell apart in a detector. They show why a vesicle a tenth of a micrometer across is nearly invisible to an instrument that sees cells easily, and why two laboratories can report different percentages from the same blood sample. The last chapters set out what a cytometer and its reagents must show before a hospital may use the result to diagnose a leukemia.

How to read this guide

The 24 chapters run in one sequence, grouped into eight parts, and each begins with the question its predecessor leaves open. Parts I to IV explain the measurement, Part V the instrument as a system, Part VI vesicles, Part VII clinical use and regulation, and Part VIII other instruments. The Lessons at the back give thirteen rules, each keyed to the chapter it rests on. Plates carry their own numbers, so any one can be cited alone. Four kinds of box recur:

Insight

Blue edge. Carries the structural point of a section, or a worked calculation.

Caution

Orange edge. Names a common misreading, a trap, or the limit of a claim.

In practice

Green edge. Maps the idea onto the reader's own work: in instrument and assay design, at the bench, in verification, or in a regulatory file.

+ What this chapter established
  • Each chapter closes with what it established, in four lines.

The mathematics stays at percentages, ratios, powers of ten and squares. One relationship, the steep fall of scattered light with size, appears as a ratio worked out with real numbers, and a few statistical ideas appear as counts and spreads rather than formulas. Where a number is derived, the arithmetic is shown once with real values and the assumptions are stated. Where a plate is schematic rather than data, it says so. The guide uses US spelling.

Inside the plates, color is a legend and never decoration. Particles, the fluid that carries them, the laser light that goes in, the fluorescence that comes back and the light that particles scatter each have one color throughout the guide. The measured readout is always blue, from the signal to every number computed from it, and one orange mark in each plate points at the detail that matters most. A key strip under every plate lists only the colors that plate uses.

The color key
THE THINGS THE PLATES TELL APART MEASUREMENT AND CONSTRUCTION PARTICLES cells, vesicles and beads: whatever crosses the laser FLUID sheath and sample fluid: the stream that carries them EXCITATION LIGHT the light that goes in: laser beams and their lines FLUORESCENCE the light dyes give back: emission and its filters SCATTERED LIGHT light the particle deflects: forward and side scatter READOUT the measured signal, and the path from signal to result FOCAL DETAIL the one detail that matters: a single orange mark per plate GRAY instruments, optics, antibodies, axes and construction DASHED GRAY below threshold, not detected, not recorded, or negative PARTICLES FLUID READOUT FOCAL DETAIL each plate's key strip lists only the colors it uses
Key — The same color means the same thing in every plate of this guide. Light keeps its color from chapter to chapter, so red is always light going in, gold and magenta always light coming back, and a blue trace is always what the instrument recorded.
The limits of this guide

This is a reference for understanding, not a laboratory protocol, an engineering specification, a regulatory opinion or clinical advice. Regulatory status, standards editions and product details are stated as of October 2026 and will date. Where a figure is a manufacturer's claim, or comes from a study written by a manufacturer's staff, the text says so. Named instruments, reagents and software are examples of a principle, not recommendations. The letters FACS, used for fluorescence-activated cell sorting, also form part of the names of products sold under the BD brand of Becton, Dickinson and Company; this guide writes "cell sorting" instead.

+ Part I · The particle, the signal, the number

What a cytometer records, and why it records particles one at a time.

The 1969 instrument wrote one number for each cell, a brightness. A modern analyzer writes one number for every detector and every pulse measurement, and a result such as a percentage of CD4-positive cells lies several steps away from any of them. Chapter 1 separates the particle that crossed the laser, the light it sent to a detector and the number written into a file. Chapter 2 shows what measuring every particle on its own reveals that a measurement of the whole tube hides. Nothing here assumes more than school biology and physics.

01 — What it measures

What a flow cytometer actually measures.

+ The questionA report says that 12 % of the cells are CD4-positive. What did the instrument record to produce that number, and what did it never see?

A number with nothing visible behind it

A clinical report or a research figure states that 12 % of the cells in a blood sample carry a protein called CD4. CD4 is one of the numbered CD names that identify proteins on the surface of cells (Chapter 5). The report's statement sounds like an observation, as if someone had looked at the cells and counted. Nothing of the kind happened. The cells were first stained with an antibody that carries a fluorescent dye. An antibody is a protein of the immune system that binds to one particular target molecule, and a fluorescent dye is a molecule that absorbs light and gives some of it back in another color.

The stained cells were suspended in fluid and drawn into an instrument that pushed them, one at a time, through a focused laser beam. Each cell crossed the beam in a few microseconds. While it was there, it deflected some of the laser light, and its dye molecules gave some light back at a longer wavelength. Detectors behind lenses and filters turned those flashes into electrical pulses, and electronics turned each pulse into a few numbers. Software then decided which of those numbers belonged to the cells the report is about.

The instrument repeated that sequence for every particle it could detect, typically several thousand per second. One manufacturer specifies an analyzer of the kind found in clinical laboratories for up to 10,000 events per second. A stream moving at a few meters per second carries each particle through a beam about 5 to 22 micrometers high along the flow, so each crossing takes a microsecond or a few. The instrument took no image of any cell, touched none and identified none as a cell. The 12 % is a ratio of two counts, and each count is a count of recorded numbers that passed a series of decisions.

Three things that are easy to confuse

That sequence contains three different things, and this guide keeps them apart in every chapter.

The particle is the physical object: a lymphocyte, a red cell, a clump of two cells, a fragment of a dead cell, a calibration bead, a bubble, or a vesicle far smaller than any cell. Lymphocytes are one kind of white blood cell, and calibration beads are small spheres, usually of plastic, with a known size or brightness, made for setting up instruments. The instrument has no direct access to any of these particles.

The signal is the light the particle sent toward a detector during its few microseconds in the beam, and the electrical pulse the detector made from that light. The signal depends on the particle, but also on the laser's power, the angle and area of the light collected, the filters chosen, the detector's settings and the background light that arrives whatever the particle does.

The number is what the electronics computed from the pulse and wrote into a data file: the height of the pulse, its area or its width, in arbitrary units that mean nothing until a calibration converts them. Software then transforms these numbers for display and subtracts the overlap between dyes. The software also groups the numbers into populations by drawing boundaries called gates.

01 — Particle, signal, number
PARTICLE the object itself; never seen directly a lymphocyte in the laser spot, inside the stream OTHER THINGS THAT CROSS two cells fragment bead bubble vesicle depends on laser power, collection angle, filters, detector settings, background SIGNAL light, then one electrical pulse scatter fluorescence lens filter detector one electrical pulse, a few microseconds long depends on height, area or width; transform, compensation, gates arbitrary units until something converts them NUMBER written into the file FSC-A 84,210 SSC-A 12,903 CD4-A 6,412 one event, illustrative values 12 % events in the gate ÷ events in its parent
ParticlesFluidExcitation lightFluorescenceScattered lightReadoutFocal detail
Plate 01 — The particle, the light it sends to a detector and the number written into the file are three different things. Every step between them depends on settings, and a result can be trusted only as far as each conversion is known.

A cytometry result is trustworthy only to the extent that each step from particle to signal and from signal to number is known. The rest of the guide follows that chain. Part II covers how particles produce light, Part III how the instrument turns light into numbers, Part IV how numbers become populations, and Part V how the whole chain is engineered, calibrated and verified.

An event is not a cell

The data file does not contain cells. It contains events. Cytometry data files follow an international standard, the Flow Cytometry Standard, or FCS. Its version 3.1, which this guide describes, defines an event as "an ordered list of the cytometric measurements for one particle." A second standard, MIFlowCyt, sets the minimum information to report about a cytometry experiment. It calls an event "a unit of data representing one particle (e.g., a cell) as detected by flow cytometer." Both definitions say particle, and both give a cell only as an example.

The difference is not pedantic. Two cells that cross the beam stuck together, or one just behind the other, produce one pulse and one event. Two experienced operators wrote a guide to cell sorting, and they note that even with modern electronics "an event can still be 2 cells." Debris from dead cells, bits of membrane and particles in the reagents produce events too. One public example file, distributed with an open-source analysis package, holds the events recorded from stained, freeze-dried control blood cells. In that file, a "not debris" gate drawn by a human analyst removed 23 % of all recorded events before any analysis began, and a second gate for single cells removed a further 4 %.

For the smallest particles the difference becomes larger still. When vesicles far below the instrument's detection limit are present at high concentration, hundreds of them can be inside the beam at the same moment, and their combined light can cross the threshold as a single event. A 2012 study showed that one such "swarm" event could represent of the order of a hundred vesicles or more. Chapter 19 returns to swarms, because a swarm is one of the ways a cytometer can report a confident number about particles it cannot see.

02 — What becomes an event
PARTICLE THRESHOLD ON THE TRIGGER DETECTOR IN THE FILE time one lymphocyte two cells stuck debris fragment vesicle swarm one vesicle many invisible vesicles, one confident event 1 event 1 event (2 cells) 1 event (debris) 1 event (swarm) no record in one public file of stained control cells, a debris gate removed 23 % of events and a singlet gate a further 4 %
ParticlesReadoutFocal detail
Plate 02 — An event is a pulse that crossed the threshold. It may be one cell, two cells, debris or many vesicles at once, and a particle whose signal stayed below the threshold leaves no record in the file.

What becomes an event at all is decided by a setting. The operator chooses one detector as the trigger and a level, the threshold, that its pulse must exceed. The trigger is often forward scatter, the light that a particle deflects through small angles in the direction of the laser beam (Chapter 4). Every pulse below the threshold is discarded and leaves no trace in the file.

FCS 3.1 provides an optional keyword, $TR, in which a file can record the trigger and threshold, and the standard states the rule: "When the threshold is exceeded, an event is declared." Some instruments record the threshold in their manufacturer's own keyword instead, and some do not record it at all. A count of events is therefore always a count of pulses that were bright enough in one chosen channel, the signal from one detector, and such a count depends on the sample and the settings together.

A count of events is not a count of particles

An event is a pulse that crossed a threshold. It may come from one cell, two cells, a fragment, or many vesicles at once, and a particle whose signal stayed below the threshold is not in the file at all. Any statement of the form "the sample contained N cells per microliter" depends on knowing which particles produced events, which did not, and what volume of sample was analyzed.

What the file does not contain

The numbers in an FCS file carry no physical units. A pulse area of 52,000 in a detector labeled for a green dye is not 52,000 of anything, because its value depends on the detector's voltage, the laser power and the optical path on that day and on that instrument. The standard provides an optional keyword, $PnCALIBRATION, for converting arbitrary units into a defined unit. One such unit is molecules of equivalent soluble fluorochrome, which expresses brightness as an equivalent number of free dye molecules (Chapter 17). Nothing requires the keyword, and most files do not carry it. Several properties that change the meaning of the numbers have no place in the standard at all: there is no keyword for the angle over which forward scatter was collected, and MIFlowCyt asks for that angle separately.

The file also leaves open what has already been done to the numbers. FCS 3.1 states that "the stored data is always uncompensated", meaning that the overlap between dyes has not yet been subtracted. Some instruments, however, mark the data in their files as compensated, in keywords of their own. A number on a plot axis has usually been transformed again for display. The value stored in the file, the value after compensation and the value displayed are three different numbers, and a report must say which it used.

Where the 12 % came from

A percentage of positive cells is the number of events inside one gate divided by the number inside another. MIFlowCyt requires the denominator to be stated: "percentage of events within the gate shall be provided specifically stating the denominator." For the CD4 example, the numerator is the events above a chosen boundary in the CD4 detector, and the denominator might be all lymphocytes, all white cells, or all events that passed the debris and single-cell gates. Each choice gives a different percentage from the same file. The boundary itself is a decision, made with the help of control samples (Chapter 11).

The vesicle problem

Most of the methods in this guide were developed for cells, which are typically 5 to 20 micrometers across and give bright, easily separated signals. This guide keeps returning to a much harder measurement. Extracellular vesicles are particles that cells release, enclosed by a lipid membrane and unable to replicate. A lipid membrane is a thin film of fat-like molecules, of the kind that encloses every cell. The International Society for Extracellular Vesicles, the field's scientific society, published its MISEV2023 guidelines in 2024. They describe small vesicles as "often" below 200 nanometers and note that measured size depends on the method. Vesicles are present in blood and other body fluids, and they are studied as possible markers of disease.

A vesicle of 100 nanometers has about a seventieth of the diameter of a lymphocyte 7 micrometers across. It scatters so little light that many instruments cannot distinguish it from the background. It carries only a few copies of any protein for an antibody to label, and it can arrive in such numbers that several vesicles are in the beam together. Measuring vesicles pushes every part of the chain from particle to number to its limit, and that is why vesicles serve as this guide's running case. The second case, in Part VII, is the diagnosis of leukemia, a cancer of the blood-forming cells. There the cells are large and bright, but the consequences of a wrong number are serious.

Write the chain down with the number

When a cytometry result will be compared, published or acted on, record with it the facts that make it interpretable. State which pulse measurement was used, height or area, and the trigger channel and threshold. Give the gates and the denominator of every percentage, say whether values were compensated and transformed, and name the instrument and its settings. MIFlowCyt lists these as minimum reporting requirements. In a regulated assay they become part of the fixed procedure, and in an instrument they become requirements on what the software must record.

+ What this chapter established
  • A cytometer pushes particles one at a time through a laser and records the light each one sends to its detectors, typically thousands per second, each in a few microseconds.
  • The particle, the signal and the number are different things; every result depends on the chain that links them.
  • An event is a pulse that crossed an operator-set threshold: it may be a cell, two cells, debris or a swarm of vesicles, and particles below the threshold leave no record.
  • The file holds arbitrary units without physical meaning unless calibrated, and every percentage depends on its gates and its stated denominator.
02 — One at a time

Why measure one particle at a time.

+ The questionA fluorometer measures the glow of a whole tube of cells at once. What does measuring every particle separately reveal that an average hides?

What an average cannot say

The simplest way to measure how much of a fluorescent label a sample of cells has taken up is to put the whole suspension in a small clear container called a cuvette, shine light through it and measure the total glow. A fluorometer does exactly that, and it is fast, cheap and precise. It cannot, however, answer the question that cytometry exists to answer, because it reports one number for millions of cells.

Suppose that 12 % of the white cells in a sample carry about 50,000 molecules of a dye each and the rest carry none. The average over all cells is 6,000 molecules per cell. A second sample in which every cell carries exactly 6,000 molecules gives the same total glow, the same average and the same reading on the fluorometer. Biologically the two samples could not be more different: one contains a distinct population of strongly labeled cells, the other a uniform population of weakly labeled ones. Only a measurement of each cell separately tells them apart.

03 — Same average, different samples
IN BULK: ONE NUMBER ONE PARTICLE AT A TIME SAMPLE A 12 % of cells at 50,000 molecules, the rest none laser detector 6,000 average per cell 88 % dark 12 % bright invisible to any average average SAMPLE B every cell at 6,000 molecules laser detector 6,000 average per cell 0 1,000 10,000 100,000 all cells 6,000 MOLECULES PER CELL schematic histograms
ParticlesExcitation lightFluorescenceReadoutFocal detail
Plate 03 — A bulk measurement reports only the average. Two samples with the same average can differ completely: one where 12 % of cells are bright and the rest dark, one where every cell is moderately bright. Measuring each particle separately tells them apart.
Three things an average destroys

Measuring each particle separately preserves three kinds of information that a bulk measurement averages away. The first is the distribution: whether a population is one group or several, and how wide each is. The second is rare events: a population that makes up 0.001 % of a sample, one cell in 100,000, changes a bulk signal by less than its noise, but it can be counted if enough cells are measured one by one. The third is correlation: whether the same particle that is bright in one color is also bright in another. Correlation is how cytometry separates helper T cells, a kind of lymphocyte that carries both CD3 and CD4, from monocytes, another kind of white cell that carries some CD4 but no CD3.

Those three properties are why cytometry became one of the standard tools of immunology and of hematology, the study of blood. Blood is a mixture of dozens of cell types, and so is bone marrow, the tissue inside bones where blood cells are made. Many of these cell types look alike under a light microscope and differ mainly in the proteins on their surfaces. A disease such as leukemia shows up as an unusual population: sometimes a large one at diagnosis, and sometimes, after treatment, a very small one hidden among normal cells. A method that measures every cell, and several properties of each, is the natural instrument for finding either.

Counting particles in a stream

Measuring one particle at a time began with counting. In 1949 Wallace Coulter filed a patent for a device that counted particles suspended in a conducting fluid as they passed one at a time through a small opening carrying an electric current. The patent was granted in 1953. Each particle displaced some of the fluid and briefly changed the resistance of the opening, so each produced an electrical pulse whose size grew with the particle's volume. The Coulter principle is electrical rather than optical, and it is still used in the hematology analyzers that count red and white cells in routine blood tests.

Optical counting of cells in a flowing stream was explored from the 1930s onward. In 1953 a paper described a way of confining the cells to the center of the stream by surrounding them with a faster-moving sheath of clean fluid. This hydrodynamic focusing is the arrangement that almost every flow cytometer still uses to put particles in single file at a fixed point in a light beam (Chapter 6).

From absorption to fluorescence

In 1965 Louis Kamentsky and colleagues described an instrument that measured how much ultraviolet light individual cells absorbed, at rates above 500 cells per second. The absorption served as an estimate of each cell's nucleic acid content, its DNA and RNA. In the same year Mack Fulwyler at Los Alamos described the first instrument that sorted cells one at a time by a measurement of each. It measured each cell's volume by the Coulter principle and then broke the stream into droplets, using a method that Richard Sweet had just published for ink-jet recording. The instrument charged the droplets that contained the cells it wanted and deflected them into a separate container. Neither instrument measured fluorescence.

Fluorescence arrived at the end of the decade. Wolfgang Dittrich and Wolfgang Göhde in Germany filed a patent in December 1968. In 1969 they published a method of measuring the fluorescence of single cells in a flowing suspension, and an instrument based on that method was sold commercially soon afterward. Also in 1969, the Los Alamos group of this guide's opening story reported measuring fluorescence from cells excited by a laser, and Leonard Herzenberg's group at Stanford published the first sorting of cells according to their fluorescence. In 1972 the Stanford group described a laser-based instrument in a paper titled "Fluorescence Activated Cell Sorting." The medical-technology company Becton Dickinson brought commercial sorters to market in the early 1970s. The name "flow cytometry" came into general use in the second half of the decade.

04 — From counting cells to fifty colors
1950 1960 1970 1980 1990 2000 2010 2020 1949 Coulter patent filed (granted 1953): electrical counting 1953 hydrodynamic focusing: a faster sheath centers the cells 1965 absorption measured at over 500 cells/s 1965 cells sorted by volume into droplets 1968–69 fluorescence measured in flow 1969 first sorting by fluorescence (Stanford) measure and keep: light decides which cell is sorted 1972 laser-based cell sorter 1975 monoclonal antibodies 2013 first commercial full-spectrum instrument COLORS MEASURED ON ONE CELL 2 colors at the start 12 17 40 50
ReadoutFocal detail
Plate 04 — Flow measurement grew in steps: electrical counting, a focused stream, fluorescence and sorting, monoclonal antibodies, then more colors on each cell until full-spectrum instruments separated dozens of dyes mathematically.

The decisive change came from biology rather than engineering. In 1975 Georges Köhler and César Milstein described how to make monoclonal antibodies, identical antibodies produced without limit by one cloned line of cells. A monoclonal antibody binds to one site on one protein, and with a fluorescent dye attached it labels every cell that carries that protein. From the late 1970s onward, panels of such antibodies turned the cytometer from an instrument that measured size and DNA content into one that could identify cell types by the proteins they display.

More colors at once

Each additional color measured on the same cell adds a dimension in which populations can be separated. The Stanford group recalled in 2002 that they had started with two colors, fluorescein and rhodamine, and by then had a twelve-color instrument. A 2004 review described seventeen-color cytometry. In 2020 a published panel used forty colors on a full-spectrum instrument, and two of its three authors worked for the instrument's manufacturer. In 2024 another published panel used fifty. It was developed on instruments from two makers, and two of its five authors worked for one of them.

The growth did not come from adding more of the same detectors. Fluorescent dyes emit over broad, overlapping ranges of wavelength, so the light of one dye reaches the detectors meant for others even when only two dyes are used, and with every added color the instrument has more to separate mathematically (Chapter 10). Full-spectrum or spectral instruments rely on that mathematical separation for every dye. Instead of one detector behind one filter for each dye, they spread the light from each cell across an array of dozens of detectors and work out the contribution of every dye from the shape of the whole spectrum. The maker of the first commercial full-spectrum cytometer announced it in 2012 and launched it in 2013. Chapter 14 compares the two architectures as a systems engineer would.

More colors are not free

Every added color brings more light from other dyes into each detector and more uncertainty into every value calculated from it. A forty-color panel is possible because of careful choice of dyes, detectors and controls, not simply because the instrument has enough detectors. A panel with fewer colors, chosen well, often resolves a given question better than a larger one chosen badly.

What stayed the same

Across seventy years the principle has not changed. A cytometer brings particles one at a time to a fixed point, measures what each one does to a beam of light or a current, and records numbers for each. Every generation has added detail to what is measured about each particle: volume, then absorption, then scatter and fluorescence, then many colors and whole spectra. None has changed the fact that the measurement is of a signal from a particle, not of the particle.

Sorting rests on the same idea. A sorter makes the same measurements as an analyzer and then acts on them while the particle is still in the stream. It charges a droplet that contains a chosen particle, so that an electric field deflects the droplet into a collection tube. This guide treats sorting in Chapter 24, as an extension of the analyzer rather than as a separate subject.

Ask what question needs single-particle data

A bulk measurement is cheaper, faster and more precise for a quantity that is uniform across a sample, such as the total concentration of a soluble protein. Single-particle measurement earns its cost when the answer depends on a distribution, a rare population or a combination of markers on the same particle. Stating which of the three a measurement needs is the first step in specifying an instrument or designing an assay, because each one sets different demands on throughput, sensitivity and the number of colors.

+ What this chapter established
  • A bulk measurement reports one average and cannot distinguish a small bright population from a uniformly dim one; measuring each particle can.
  • Single-particle data preserve distributions, rare events and correlations between markers on the same particle.
  • Flow measurement grew from Coulter's electrical counting, with a patent filed in 1949, through absorption and volume sorting in 1965 to fluorescence between 1968 and 1972, monoclonal antibodies in 1975 and full-spectrum instruments in 2013.
  • Every generation added detail to the signal; none changed the principle that the cytometer measures a signal from each particle, one particle at a time.

+ Part II · Light meets matter

How a particle produces the light a cytometer measures.

A dye excited by blue light at 488 nanometers glows green, not blue. That shift in color lets a filter pass a faint glow while it blocks a far brighter laser. Fluorescence is one of the two ways a particle sends light back. The other is scatter: the particle itself deflects light, by an amount that depends on its size, its refractive index and the angle from which it is watched. Chapter 3 explains fluorescence and Chapter 4 explains scatter. Chapter 5 shows how antibodies carry dyes to particular proteins on a cell or a vesicle, and what decides how bright the result looks.

03 — Fluorescence

Why a molecule glows a different color.

+ The questionWhy does a dye give back light of a longer wavelength than the light it absorbed, why does that difference make fluorescence measurable, and why does one dye's light reach the detectors meant for others?

Light in, different light out

Light carries its energy in small packets called photons, and the more energy a photon carries, the shorter its wavelength. A fluorescent molecule absorbs a photon and emits one a few billionths of a second later. The emitted photon almost always has less energy than the absorbed one, which means a longer wavelength: a dye excited by blue light at 488 nanometers glows green, and one excited by red light at 640 nanometers glows in the deep red.

The reason lies in what happens between absorption and emission. Absorbing a photon lifts one of the molecule's electrons into a higher energy state, and usually into a vibrating version of that state with some energy to spare. The molecule sheds that spare energy as heat to the surrounding water within a tiny fraction of the time it spends excited. It then falls from the bottom of the excited state back to its lowest state and emits a photon, which carries less energy than the photon that arrived. A rule named for the chemist Michael Kasha states the regularity: molecules of this kind emit light with appreciable yield only from their lowest excited state, whichever higher state the absorbed photon reached.

05 — Why a molecule glows a different color
S₁ EXCITED S₀ GROUND absorb: blue photon, 488 nm relax as heat, picoseconds the energy lost as heat is why the color changes stays excited for a few nanoseconds emit: green photon, longer wavelength or lost as heat instead 450 500 550 600 WAVELENGTH, nm 488 ≈ 520 emitted light is redder: longer wavelength, lower energy per photon
Excitation lightFluorescenceFocal detail
Plate 05 — A dye molecule absorbs a photon, loses a little energy as heat within picoseconds and emits the rest as a photon of lower energy, so fluorescence is almost always at a longer wavelength than the light that excited it.

The gap between the peak of absorption and the peak of emission for the same transition is the Stokes shift. The International Union of Pure and Applied Chemistry sets the standard terms of chemistry. It defines the Stokes shift as the difference between the band maxima of absorption and fluorescence "arising from the same electronic transition." A band is the range of wavelengths over which a molecule absorbs or emits, and its maximum is the band's peak. The shift is usually expressed in frequency units rather than in nanometers, because a gap of 10 nanometers in the red corresponds to less energy than a gap of 10 nanometers in the blue.

The Stokes shift is what makes fluorescence measurable at all in a cytometer. The laser delivers far more light to the particle than any dye gives back, and much of that light is scattered toward the detectors at the laser's own wavelength. Because the fluorescence comes out at longer wavelengths, an optical filter can block the laser light and pass the dye's glow. Without that difference in color, the faint emission would be lost in the far brighter laser light.

How bright is a dye

Two properties of a molecule decide how much light it can give back. The molar absorption coefficient measures how strongly the molecule absorbs light of a given wavelength, and it is often still called the extinction coefficient. The quantum yield is the fraction of absorbed photons that come back out as fluorescence; the rest of the energy is lost as heat or through other processes. Fluorescein was the dye of the earliest two-color instruments. A technical report of the International Union of Pure and Applied Chemistry gives its quantum yield as about 0.93 in alkaline solution, so in that solution nine of every ten photons that fluorescein absorbs return as light.

The product of the two properties is the usual measure of a dye's intrinsic brightness. The authors of a 2005 review of fluorescent proteins defined brightness in their tables as the "product of extinction coefficient and quantum yield," and the convention is common throughout fluorescence work. The two protein dyes most used in cytometry are R-phycoerythrin, or PE, and allophycocyanin, or APC.

For PE, a 1982 paper and one manufacturer's handbook agree on an absorption coefficient of 1,960,000 and a quantum yield of 0.82. For APC the handbook gives 700,000 and 0.68 for the whole molecule, which weighs about 104,000 daltons; a dalton is a unit of molecular mass, about the mass of one hydrogen atom. The 1982 paper gives the same quantum yield and a coefficient of 232,000 for one of the molecule's three identical units, each of 33,000 daltons. Three times that coefficient is about 700,000, the handbook's figure for the whole molecule.

Intrinsic brightness, worked

PE: 1,960,000 × 0.82 ≈ 1.6 million. APC: 700,000 × 0.68 ≈ 476,000. The comparison is between whole molecules, as they are attached to antibodies, and on intrinsic brightness PE is about 3.4 times brighter than APC. The units of the absorption coefficient, liters per mole per centimeter, are the same for both and cancel in the ratio. The comparison assumes each dye is excited at its own absorption peak and that every emitted photon is counted, which no cytometer achieves.

Why the ranking does not survive the instrument

The 2005 review also warned that perceived brightness depends on much more: the wavelength and intensity of the illumination, the spectra of the filters and mirrors, and the sensitivity of the detector to the emitted color. A cytometer imposes all three. It excites a dye with whichever laser line it has, meaning the single wavelength of one of its lasers, and that line may sit well away from the dye's absorption peak. The filter in front of the dye's detector passes only part of the dye's emission. The detector converts photons to electrons with an efficiency that varies with wavelength, and background light from other sources sets the floor against which the signal must be seen.

The effect can be large. One manufacturer's application note reports measurements made on its own instruments with the same antibody against CD4, labeled once with PE and once with APC. The separation of stained from unstained cells differed between the two dyes by only about 10 %, against the threefold difference in intrinsic brightness. The comparison mixes many factors, from laser power to the number of dye molecules on each antibody, and that mixing is the point. The current community guidelines for cytometry in immunology make the same point in a figure caption: "fluorochrome brightness can be instrument-specific."

06 — Laser line, dye and filter
0 0.5 1 400 450 500 550 600 650 700 WAVELENGTH, nm RELATIVE INTENSITY schematic spectra 530/30 filter passes 515–545 nm excitation emission 488 nm laser Stokes shift scattered laser light at 488 nm: blocked by the filter the detector sees only this slice
Excitation lightFluorescenceScattered lightFocal detail
Plate 06 — The laser excites a dye wherever its line falls on the excitation spectrum, rarely at the peak, and the detector sees only the part of the emission its filter passes. What the instrument measures is a slice of the dye's light, not all of it.
Brightness belongs to the dye and the instrument together

A table of dyes ranked by intrinsic brightness is a starting point for panel design, not an answer. What matters in a cytometer is how well a dye separates labeled from unlabeled particles on that instrument, with its lasers, filters and detectors, and that has to be measured on the instrument.

A nanosecond inside a microsecond

A dye molecule typically stays excited for a few nanoseconds before it emits, while a cell spends about a microsecond or a few in the laser beam. In principle each molecule could therefore be excited and emit hundreds of times during one pass, and more laser power would give proportionally more light.

In practice the light does not grow in proportion. At the high intensities in a focused laser spot, some molecules cross into a long-lived "dark" state from which they cannot be excited again for a while, and some are destroyed altogether, which is called photobleaching. A 1997 study measured fluorescein, PE and APC on cells and found them "considerably saturated and bleached in standard flow cytometric conditions." For APC excited with red light, the study raised the laser power about fourteenfold, from 35 to 510 milliwatts, and the maximum fluorescence rose only about elevenfold. Long illumination at high power caused serious bleaching.

07 — More laser power, not proportionally more light
0 4 8 12 16 0 100 200 300 400 500 LASER POWER, mW RELATIVE FLUORESCENCE (35 mW = 1) 35 mW: linear linear expectation: 14.6 510 mW: 14.6× power, 11× light saturation and bleaching APC, 647 nm light, 1997 study schematic between the two measured points
ReadoutFocal detail
Plate 07 — At the intensities of a focused laser spot, dyes saturate and bleach. For APC excited with red light, raising the power about fourteenfold, from 35 to 510 milliwatts, raised the fluorescence only about elevenfold.

Saturation matters to an engineer for two reasons. Once a dye saturates, doubling laser power does not double the signal, so a more powerful laser adds less signal than its rated power suggests. And because the shortfall depends on the dye, the intensity of the beam and how long the particle spends in it, two instruments with different lasers or flow speeds can rank the same dyes differently.

Broad colors that overlap

Fluorescence spectra are broad. A typical dye emits over a range of many tens of nanometers, with a long tail toward longer wavelengths, because the emitting molecule can land in any of many vibrational levels of its lowest state, the ground state. The Stokes shift of the protein dyes is small, about 13 nanometers for PE and 10 for APC. Cytometers therefore excite them away from their absorption peaks and collect their emission with filters placed to one side of the laser line.

The breadth of the spectra has a consequence that shapes the rest of the guide. When several dyes are used on the same particle, the tail of one dye's emission falls inside the filter meant for another. That overlap is called spillover. Better filters cannot remove it without throwing away most of each dye's light, and spillover is the reason a cytometer measuring many colors must separate the dyes mathematically (Chapter 10).

Rank dyes on the instrument that will be used

When designing a panel or specifying an instrument, measure how well each candidate dye separates stained from unstained particles on the instrument itself, with the antibody it will actually carry. Do not rely on tables of intrinsic brightness or on another instrument's results. For an instrument specification, state sensitivity per detector with the laser line and filter, because a single figure for "sensitivity" cannot describe how each dye will look.

+ What this chapter established
  • A fluorescent molecule absorbs a photon, loses some energy as heat, and emits a photon of longer wavelength; that Stokes shift lets filters separate the glow from the laser light.
  • Intrinsic brightness is absorption coefficient times quantum yield: PE is about 3.4 times APC by that measure.
  • Measured brightness depends on the laser line, filters, detector and background, and on one manufacturer's analyzers PE and APC differed by only about 10 %; brightness is instrument-specific.
  • At high laser intensities dyes saturate and bleach, so their light stops growing in proportion to power, and their broad, overlapping spectra cause spillover between detectors.
04 — Scatter

What scattered light can and cannot tell you.

+ The questionWhy is forward scatter a poor measure of size, and why does a vesicle of 100 nanometers scatter almost no light at all?

Light the particle itself redirects

A polystyrene bead 100 nanometers across sends a side-scatter detector about as much light as a vesicle of about 175 nanometers. The detector is working correctly: scatter depends on more than size.

Fluorescence needs a dye. Scatter needs nothing but the particle. A material's refractive index measures how much it slows light compared with a vacuum. Any object whose index differs from that of the surrounding fluid deflects some of the light that strikes it. The deflected light keeps the wavelength of the light that arrived, and a cytometer collects it at two places.

Forward scatter is the light deflected through small angles and collected by a lens or detector placed opposite the laser. The angles run from about one degree to roughly fifteen, depending on the instrument. The direct laser beam is far brighter than this light, so a small opaque strip called an obscuration bar blocks the beam itself and lets only the slightly deflected light through. Side scatter is light deflected roughly at right angles to the beam. It is collected by the same lens that gathers fluorescence, a high-aperture lens that accepts light over a wide cone, and it reaches its own detector through a filter at the laser's wavelength.

08 — Where scattered light goes
laser focusing lens FORWARD SCATTER small angles interrogation point stream, seen end-on obscuration bar blocks the beam, and with it the smallest angles side collection lens, at about 90° dichroic SIDE SCATTER laser wavelength FLUORESCENCE behind bandpass filters
ParticlesFluidExcitation lightFluorescenceScattered lightFocal detail
Plate 08 — Forward scatter is collected at small angles around the beam, behind a bar that blocks the laser itself; side scatter and fluorescence are collected at about 90 degrees by a separate lens. Each path sees different light from the same particle.

Because every particle scatters, scatter is the usual trigger that decides what becomes an event (Chapter 1), and the familiar first plot of almost every analysis is forward scatter against side scatter. On that plot, blood separates into three clouds that correspond, more or less, to lymphocytes, monocytes and granulocytes. Granulocytes are white cells whose interior holds many small granules. The plot is the origin of two habits of speech: forward scatter as "size" and side scatter as "granularity."

What forward scatter is called, and what it is

Neither habit is a measurement. A 2011 study tested how well optical signals track the volume of cells, and it found that the area of the forward-scatter pulse "performed poorly" as an indicator of volume. The authors listed the reasons: forward scatter is influenced by the difference in refractive index between particle and fluid, by light-absorbing substances inside the particle, and by the optical design of the forward-scatter path. In some cell lines side scatter tracked volume better than forward scatter did. For particles comparable in size to the wavelength of light, the relation is not even monotonic: scattered light can rise and fall as size increases, because light waves scattered from different parts of the particle interfere.

A specification sheet that quotes a forward-scatter "resolution" of 1 micrometer describes how well the instrument separates beads of known size from one another. The figure is not a claim that forward scatter measures diameter, and the size it implies holds only for particles made of the same material as the beads.

"Size" and "granularity" are labels, not quantities

Forward scatter depends on size, refractive index, shape, absorption and the instrument's collection angles. Side scatter depends on internal structure and on size as well. Both are useful for separating populations whose differences are already known, and neither measures a physical dimension unless the instrument has been calibrated with a model of the particle's optical properties (Chapter 17).

Refractive index decides as much as size

Scatter depends on the contrast in refractive index between particle and medium. Water at 488 nanometers has an index of about 1.33. Most calibration beads are made of polystyrene, which has an index of about 1.61 at that wavelength, and silica has about 1.44.

Living cells are close to water: a 2016 review gives about 1.35 for most normal cells, with higher values for some cancer cells and for red cells. Extracellular vesicles are also close to water, though further from it than most cells. Published estimates for vesicles run from about 1.37 to 1.45, and values near 1.39 to 1.40 are used most often. Plasma, the liquid part of blood, also carries lipoproteins: particles of fat and protein that transport fats around the body. Lipoprotein particles outnumber vesicles in plasma and have higher indices, near 1.47 in one study.

The contrast matters enormously. At 100 nanometers, a sphere of polystyrene scatters about seventeen times as much light as a vesicle of the same diameter, and at 1 micrometer about ten times as much. A 2010 review noted that a gold particle of 200 nanometers scatters 27 times more than a polystyrene sphere of similar size, which in turn scatters 15 times more than a vesicle. Even a small change matters: if the index assumed for a vesicle falls from 1.40 to 1.36, its expected scatter falls about sixfold.

09 — Same size, different scatter
0 5 10 15 RELATIVE SIDE SCATTER (VESICLE OF n = 1.40 = 1) polystyrene n ≈ 1.61 silica n ≈ 1.44–1.46 vesicle n = 1.40 vesicle n = 1.36 17× about 17 times a vesicle of the same size 2.6–3.7× 1 the reference 0.16 about one sixth, from a small change of index all particles 100 nm, in water (n = 1.333); side scatter at 488 nm, derived (Mie)
ParticlesScattered lightFocal detail
Plate 09 — Scatter depends on refractive index as much as size. At the same 100-nanometer diameter, polystyrene scatters about 17 times as much as a vesicle of index 1.40, so a bead size is not a vesicle size.

The sixth power

For particles much smaller than the wavelength of light, scattering follows a simple law worked out by the physicist Lord Rayleigh. The scattered light grows with the sixth power of the diameter and falls with the fourth power of the wavelength, and a factor set by the refractive-index contrast multiplies the result. A 2010 review of vesicle detection put the consequence plainly: "If a microvesicle is only 10-fold smaller than another microvesicle, the scattering cross-section and thus the scattered amount of light decreases 10⁶-fold."

How fast scatter falls

Under Rayleigh's law, halving the diameter divides scattered light by 2⁶ = 64. Vesicles of 100 to 200 nanometers are at the edge of that law in blue light, and for them the full theory of scattering by spheres, called Mie theory, applies instead. This guide made a Mie calculation for vesicles of index 1.40 in water at 488 nanometers, and it gives a factor of 53 between 50 and 100 nanometers rather than 64. The same calculation gives a 1-micrometer polystyrene bead about 300,000 times the total scatter of a 100-nanometer vesicle, and a sphere the size of a lymphocyte about ten million times. A 2014 study reported the same order of magnitude: the smallest and largest vesicles in one sample typically differ 25-fold in size and 10,000,000-fold in scattered light.

The steep fall of scatter with size is why a cytometer that sees every white cell with ease can miss most vesicles entirely. A cell scatters millions of times more light in total than a 100-nanometer vesicle of low refractive index. On a conventional instrument, such a vesicle sends so few photons that the signal is indistinguishable from the light that the optics, the fluid and the detector produce with no particle present. A 2010 survey put the lower detection limit of commercial cytometers at 300 to 500 nanometers for polystyrene beads, and because vesicles scatter far less than polystyrene, the smallest vesicle detectable on the same instruments was larger still.

10 — Scatter falls with the sixth power
0.1 10 1,000 100,000 10,000,000 50 100 200 500 1,000 DIAMETER, nm (LOG SCALE) SCATTERING CROSS-SECTION, nm² (LOG SCALE) detection floor (schematic) Rayleigh, d⁶ polystyrene vesicle, n = 1.40 50 → 100 nm: 53× 53-fold for a doubling of diameter derived (Mie), 488 nm, in water schematic between the marked values
Scattered lightFocal detail
Plate 10 — Below a few hundred nanometers, scatter falls roughly with the sixth power of diameter: halving a vesicle from 100 to 50 nanometers cuts its scatter about 53-fold. Below a size set by each instrument, vesicles drop beneath its detection floor.

Seeing small particles with side scatter

The same physics points to the remedies. A particle much smaller than the wavelength scatters light over a wide range of angles, so the side-scatter path, with its large collecting lens, gathers more of that light than the narrow forward path, which must also contend with glare around the obscuration bar. The Mie calculation above took side scatter as 45 to 135 degrees and forward scatter as 1.5 to 15 degrees. On those angles, a 100-nanometer vesicle sends about nineteen times more light to the side than forward. A shorter wavelength helps through the fourth-power term. Moving from blue light at 488 nanometers to violet at 405 roughly doubles the scatter of a small particle, which is why some instruments offer violet side scatter for small particles.

In 2020 a group showed how far an instrument can be pushed. The group rebuilt a common clinical analyzer step by step: a laser ten times more powerful, a photomultiplier in place of the forward-scatter photodiode, a redesigned obscuration bar, a pinhole to reject stray light and a narrower sample stream. The changes improved the separation of particles from noise about 30-fold on side scatter. With them, the estimated detection limits for vesicles of index 1.40 were 246 nanometers on forward scatter and 91 nanometers on side scatter.

Beads cannot substitute for a calculation of that kind, made with the refractive index of vesicles. Because polystyrene scatters so much more than a vesicle, the 100-nanometer bead of this chapter's opening gives the side scatter of a vesicle of about 175 nanometers. In 2012 a widely used bead mixture for setting size gates was tested on one instrument, and it selected single vesicles between 800 and 2,400 nanometers across. The reporting framework for vesicle cytometry was published in 2020, and it concludes that "a gating strategy based on polystyrene beads alone is not a sound standardization methodology."

Specify scatter by angle, wavelength and model

Specify an instrument meant for small particles by its scatter detection limit for a stated material and refractive index, at a stated wavelength and collection angle, rather than by a bead size alone. A method that reports particle size from scatter should state the optical model it used, the refractive index it assumed and the instrument's collection angles, as Chapter 17 describes.

+ What this chapter established
  • Scatter is laser light deflected by the particle itself: forward scatter at small angles, side scatter near right angles; it needs no label and usually triggers events.
  • Forward scatter is not size and side scatter is not granularity: both depend on refractive index, shape, absorption and the instrument's optics.
  • Refractive index matters as much as diameter: at 100 nanometers, polystyrene scatters about 17 times more than a vesicle of the same size.
  • Below a few hundred nanometers scatter falls roughly with the sixth power of diameter, so small vesicles vanish into the noise unless the optics are built and calibrated for them.
05 — Labels

Turning a molecule into a light source.

+ The questionHow do antibodies and dyes make the copies of a protein on a cell give off light, and what decides how bright the result looks?

Making a protein visible

Scatter reveals little about what kind of cell a particle is. The proteins on its surface reveal a great deal, because different kinds of cell display different combinations of them. Helper T cells carry CD3 and CD4, B cells carry CD19, and immature blood cells carry CD34. B cells are the lymphocytes that make antibodies. The CD numbers come from an international scheme, the clusters of differentiation, that names surface proteins recognized by antibodies.

A cytometer cannot see a protein, so the protein is made into a source of light. An antibody binds to one site on the protein, its epitope. The antibody is chemically joined to a fluorescent dye, and this conjugate of antibody and dye is mixed with the cells. Each antibody that binds brings its dye molecules with it, so the fluorescence of a stained cell grows with the number of antibodies bound, which in turn depends on how many copies of the protein the cell carries. The molecule that an antibody recognizes is its antigen, and the number of copies of the antigen on a cell is the antigen density. The antigen density differs widely between proteins and between cell types.

Calibrated measurements give a sense of the range. The US National Institute of Standards and Technology is the country's national measurement laboratory. A 2024 study from the institute treats about 40,000 antibodies bound per cell as the known value for CD4 on the CD4-positive T cells of fixed whole blood, with one widely used reagent. Fixed blood has been treated with a chemical that preserves its cells. A count of antibodies bound is not a count of protein copies, because it depends on the reagent and on whether each antibody binds one copy or two (Chapter 17). The same study measured roughly 9,000 to 11,000 for CD19 and 4,000 to 5,000 for CD22 on control cells. Some proteins of interest are present at a few hundred copies, and others at hundreds of thousands. An antibody against a protein with a few thousand copies must carry a bright enough dye, or the stained cells will not separate from unstained ones.

11 — Turning a protein into a light source
SMALL-MOLECULE DYE several per antibody, compact, moderately bright PE PE ≈ 240,000 DALTONS one protein label, very bright a single PE molecule is heavier than its antibody donor acceptor TANDEM donor passes energy to acceptor, which glows at a longer wavelength cell membrane with surface proteins (antigens) schematic; not to scale, except PE larger than its antibody antibody
ParticlesExcitation lightFluorescenceFocal detail
Plate 11 — An antibody carries dye to every copy of its target protein, so fluorescence grows with antigen density. Labels differ enormously in size: phycoerythrin, at about 240,000 daltons, outweighs the antibody it rides on.

Three families of dye

The dyes attached to antibodies fall into three families, and each brings different strengths and weaknesses.

Small-molecule dyes, such as fluorescein and its modern successors, are compact and stable, and several can be attached to one antibody. They are moderately bright. Phycobiliproteins are light-harvesting proteins from algae and cyanobacteria, and they were introduced as labels in 1982. They are extraordinarily bright and enormous: R-phycoerythrin weighs about 240,000 daltons and allophycocyanin about 104,000, while an antibody weighs about 150,000, so a single PE molecule is heavier than the antibody it is attached to. Polymer dyes are long chains of light-absorbing units that act as one large chromophore, the part of a molecule that absorbs light. They were introduced for cytometry in the 2010s and made bright labels available for the violet and ultraviolet lasers, where few had existed.

Tandem dyes extend the range of colors that one laser can excite. A tandem joins two dyes so closely that the first, the donor, passes its absorbed energy to the second, the acceptor, without emitting light, and the acceptor then emits at its own longer wavelength. In a PE–cyanine tandem, PE is joined to a synthetic cyanine dye, and the tandem is excited by the same laser as PE but glows in the far red. The gap between the donor's absorption and the acceptor's emission is large, but it is not a Stokes shift in the strict sense, because a Stokes shift belongs to a single transition (Chapter 3).

Tandems have a weakness that matters in practice: the link between donor and acceptor can fail. Light, extremes of temperature, prolonged fixation and processes in some living cells cause the acceptor to stop receiving energy, so the tandem loses its far-red emission and the donor glows in its own color instead. How much light a tandem loses to the donor's color varies from one manufacturing lot to another. Staff of one manufacturer wrote a guideline on controls in 2006, and it warned that, with tandems, using a different antibody for compensation from the one in the test samples "is a risky practice" (Chapter 10).

A tandem's color can change after the vial is opened

Degraded tandems glow partly in the donor's color, so a tandem-stained population can appear falsely positive in the donor's detector and dimmer in its own. Controls for compensation must use the same reagent, from the same lot, handled the same way as the stained sample. A control made with a different lot or an older vial can introduce errors that look like biology.

Brightness meets antigen density

What matters in a measurement is not a dye's brightness but how well the dye separates labeled cells from unlabeled ones. The labeled cells form the positive population and the unlabeled cells the negative population. The common measure of their separation is the stain index: the difference between the median fluorescence of the positive and negative populations, divided by twice the standard deviation of the negative population, a measure of how widely its values spread around their average. A large stain index means the positive cells sit far above the spread of the negatives.

Stain index, worked

Suppose the negative population has a median of 200 and a standard deviation of 100 in a detector, and the stained population a median of 6,200. The difference is 6,000, twice the spread is 200, and the stain index is 6,000 ÷ 200 = 30. Lowering the stained median to 3,200, which halves its distance above the negatives, halves the index to 15. Doubling the negatives' spread to 200 also halves it, even though no dye molecule changed: a wider negative population, from background or from other dyes' light, is as damaging as a dimmer stain. Software sometimes uses a robust version of the standard deviation, one less affected by outlying events, so a reported stain index should state which version it used.

The manufacturer's application note of Chapter 3 gives stain indices measured on two of its analyzers for fifteen dyes, all attached to the same antibody clone against CD4. A clone here means one particular monoclonal antibody, made by one cloned line of cells. A PE–cyanine tandem gave the highest index, 353, followed by PE at 302 and APC at 278, while fluorescein gave 56 and two dyes gave 25 or less. The manufacturer's note also warned that the variety of instrument configurations makes it impossible to define the best combinations of dyes for six, eight or more colors.

12 — Separation, not brightness
stain index = (positive median − negative median) ÷ (2 × negative spread) PE-Cy5 353 PE 302 APC 278 Alexa Fluor 647 214 PE-Cy7 139 PerCP-Cy5.5 107 V450 85 Pacific Blue 80 Alexa Fluor 488 73 Alexa Fluor 700 61 FITC (fluorescein) 56 APC-Cy7 37 PerCP 37 AmCyan 25 APC-H7 24 0 100 200 300 STAIN INDEX manufacturer data, anti-CD4, two analyzers averaged about a fifth of PE on the same antibody
ReadoutFocal detail
Plate 12 — On the same antibody, dyes separate stained from unstained cells very differently: in one manufacturer's measurements PE scored 302 and fluorescein 56. The stain index measures separation, which is what panel design needs.

Panel design follows from these numbers. A panel is the set of antibodies, each with its dye, used together on one sample. The general practice is to pair the brightest dyes with the proteins present at the fewest copies, and the dimmer dyes with abundant proteins that separate easily anyway. The practice is a design rule rather than a law of physics. It has to be weighed against how much light each dye sends into the other detectors, and Chapter 10 shows that this light can make a bright dye costly to the dyes in neighboring detectors.

Labels that are not about proteins

Some dyes report the state of the cell rather than a protein. Viability dyes are kept out of living cells by an intact membrane and enter dead ones, where they either bind DNA or react with the proteins inside. Dead and dying cells matter because they bind many antibodies nonspecifically, that is, regardless of the protein each antibody is meant to detect, so in a stained sample they appear as false positives in almost every color. Excluding dead cells with a viability dye is one of the simplest ways to make sure that positive populations are real. DNA dyes measure the DNA content of each cell, which is how cytometers measure the cell cycle and some abnormalities of chromosome number. The cell cycle is the sequence in which a cell grows, copies its DNA and divides.

Cells can also bind antibodies through Fc receptors, proteins on some white cells that hold antibodies by their constant tail rather than by their binding site. That binding is unrelated to the protein the antibody was meant to detect. Blocking it with excess unlabeled antibody or with a blocking reagent is part of many staining procedures.

A vesicle carries a thousandth of a platelet's label

For vesicles the label is a hard problem too, not just the scatter. A vesicle of 100 nanometers has a surface area of about 0.031 square micrometers, roughly a nine-hundredth of the surface of a platelet 3 micrometers across. Platelets are the small bodies in blood that help it to clot. If a protein were spread with the same number of copies per unit area on a 100-nanometer vesicle as on the platelet that released it, the vesicle would carry about a thousandth of the platelet's copies and give about a thousandth of its fluorescence. The estimate is geometry only. Proteins are not sorted into vesicles evenly, and many vesicles may carry none of a given protein.

13 — A vesicle carries a thousandth of a platelet's label
platelet 3 µm, surface ≈ 28 µm² same scale ×20 vesicle 100 nm surface ≈ 0.031 µm² ≈ 1/900 of the surface → ≈ 1/1,000 of the label a handful of dyes at most geometry only; proteins are not sorted into vesicles evenly
ParticlesFluorescenceFocal detail
Plate 13 — A 100-nanometer vesicle has about a nine-hundredth of the surface of a 3-micrometer platelet. With the same number of copies of a protein per unit area, it carries roughly a thousandth of the platelet's label, close to the detection limit of most cytometers.

A signal a thousand times dimmer than a platelet's lies close to the background of most detectors. A 2025 comparison across many laboratories found that the more sensitive half of the instruments detected vesicle labels of the order of 10 to 100 molecules of equivalent soluble fluorochrome, a calibrated unit explained in Chapter 17. Its authors included staff of the company that made the calibration beads used and a cofounder of a calibration company. Many instruments could not reach that level. A vesicle that carries only a handful of antibodies is therefore near the limit of what a well-built cytometer can register at all.

Specify reagents with the instrument

In an assay specification, treat each antibody–dye conjugate as a component with its own identity: clone, dye, lot, storage and handling limits, and the instrument channel it is assigned to. Record antibodies bound per cell where calibration allows, so that the brightness a panel needs can be stated in physical terms. A change of clone, dye or lot is a change to the assay and must be checked as one.

+ What this chapter established
  • Antibodies conjugated to dyes make particular surface proteins into sources of light; fluorescence grows with the number of antibodies bound, about 40,000 per CD4-positive T cell for CD4 with one reagent.
  • Small-molecule, phycobiliprotein and polymer dyes differ in brightness and size; tandems extend colors through energy transfer but degrade, and vary by lot.
  • The stain index measures separation, not brightness: on one manufacturer's analyzers PE scored 302 and fluorescein 56 on the same antibody.
  • A 100-nanometer vesicle carries roughly a thousandth of the label of a 3-micrometer platelet with the same number of protein copies per unit area, close to the detection limit of most cytometers.

+ Part III · The instrument, piece by piece

How light from a particle becomes a number.

The instrument described in 1969 had one laser, a 20-centimeter lens to focus it, a pair of movie-projector lenses to collect the light and one photomultiplier. A modern analyzer has several lasers and detectors, and each part of it has a job. The fluidics bring each particle to one point in the beam, and the lasers illuminate it. The optics and detectors collect the light that comes back, and the electronics turn a flash lasting a few microseconds into numbers in a file. Chapters 6 to 9 take those jobs in turn. Each job is simple to state and needs care to do well, and each sets a limit on what the instrument can see.

06 — Fluidics

One particle at a time past a fixed point.

+ The questionHow does a stream of fluid line particles up in single file at one point in a laser beam, and what happens when two of them arrive together?

Bringing particles to a point

A lymphocyte crosses the laser of an older analyzer in about five microseconds, at the stream speed of six meters per second that one manufacturer gives for that instrument. At a low sample flow rate, the stream holds the cell within about three micrometers of the center of a beam 66 micrometers wide.

A cytometer measures how much light each particle sends to its detectors, and it compares particles by that light. The comparison is fair only if every particle receives the same illumination. A focused laser beam is not uniform: its intensity is highest at the center and falls away toward the edges, usually in the bell-shaped profile called Gaussian. A particle that passes through the edge of the beam therefore glows less than an identical particle that passes through its center. The fluidics have two jobs as a result. They must bring particles to the beam one at a time, and they must bring every particle through nearly the same spot.

Most commercial cytometers do this by hydrodynamic focusing. The sample is injected through a fine tube into the middle of a faster-flowing stream of clean fluid, the sheath, inside a channel that narrows. The narrowing accelerates the whole flow and squeezes the sample into a thin thread along the axis, the core stream, without any wall touching it. The particles in the core are carried in single file through the laser beam, which crosses the stream at a fixed point called the interrogation point.

14 — Hydrodynamic focusing
LASER SAMPLE SHEATH SHEATH narrowing accelerates the flow CORE STREAM INTERROGATION POINT every particle through nearly the same spot
ParticlesFluidExcitation lightFocal detail
Plate 14 — Sheath fluid flowing faster around the sample squeezes it into a thin core as the channel narrows, so particles cross the laser one at a time at nearly the same point of the beam.

Pushing the sample harder raises the rate but widens the core, so speed is traded against the ability to resolve single cells. A guide to high-speed cell sorting states this trade-off in two sentences. The diameter of the core stream "is dependent on the differential pressure between the sample and the sheath fluids," and "as the sample pressure is increased to raise the cell analysis rate, the ability to resolve single cells will decrease."

How wide the core is

The width of the core follows from conservation of volume. The volume of sample that enters the channel each second must leave through the core in the same second, so for a core moving at a given speed, the core's cross-sectional area grows in proportion to the sample flow rate and its diameter grows with the square root of the rate.

Core width from flow rate

One manufacturer gives the particle velocity in the flow cell of an older, once widely used analyzer as about 6 meters per second. At 12 microliters per minute, a core moving at that speed must be about 6.5 micrometers across; at 60 microliters per minute, it must be about 14.6 micrometers across. Quadrupling the sample flow rate doubles the core's diameter. Now take the beam as Gaussian and 66 micrometers wide between the points where its intensity falls to 13.5 % of the value at the center, a measure called the 1/e² width. A particle at the outer edge of the 6.5-micrometer core receives about 98 % of the light at the center. One at the edge of the 14.6-micrometer core receives about 91 %. These figures are derived for this guide from the stated velocity and beam size. They assume that the core moves as a uniform plug and that the 66 micrometers quoted is the 1/e² width.

Running a sample faster therefore does more than count it faster. In a wider core, particles pass through a wider range of beam intensities, so a population of physically identical particles produces a broader spread of signals. The community guidelines for cytometry in immunology give a second cause: increasing the flow rate on instruments with hydrodynamic focusing increases coincidence "and thus higher CV." The CV, or coefficient of variation, is the standard deviation of a population's signals divided by their mean, so it measures the width of the population's signal relative to its brightness. Measurements of DNA content depend on a narrow peak, so the instruments built for them are run at low sample flow rates.

15 — A faster sample makes a wider core
6 12 18 24 30 60 90 120 0 core diameter, µm sample flow rate, µL/min 6.5 11.1 14.6 20.6 diameter grows with √(sample flow rate) 100 % 98 % 91 % 80 % intensity, % of center (axis from 80 %) 6.5 µm core: 98 % at edge 14.6 µm core: 91 % at edge a broader spread of signals from identical particles derived; plug flow and a Gaussian beam 66 µm wide (1/e²) assumed, central 22 µm shown; 6 m/s per manufacturer
FluidExcitation lightFocal detail
Plate 15 — The core's diameter grows with the square root of the sample flow rate: at 6 meters per second it is about 6.5 micrometers at 12 microliters per minute and 14.6 at 60. Particles at the edge of the wider core see about 91 % of the central intensity instead of 98 %.

Speed and time in the beam

The speed of the stream sets how long each particle is illuminated. At the same manufacturer's 6 meters per second, a lymphocyte 7 micrometers across gives a pulse lasting about 5 microseconds as it crosses a beam about 22 micrometers high along the direction of flow, because it must travel the beam's height plus its own diameter. In a jet-in-air sorter, the stream leaves the nozzle as a free jet, and speeds are higher. The sorting guide gives about 28 meters per second at a typical pressure, so that the cell is in the laser beam for about 900 nanoseconds.

Where the measurement happens also matters. In a flow cell analyzer, the laser meets the stream inside a small quartz cuvette. A lens with a high numerical aperture, around 1.2, can then be coupled closely to the glass to collect light over a wide cone. In a jet-in-air sorter, the beam strikes the free stream instead. The stream acts as a small cylindrical lens and scatters a bright line of laser light, which must be blocked, and blocking it removes some fluorescence as well. The sorting guide notes that cuvette systems "can be more sensitive than jet-in-air sorters (particularly notable at certain wavelengths, e.g., long red)." In a 2018 comparison of 23 instruments, the jet-in-air sorters were among the instruments with the lowest detection efficiency (Chapter 8). The comparison's authors included staff of a cytometer manufacturer and of an analysis-software company.

Acoustic focusing

A second way to line particles up uses sound. The channel is driven by ultrasound at a frequency chosen so that a standing pressure wave forms across it. The wave's acoustic radiation force pushes particles toward the pressure node at the center of the channel. A cytometer can then position particles without relying only on a large flow of sheath. The method was developed at Los Alamos in the 2000s, and in December 2009 a manufacturer announced what its press release called the first commercial acoustic-focusing cytometer. Because the particles are already in line before they reach the beam, the sample can move through the beam more slowly, so that each particle is illuminated for longer, or it can be run at higher volumetric rates without the core widening in the same way. As of October 2026, the company that makes the instrument line claims sample flow rates of up to 1,000 microliters per minute, against the 12 to 60 microliters per minute of the older analyzer earlier in this chapter.

When two arrive together

Particles in a suspension do not arrive at evenly spaced intervals. They arrive at random and independently of one another, so the number arriving in any short interval follows Poisson statistics, named for the mathematician Siméon Denis Poisson. These statistics describe any events that occur independently at a steady average rate, such as raindrops falling on a paving stone. Some particles therefore arrive so close behind the one before that the electronics cannot separate their pulses.

How often a particle has a neighbor

Suppose events arrive at an average rate R and the electronics need a window of time τ to process each one. The expected number of other arrivals within a window is then R × τ. Poisson statistics turn that expected number into the chance that a given event has a neighbor inside its window, 1 − e^(−Rτ), where e is a constant of about 2.718. When R × τ is small, the chance is close to R × τ itself. With a window of 3 microseconds, that chance is about 0.3 % at 1,000 events per second, about 3 % at 10,000, about 9 % at 30,000 and about 26 % at 100,000. With a 10-microsecond window, the figures roughly triple at low rates. These are illustrative figures derived for this guide; real windows are instrument settings.

16 — How often a particle has a neighbor
0 20 40 60 1,000 3,000 10,000 30,000 100,000 CHANCE OF A NEIGHBOR, % EVENT RATE PER SECOND (LOG SCALE) τ = 10 µs τ = 3 µs about 3 % at 10,000/s RANDOM ARRIVALS time τ neighbor in the window chance of a neighbor = 1 − e^(−Rτ) events/s 1,000 10,000 30,000 100,000 τ = 3 µs 0.3 % 3.0 % 8.6 % 25.9 % τ = 10 µs 1.0 % 9.5 % 25.9 % 63.2 % illustrative; windows are instrument settings
ParticlesReadoutFocal detail
Plate 16 — Arrivals are random, so the chance that a particle has a neighbor inside its processing window is 1 − e^(−Rτ): with a 3-microsecond window about 3 % at 10,000 events per second and 26 % at 100,000.

When two pulses overlap, the instrument does one of two things. It records them as one event, which may later look like a single bright or large cell, or it discards them as an electronic abort. The file standard FCS 3.1 provides optional keywords for two kinds of loss: $ABRT for events lost to coincidence in the electronics, and $LOST for events lost because the computer was busy. Neither keyword records pulses merged into one event. Losses matter whenever particles are counted in a measured volume, as in volumetric counting and in the vesicle concentrations of Chapter 17. Such a count is low by the fraction lost, unless the instrument corrects for it. The bead-ratio method of Chapter 21 cancels the losses that strike beads and cells alike.

For particles much smaller than the beam, coincidence takes a different form: several of them can be inside the illuminated volume at the same moment. A 2012 study calculated the illuminated volume of the same analyzer at its highest sample flow rate as about 54 picoliters, taking the core to be 56 micrometers wide. The 6 meters per second above gives a core of about 15 micrometers at that rate, and a volume of about 4 picoliters. The manufacturer's speed and the study's core width cannot both hold. Concentrations reported for vesicles in plasma are of the order of ten billion particles per milliliter. At that concentration, even the smaller volume holds dozens of particles at any instant, and the larger one holds hundreds. Each particle alone is too faint to cross the threshold, but their combined light can cross it. Chapter 19 calls this swarm detection and shows how dilution reveals it.

A faster run is a different measurement

Raising the sample flow rate widens the core, broadens the spread of signals and raises the fraction of coincident events. A result obtained at one flow rate is therefore not automatically comparable with one obtained at another. Validation shows by testing that an assay meets the requirements of its intended use under stated conditions, so an assay that has been validated at a stated rate should be run at that rate.

Specify the fluidics by rate

In an instrument specification, state the measurement precision as a function of sample flow rate, expressed as the coefficient of variation of a reference bead population. State the maximum event rate together with the coincidence or abort fraction at that rate. In an assay procedure, fix the sample flow rate, the sample concentration and the dilution, and record them with the data. For small particles, include a dilution series to show that counts fall in proportion to dilution.

+ What this chapter established
  • Hydrodynamic focusing squeezes the sample into a thin core inside a sheath so that particles cross the laser one at a time at nearly the same point of the beam.
  • The core's diameter grows with the square root of the sample flow rate; a wider core means particles see more varied illumination and populations look broader.
  • Particles cross the beam in about a microsecond in a jet-in-air sorter and a few microseconds in a flow-cell analyzer; cuvette systems can collect light better than jets in air.
  • Arrivals are random, so coincidence rises with event rate, to about 3 % at 10,000 events per second in a 3-microsecond window, and small particles at high concentration can sit in the beam by the dozen, or by the hundred if the wider published core is right.
07 — Lasers

Why the lasers cross the stream at different places.

+ The questionHow does an instrument with several lasers choose and shape them, and know which flash of light belongs to which particle?

Why lasers

A cytometer needs a light source with three properties. Its light must focus to a spot between about 5 and 22 micrometers high, and it must deliver enough power to make a dim particle glow measurably in a microsecond. It must also have a single, narrow color, so that a filter can block it completely and pass the fluorescence beside it. A laser does all three. Early instruments used mercury arc lamps, and some still use light-emitting diodes for particular purposes, but the laser has been the standard source since the 1970s.

The colors in use come in families set by the dyes they excite. A 2015 review of near-infrared lasers in cytometry lists the laser lines in use. They run from ultraviolet at 355 nanometers through violet diodes at 405 to blue at 488, a line originally produced by argon-ion lasers. Green and yellow lines at 532 to 561 nanometers suit phycoerythrin and the red fluorescent proteins, labels that cells can be engineered to make themselves. Red lines run from 633 to 640 nanometers, and near-infrared diodes from 660 to 730. Some current instruments go further into the infrared. One manufacturer states that its current five-laser analyzer carries lines at 355, 405, 488, 561 and 637 nanometers, at powers between 60 and 200 milliwatts.

17 — Laser lines and the dyes they excite
300 400 500 600 700 800 WAVELENGTH, nm UV 355 UV dyes violet 405 violet polymer dyes blue 488 fluorescein and PE green–yellow 532–561 PE and red fluorescent proteins red 633–640 APC near-IR 660–730 near-IR dyes some instruments go further into the infrared the original blue line, once from argon-ion lasers families per a 2015 review; one current analyzer: 355, 405, 488, 561 and 637 nm at 60–200 mW (manufacturer)
Excitation lightFluorescenceFocal detail
Plate 17 — Laser lines come in families set by the dyes they excite, from ultraviolet at 355 nanometers to near-infrared diodes beyond 660. Each added laser adds dyes that can be told apart by where and when their light arrives.

Matching lines to dyes

A laser excites a dye only if the laser's wavelength falls within the dye's absorption band, the range of colors that the dye absorbs (Chapter 3). Each dye can therefore be paired only with the lasers it absorbs. Phycoerythrin absorbs strongly in the green and yellow, so it is excited well by a 561-nanometer laser and less well, though still usefully, by the blue line at 488. Allophycocyanin needs a red laser. The polymer dyes of Chapter 5 made bright labels available for the violet and ultraviolet lasers.

Adding lasers is one of the most effective ways to add colors. Dyes excited by different lasers can emit at similar wavelengths and still be told apart, because their light arrives at the detectors at a different moment and through a different collection path, as the rest of this chapter shows. A cytometer with five lasers can therefore use many more dyes, with less overlap between them, than one with a single laser and the same number of detectors.

Shaping the spot

The beam is focused to an ellipse rather than a circle. Its short dimension lies along the direction of flow and sets how long each particle is illuminated, and therefore how close behind one another two particles can pass and still be resolved as two (Chapter 6). Its long dimension lies across the stream and gives tolerance: a particle slightly off the axis of the core still receives nearly the full intensity. Manufacturers quote spots of 22 by 66 micrometers on an older analyzer, 9 by 65 on a newer one and 5 by 80 on another. Some instruments shape the beam so that its intensity is flat across the center rather than Gaussian. The design intent is to make the illumination less sensitive to where a particle crosses the beam, but this guide found no published comparison that measured the benefit.

18 — An elliptical spot
flow sheath core laser spot 65 µm across 9 µm along the flow sets the time each particle spends in the light one manufacturer's figure; others quote 22 × 66 µm (older analyzer) and 5 × 80 µm Gaussian flat-top core INTENSITY ACROSS THE STREAM schematic profiles; no published measurement of the flat-top benefit found
ParticlesFluidExcitation lightFocal detail
Plate 18 — The spot is short along the flow, which sets how long each particle is illuminated, and long across it, so a particle slightly off the axis still sees nearly full intensity. Some instruments flatten the profile across the stream.
How intense the spot is

The mean intensity of a focused beam is its power divided by the area of the spot. Twenty milliwatts focused into an ellipse 9 by 65 micrometers gives about 4 × 10⁷ watts per square meter, roughly forty thousand times the intensity of sunlight at the Earth's surface. The 1997 study of Chapter 3 described fluorescein, PE and APC as considerably saturated and bleached in standard cytometer conditions. Its clearest case, APC, gave only about eleven times more light for fourteen times more power, at a mean intensity of about 10⁹ watts per square meter. On these figures, typical analyzers run one to two orders of magnitude below that intensity. A 50-milliwatt source in a 5-by-80-micrometer spot comes within a factor of ten of it, and sources of 100 to 200 milliwatts focused to a similar spot approach it. Fluorescein and PE lost signal within microseconds in the same study, so a lower intensity does not guarantee a linear response. The powers quoted by manufacturers are measured at the laser, so the intensity at the stream is lower still. The comparison is derived for this guide.

The intensity of the spot also bears on how much laser power to use. Jet-in-air sorters move particles faster than analyzers, so each particle spends less time in the beam, and the sorting guide of Chapter 6 notes that "higher laser powers are generally required to illuminate the cell with the same number of photons." For dyes that already saturate, however, extra power adds little signal, and it can bleach a dye partway through the beam. The best power for a measurement therefore depends on the dye, the flow speed and the spot.

One stream, several beams

An instrument with several lasers could focus them all on the same spot. Most do not. They place the beams at separate points a short distance apart along the stream, so that each particle passes through one laser, then the next. The light produced at each point is collected by its own optics and sent to its own set of detectors. A dye excited only by the red laser then produces a signal only at the red point, even if its emission overlaps with that of a dye excited at the blue point.

Separating the beams in space separates them in time. A particle crosses the first beam, which usually triggers the event, and reaches the next one microseconds or tens of microseconds later. The electronics must assign the second pulse to the same event by waiting a fixed interval, the laser delay, before looking for it. The delay depends on the distance between the beams and on the speed of the stream, which in turn depends on the sheath pressure. The delay must therefore be measured with beads and checked as part of routine setup.

19 — Laser delay
flow 488 nm 561 nm 640 nm distance ÷ stream speed = laser delay delay −91 µs (corrected): 97.6 % double-positive 488 nm 561 nm 640 nm laser delay delay −93 µs (2 µs off): 89.4 % double-positive 2 µs 2 µs is comparable to the whole pulse missed part one core facility; schematic time scale, pulse ≈ 5 µs
ParticlesFluidExcitation lightReadoutFocal detail
Plate 19 — Separate beams are separated in time, so the electronics wait a set laser delay before reading the next beam. A delay two microseconds off read 89.4 % double-positive cells where the corrected delay read 97.6 %.

A wrong delay does not stop the instrument working. It makes the second laser's detectors integrate the wrong part of the pulse, or the tail of the previous particle. A note from one core facility, a laboratory that runs shared instruments, records a delay corrected from −93 to −91 microseconds. Before the correction, a population that should have been almost entirely positive for two markers read 89.4 % double-positive; after it, 97.6 %. Two microseconds is a large part of a pulse at analyzer speeds. The same note records that the affected channel's fluorescence intensity read about 11 % lower before the correction, enough to push part of the population out of the positive gate.

The laser delay is part of the measurement and is not in the standard file

Whether a fluorescence value belongs to the right particle depends on the delay setting. Yet the file standard FCS 3.1 has no keyword for laser delays, windows or sheath pressure. Some instruments write these settings into their own keywords, in units that the standard does not define. A data set exchanged between laboratories can therefore lose the one setting that decides whether its multi-laser values are valid.

Measure what reaches the stream, and check timing daily

For an instrument specification, state each laser's wavelength, its power at the interrogation point rather than at the laser, the spot dimensions and profile, and the spacing between beams. For daily operation, include verification of the laser delays with beads in the setup procedure, and record the delays with the data. Repeat the check after any change of sheath pressure, nozzle or flow cell. The reporting standard MIFlowCyt asks for the power measured "at the intersection of the light source beam with particles" where possible.

+ What this chapter established
  • Lasers give a narrow, intense, focusable color; current instruments use lines from about 355 to beyond 730 nanometers at tens to a couple of hundred milliwatts.
  • Each laser excites only the dyes that absorb at its line, and adding lasers adds colors with less overlap than adding detectors to one laser.
  • The spot is an ellipse, short along the flow and long across it; typical analyzers run one to two orders of magnitude below the intensity at which APC clearly saturated in a 1997 study, though some dyes lose signal at lower intensities.
  • Separate beams along the stream are separated in time, and a laser delay assigns each pulse to its event; a delay off by two microseconds can turn 97.6 % into 89.4 %.
08 — Detection

Whether a photon becomes a count.

+ The questionOf the photons a particle sends out, how many reach a detector, and what sets the dimmest signal the instrument can see?

Most of the light never arrives

Of the light a fluorescent particle gives off, a cytometer with a good lens collects about a third, and its filters pass only part of that to a detector.

A fluorescent particle emits light in every direction. A cytometer collects that light with a lens placed close to the stream, and the fraction the lens can gather is set by its numerical aperture, a measure of the width of the cone of light it accepts. One manufacturer states that its analyzer's lens has a numerical aperture of 1.2 and is coupled to the quartz cuvette with optical gel, and another claims more than 1.3. Chapter 6 gave about 1.2 as typical for cuvette instruments.

Even so, most of the light is lost. For light emitted equally in all directions into water, a lens of numerical aperture 1.2 collects about 28 %, and one of 1.3 about 39 %. A lens of 0.5 in air would collect less than 7 %. The collected light then passes mirrors and filters that let through only part of each dye's emission band, and finally it reaches a detector, which converts only a fraction of the photons that strike it into electrons, called photoelectrons. That fraction is the detector's quantum efficiency.

A photon budget

Take a dye that emits 10,000 photons while a particle crosses the beam. A lens of numerical aperture 1.2 collects about 2,800. A filter that passes half of the dye's emission band leaves about 1,400. A photomultiplier with a quantum efficiency of 25 % at that color converts about 350 of them into photoelectrons. The figures are illustrative and derived for this guide. Real budgets depend on each component, and losses at every surface and mirror reduce them further. The pattern holds generally: of every hundred photons emitted, a few become the signal.

Filters and mirrors sort the colors

The collected light contains every color the particle produced. A series of dichroic mirrors divides it by wavelength: a long-pass mirror reflects light shorter than a stated wavelength and transmits longer light, and a short-pass mirror does the reverse. The light in each branch then passes through a bandpass filter in front of its detector, and the filter defines exactly which colors that detector sees. The notation 530/30 means a filter centered on 530 nanometers with a band 30 nanometers wide, passing light from 515 to 545 nanometers. The order of mirrors along the path matters, because each mirror decides which colors continue. MIFlowCyt asks that the components be listed in that order.

20 — Where the photons go
detector NA 1.2: about 28 % LONG-PASS DICHROIC reflects shorter, passes longer BANDPASS FILTER 530/30 = 515–545 nm emitted 10,000 collected: lens, 28 % 2,800 through filter: half 1,400 photoelectrons: QE 25 % 350 a few percent of what was emitted illustrative budget, derived
ParticlesFluorescenceReadoutFocal detail
Plate 20 — Even a good lens collects only about 28 % of the light, filters pass part of each dye's band and detectors convert only some photons. Of 10,000 photons emitted, about 350 become photoelectrons.

Filters age. Their coatings degrade with time, humidity and intense light. MIFlowCyt asks for each filter's installation date, because "filter performance needs to be monitored at intervals." A filter that has drifted changes the fraction of each dye's light that reaches each detector, and so it changes the overlap that Chapter 10 subtracts.

Three kinds of detector

The detector converts photons into an electrical signal, and three types are in use. The photomultiplier tube has been the standard for decades. Its light-sensitive surface, the photocathode, can free an electron when a photon strikes it, and a chain of electrodes then multiplies that electron into a measurable pulse, by a factor of up to about ten million depending on the voltage applied. One manufacturer's datasheet for a common tube gives a quantum efficiency of about 30 % at the tube's best wavelength, 260 nanometers in the ultraviolet. The datasheet gives lower values across the visible, falling toward the red, and a gain of about ten million at 1,000 volts.

The avalanche photodiode is a semiconductor detector that converts photons more efficiently but has much less internal gain, so its own electronic noise matters more. One manufacturer's comparison gives it an efficiency of up to about 80 % in the red and near-infrared. The silicon photomultiplier is an array of tiny photodiodes, each operated so that it fires on a single photon. It has high gain at the cost of more noise, and the same manufacturer's comparison gives it a photon detection efficiency of up to about 50 %. Instruments now use all three: photomultiplier tubes in many analyzers and spectral instruments, arrays of avalanche photodiodes in others, and silicon photomultipliers in some.

No type is best everywhere. The choice trades efficiency at each color against noise, dynamic range and cost, and it changes how dim a signal each channel can detect. The rest of this chapter therefore measures detectors by what they deliver rather than by type.

Counting photoelectrons

The signal from a dim particle is ultimately a count of photoelectrons, and counts of independent random events fluctuate. A 2006 paper states the rule for cytometry precisely: the spread of repeated measurements "scales with the square root of the number of photoelectrons detected." A population of identical particles that each give 100 photoelectrons on average shows a spread of about 10 % from counting alone. At 1,000 photoelectrons the spread falls to about 3 %, and at 10,000 to 1 %.

21 — Dim populations always look broad
0 10 20 30 10 100 1,000 10,000 100,000 CV FROM COUNTING, % PHOTOELECTRONS PER PARTICLE (LOG) 10 % 3.2 % 1 % CV = 1 ÷ √N no software can narrow this N = 100 CV 10 % N = 1,000 CV 3.2 % N = 10,000 CV 1 % 0.7 1.0 1.3 SIGNAL ÷ POPULATION MEAN counting statistics only
ReadoutFocal detail
Plate 21 — Counts of photoelectrons fluctuate by their square root, so a population of identical particles giving 100 photoelectrons spreads by about 10 %, at 1,000 by about 3 % and at 10,000 by 1 %. The width of a dim population is physics.

Counting statistics explain why dim populations always look broad, however uniform the particles. They also explain why better software cannot separate a dim population from an unlabeled one. The width is a physical limit, set by how many photoelectrons the instrument extracts from each particle.

Q and B decide the dimmest signal

Two numbers describe what a detection channel can do. Q, the detection efficiency, is the number of photoelectrons the channel produces per unit of dye on the particle. A unit of dye is a fixed amount of fluorescence defined with calibrated beads, such as the light of one dye molecule in solution (Chapter 17) or of one dye-labeled antibody. B, the background, is the light and electronic noise that the channel registers even when no labeled particle is present. It comes from the sheath fluid, stray laser light, the optics and the electronics. A dim signal is lost either because it produces too few photoelectrons or because it sinks into the background.

The 2018 comparison of Chapter 6 measured Q and B on 23 instruments in nine laboratories, using light pulses from a stable LED source and beads at several levels of brightness. Its authors included staff of a cytometer manufacturer and of an analysis-software company. Among eight analyzers of the same model, Q ranged over not much more than a factor of two in some channels and over an order of magnitude in others. The method also identified defective channels in need of service. The three jet-in-air sorters had Q values far below the median, and the one instrument that used avalanche photodiodes had the highest Q in every channel.

What the dimmest signal is

The same study defines the dimmest resolvable signal by a rule of separation. A positive population is resolved when a point two of its own standard deviations below its mean still sits two standard deviations above the negatives. Counting statistics plus background give that level as 4 × (1 ÷ Q + the background's standard deviation), both in units of dye. One manufacturer published example values for one channel: Q = 0.306 photoelectrons per unit of dye, and B = 326 units of dye, which is the background light expressed as an equivalent dye signal. The background's counting spread is √(B ÷ Q) = √(326 ÷ 0.306), about 32.6 units. The counting term 1 ÷ Q is then about 3.3 units and the background term 32.6, so the dimmest resolvable signal is about 4 × 36 ≈ 144 units. Background, not the detector's efficiency, dominates. The arithmetic is derived for this guide from the published formula and values.

22 — Background decides the dimmest signal
dimmest resolvable signal = 4 × (1 ÷ Q + background spread) Q = 0.306 photoelectrons per unit of dye B = 326 units of dye; spread √(B ÷ Q) ≈ 32.6 4 × ≈ 36 units of dye ≈ 144 units of dye 1 ÷ Q ≈ 3.3 background ≈ 32.6 background dominates 2 SD 2 SD negatives dimmest positive ≈ 144 units of dye between the means manufacturer example values; arithmetic derived; distributions schematic
ReadoutFocal detail
Plate 22 — The dimmest resolvable signal is 4 × (1 ÷ Q + background spread). With one manufacturer's example values, the counting term is about 3.3 units and the background term 32.6, giving about 144: background, not detector efficiency, dominates.

A rule of thumb follows: background decides how dim a signal can be seen, and Q decides how precisely a bright one is measured. For vesicles, which sit at the bottom of the scale, background is the limit that matters. A compendium of methods for measuring single vesicles by flow cytometry notes that, unlike the signals of cells, "signals originating from EVs partly overlap with the background noise." A 2014 study gave lower size limits for vesicles of 270 to 600 nanometers on a conventional cytometer and 150 to 190 nanometers on one built for small particles. In the 2020 rebuild described in Chapter 4, a pinhole that rejected stray light improved side-scatter separation fivefold on its own.

Datasheet sensitivity comes from each maker's own beads and method

Instrument specifications often state sensitivity as a number of fluorescent molecules equivalent to the faintest detectable signal. The US National Institute of Standards and Technology and the International Society for Advancement of Cytometry coordinated a study, published in 2012, in which different groups assigned values to the same reference beads. Their values "varied by orders of magnitude in most cases." A figure measured with one maker's beads and method therefore cannot be compared with another maker's figure, and it describes one channel, not the instrument.

Specify each channel by Q and B

State detection performance channel by channel rather than as one sensitivity figure for the instrument. For each channel, give Q and B measured by a stated method, or a calibrated detection threshold with its method and bead lot. Track Q and B over time as part of performance qualification, because a falling Q or a rising B reveals an aging detector, a degraded filter or a misaligned laser before the fault shows up in patient or experimental data.

+ What this chapter established
  • A lens of numerical aperture 1.2 collects about 28 % of the light; filters and detector efficiency leave only a few percent of emitted photons as signal.
  • Dichroic mirrors and bandpass filters such as 530/30 decide which colors reach which detector; filters age and must be monitored.
  • Photomultipliers, avalanche photodiodes and silicon photomultipliers trade efficiency, gain and noise; counting statistics make dim populations broad, with a spread of about 1 ÷ √N for N photoelectrons.
  • The dimmest resolvable signal is 4 × (1 ÷ Q + background spread); background dominates in the published example, and it is what hides vesicles.
09 — Pulses

How a flash of light becomes a number.

+ The questionHow does a pulse lasting a few microseconds become a height, an area and a width, and who decides which pulses count as events at all?

The shape of a pulse

As a particle moves through the laser spot, the light it sends to a detector rises, peaks and falls. The detector turns that light into a current that follows the same course, and the electronics see a pulse: a bump in the signal lasting from under a microsecond in a fast sorter to a few microseconds in an analyzer. The pulse's shape is set by the profile of the beam along the direction of flow and by the size of the particle, because a large cell takes longer to enter and leave the beam than a small one.

Three numbers are taken from each pulse. One manufacturer's technical bulletin defines them simply: the height is the peak intensity of the pulse, the width is the time the particle takes to pass through the interrogation point, and the area is "calculated by integration and represents the whole pulse." Area grows with the total light collected during the passage, height with the brightest moment, and width with the time spent in the beam. Most software attaches the suffixes -A, -H and -W to these values, but FCS 3.1 does not define them; they are naming habits. MIFlowCyt requires a report to say which pulse measurement it used.

23 — Height, area and width
BEAM PROFILE ALONG THE FLOW FLOW large particle → longer pulse: more time inside the beam 0 1 2 3 4 5 µs DETECTOR SIGNAL threshold WIDTH HEIGHT area grows with all the light collected 3 µs pulse sampled at 10 MHz ≈ 30 samples (derived)
ParticlesFluidExcitation lightReadoutFocal detail
Plate 23 — Each pulse yields three numbers: its height, the brightest moment; its area, the total light collected; and its width, the time spent in the beam. Software computes them from the converter's samples.

Telling one particle from two

The three measurements together reveal clumps. Two cells stuck together, or passing one directly behind the other, produce a pulse that is longer than one cell's and carries about twice its area. The pulse's height rises much less, so area and height no longer keep the ratio that single cells show. On a plot of area against height, single cells fall along a diagonal line and pairs fall above it. A plot of width against height does the same, with pairs at greater width. Drawing a gate on such a plot to keep only single particles is called doublet discrimination, and it is a routine first step of analysis.

24 — Telling one particle from two
TIME SIMILAR HEIGHT SINGLET DOUBLET ≈ 2× AREA FSC-A FSC-H SINGLETS DOUBLETS two cells that would read as one schematic; works only when particles are comparable to the beam height
ParticlesReadoutFocal detail
Plate 24 — Two cells passing together give a longer pulse with about twice the area of one cell's, while its height rises much less. On area against height, singlets fall on a diagonal and doublets fall off it.

Doublet discrimination has limits. The sorting guide of Chapter 6 notes that pulse processing reduces doublets but "can never completely eliminate" them. The method also works only when a particle is comparable to or larger than the height of the beam. Two small particles side by side across the stream, or several vesicles inside the beam at once, produce a pulse that looks like one particle's. A doublet of two cells that is not removed can look like a single cell positive for both their markers. Immunophenotyping, which identifies kinds of cell by the combinations of proteins they carry, looks for exactly such populations.

The threshold decides what exists

Most of the time, nothing is passing the beam, and the detectors register only background. The electronics need a rule for deciding when a particle has arrived. The rule is the trigger and threshold: one chosen detector, and a level that its signal must exceed (Chapter 1). When the signal exceeds that level, the electronics open a window, measure the pulse in every detector and record an event. Everything below the threshold is discarded and leaves no record.

The choice of trigger shapes the data as much as any other setting. A threshold set too high discards real but dim particles, and one set too low fills the file with noise events and increases the overlap of pulses, which leads to more electronic aborts (Chapter 6). Through its $TR keyword, FCS 3.1 can record one trigger detector and its threshold, in channel numbers, the instrument's own arbitrary scale. More elaborate triggers, such as an event declared when either of two detectors crosses its level, have no standard representation.

For vesicles, the choice of trigger is decisive. Their scatter is so weak that a scatter trigger set above the noise misses most of them. Triggering on fluorescence instead declares an event when a labeled particle glows, and it changes the count dramatically. In a 2016 study of plasma vesicles, fluorescence triggering raised the number detected 15-fold for vesicles from red cells, 40-fold for those labeled with annexin V and 75-fold for those from platelets. Annexin V is a protein that binds phosphatidylserine, a membrane lipid that some vesicles expose on their outer surface.

MIFlowCyt asks for the threshold to be stated, and its extension for vesicle cytometry asks for the trigger channel and threshold, preferably in calibrated units rather than in channel numbers. A scatter threshold can then be given as a cross-section in square nanometers, a measure of how much light a particle scatters into the detector, and a fluorescence threshold as a level in calibrated molecules (Chapter 17).

25 — The trigger decides what exists
SCATTER TRIGGER FLUORESCENCE TRIGGER threshold noise events threshold noise events red-cell vesicles ×15 annexin V ×40 platelet vesicles ×75 scatter trigger = 1 the same sample, a different trigger 2016 study of plasma vesicles; traces schematic
FluorescenceScattered lightReadoutFocal detail
Plate 25 — For vesicles, the choice of trigger is decisive. Triggering on a labeled vesicle's fluorescence instead of its weak scatter raised counts 15-fold for red-cell vesicles, 40-fold for annexin V-labeled ones and 75-fold for platelet vesicles in a 2016 study.

From current to digits

Modern cytometers are described as digital, but the sorting guide states plainly: "A fully digital flow cytometer does not exist. All cytometers, including sorters, are hybrid analog–digital systems." The detector's current is converted to a voltage and amplified by analog electronics. An analog-to-digital converter then samples the voltage tens of millions of times a second, typically at 10 to 100 megahertz according to the same guide. Software computes height, area and width from the samples.

Bits, decades and samples

A converter with n bits distinguishes 2ⁿ levels: 16 bits give 65,536. The number of decades is the span from the smallest step to the largest value, counted in powers of ten: 16 bits span about 4.8 decades, 18 bits about 5.4 and 22 bits about 6.6. One manufacturer quotes "22-bit 6.5 log decades," consistent with that arithmetic. But a linear converter has very few steps at the bottom of its range: in an 18-bit range, the first decade, from 1 to 10, contains only nine integer steps. A pulse lasting 3 microseconds yields about 30 samples at 10 megahertz and about 180 at 60 megahertz. The figures are derived for this guide.

The bit depth printed in a specification does not always describe the converter. Some instruments combine two 16-bit converters per channel to produce data with an effective 23-bit range. An area stored as a 32-bit number is a sum of many samples, not a 32-bit conversion. What matters to the measurement is the noise and resolution at the bottom of the scale, where dim particles fall.

Log amplifiers and logarithmic displays

Older instruments did not digitize a linear signal. They passed it through logarithmic amplifiers that compressed four decades of signal into 1,024 channel numbers, which made bright and dim populations visible on the same axis. Analog log amplifiers were never perfect: one manufacturer's patent notes that their transfer function "can contain 'ripples' that may distort the input signal." In the 2018 comparison of 23 instruments in Chapter 8, the study's estimates of Q and B were less precise on instruments with log amplifiers than on linear ones: 85 % of their standard errors were below 10 %, against 90 % below 3 % on linear instruments. The comparison's authors included staff of a cytometer manufacturer and of an analysis-software company.

Linear digitization removed the hardware but not the habit of viewing data on a logarithmic axis, and the habit causes a problem once data are compensated. Compensation subtracts one dye's light from another dye's detector, and for cells that carry none of a dye it leaves values near zero and below zero, which a logarithmic axis cannot show (Chapter 10). The 2006 paper of Chapter 8 described how log displays "often show a peak above the actual mean or median of the population with a pileup of events on the baseline," a distortion known as the log artifact. The paper's remedy is the logicle, or biexponential, display, which is linear near zero and logarithmic far from it. Chapter 12 shows that this display is a choice that can change how a plot looks without changing the data.

The threshold, the pulse measurement and the transform travel with the number

Height and area of the same pulse can rank particles differently. The threshold decides which particles exist at all, and the transform, the scale on which the data are displayed, decides how populations look. A number reported without these three facts cannot be reproduced on another instrument or in another laboratory.

Specify electronics by what reaches the bottom of the scale

In an instrument specification, state the sampling rate, the converter resolution, the electronic noise and the baseline stability in units of the detector signal. Test linearity down to the dimmest populations the instrument is meant to measure. In an assay, fix the trigger channel, threshold and pulse measurements, and record them. For small particles, express the threshold in calibrated units so that it means the same on another instrument.

+ What this chapter established
  • Each pulse yields a height, an area and a width; the suffixes are conventions, and a report must say which measurement it used.
  • Area against height separates single particles from doublets when particles are comparable to or larger than the beam height, but never perfectly.
  • The trigger and threshold decide what becomes an event; for plasma vesicles, fluorescence triggering found 15 to 75 times more particles than scatter triggering.
  • Cytometers are hybrid analog–digital systems; linear converters, which have few steps at the bottom of the scale, replaced log amplifiers, and logicle displays, linear near zero, show the compensated values near and below zero that logarithmic axes cannot.

+ Part IV · From signals to populations

How rows of numbers become kinds of cell.

Two analysis programs given the same file can report different percentages. Nothing in the instrument can account for that difference, because both programs read the same data. Chapter 10 explains how software separates dyes whose light reaches the same detectors. Chapter 11 covers the controls that decide where a positive signal begins, and Chapter 12 the boundaries that group events into the populations a result reports. Each of these steps is taken by people or software after the instrument has finished, and each can change the answer.

10 — Compensation

When two dyes land in one detector.

+ The questionWhat does compensation fix when it subtracts one dye's light from another dye's detector, what can it never fix, and why is spectral unmixing the same problem?

Every detector sees more than one dye

Compensating a forty-dye panel would mean measuring 1,560 spillover values, one for each dye in each of the 39 other dyes' detectors.

The emission band of a dye is broad, tens of nanometers wide, with a long tail toward the red (Chapter 3). A bandpass filter passes a slice of the spectrum to each detector, and that slice usually contains the tail of a neighboring dye as well as the peak of the detector's own dye. Fluorescein glows most strongly near 520 nanometers, but part of its light reaches a detector set for phycoerythrin near 575. The fraction of a dye's signal that appears in another dye's detector is called spillover, which puts a number on the overlap of Chapter 3. Spillover is a property of the dye, the filters and the detector settings, not of the cell, so it is the same for every cell measured under the same conditions, except where a tandem dye degrades on some cells (Chapter 5).

26 — Every detector sees more than one dye
RELATIVE EMISSION 500 550 600 650 700 nm 530/30 575/26 FLUORESCEIN PHYCOERYTHRIN (PE) schematic spectra; spillover values illustrative 2 % spillover: the same for every cell 15 % of fluorescein's signal (illustrative)
FluorescenceFocal detail
Plate 26 — A dye's emission is broad, so part of fluorescein's light falls in the phycoerythrin detector's window. That fraction, the spillover, is a property of dyes, filters and settings, the same for every cell.

Spillover is also linear. A cell carrying twice as much fluorescein sends twice as much light into the phycoerythrin detector, so each detector's reading is a sum of contributions, one from each dye, and each contribution is proportional to the amount of that dye on the cell. That linearity is what makes the problem solvable: if the fraction each dye contributes to each detector is known, the readings can be converted back into the amount of each dye.

Compensation undoes the mixing

Compensation is that conversion. In a 2001 review, Mario Roederer called it "a simple application of linear algebra, with the goal to correct for spillovers of all dyes into all detectors." The fractions are measured with single-stain controls: samples each stained with only one of the panel's dyes, so that any light in the other detectors must be spillover. With two dyes there are two fractions to measure. In general there is one value for each dye in each detector other than its own, the number of dyes times one less than that number, so an eight-color panel has 56 spillover values and a twenty-color panel 380. Together the values form a table, the spillover matrix, with one row for each dye and one column for each detector.

Two dyes, worked

Suppose 15 % of fluorescein's signal spills into the phycoerythrin detector and 2 % of phycoerythrin's into the fluorescein detector. A cell carrying fluorescein worth 10,000 and phycoerythrin worth 4,000 reads 10,080 in the fluorescein detector and 5,500 in the phycoerythrin detector. Subtracting 15 % of the first reading from the second leaves 3,988. Dividing by 1 − 0.15 × 0.02, which is 0.997, restores 4,000. The same steps restore 10,000 for fluorescein. The correction is exact for the averages, and the division changes the result noticeably only when two dyes spill heavily into each other, which makes the divisor small. The values are illustrative, chosen for this guide.

The calculation is done by software, not by the instrument. The FCS 3.1 file stores the detector readings as measured and can carry the spillover values alongside them, and the standard states that "the stored data is always uncompensated." A laboratory can therefore recompute compensation with a better matrix long after acquisition. Older instruments that compensated in their electronics did not allow such a recalculation. Chapter 18 shows what happens when software drops the matrix.

What compensation can never remove

Compensation restores the average amount of each dye. It cannot restore the precision that spillover took away. The light that spills into a detector arrives as photons, and the photoelectrons they produce fluctuate by the square root of their number (Chapter 8). Subtracting the average spillover leaves the fluctuation behind, so a population that carries none of the second dye ends up centered on zero but spread more widely than cells that carried neither dye. In the 2001 review, Roederer showed that the spread rises with the square root of the spilled signal and that subtracting more cannot remove it, "because compensation is a linear process."

How much spread spillover adds

On average, a cell bright in fluorescein spills light worth 400 photoelectrons into the phycoerythrin detector. Counting statistics give that light a spread of about 20 photoelectrons, the square root of 400. After compensation the cell's phycoerythrin value is centered on zero, with that spread around it. A cell four times brighter spills 1,600 photoelectrons and leaves a spread of 40: four times the light, twice the spread. A dim phycoerythrin label that adds 30 photoelectrons to a positive cell is lost within the spread of the bright cells, though it would stand clear of unstained ones. The figures are illustrative, derived for this guide.

On a plot, the effect looks like a fan: the compensated negatives widen as the first dye grows brighter, and the widened edge can look like a dim positive population. The authors of a 2013 study named the effect spillover spreading. They defined a value for each dye and each detector it spills into, which measures the spreading independently of how brightly the cells are stained, and they collected the values into a spillover spreading matrix for each instrument. The authors of a 2021 study showed that this value changes with detector voltage, so it describes an instrument at its settings, not the dyes alone. They proposed an index that does not change with voltage.

27 — What compensation cannot remove
10² 10³ 10⁴ 10⁵ FLUORESCEIN (LOG) −100 +100 0 COMPENSATED PE (PHOTOELECTRONS, LINEAR) dim PE positive, +30 400 spilled SPREAD ±20 1,600 spilled ±40 4× LIGHT → 2× SPREAD lost in the spread, not the average schematic; values from the worked example
ReadoutFocal detail
Plate 27 — Compensation centers negatives on zero but cannot remove the counting noise of spilled light. Four times the light gives twice the spread, so a dim marker read in the receiving detector is lost in the fan.

The spillover spreading matrix completes the panel-design rule of Chapter 5. The first half of that rule is to pair the brightest dyes with the scarcest proteins. The second half is to avoid reading a dim marker in a detector that receives heavy spread from a dye that is bright on the same cells. Vesicle labels lie near the detection limits that the more sensitive instruments of Chapter 5 reached, of the order of 10 to 100 molecules of equivalent soluble fluorochrome, so every source of spread raises the level that a vesicle's label must clear, which argues for few colors and well-separated dyes.

A compensated plot can show cells that are not there

Too little compensation leaves a diagonal population that looks positive for two dyes. Too much pushes negatives below zero and can hide dim positives. Spillover spreading can look like a dim population. Editing the matrix by eye until a plot looks clean changes the averages to hide a spread that compensation cannot remove, and it makes the result wrong in a way that no later reader can detect.

Unmixing is the same arithmetic with more detectors

A full-spectrum or spectral cytometer replaces one detector per dye with many detectors per laser (Chapter 2). Each dye is then recorded as a signature: the pattern of its light across all the detectors. A cell's readings are the sum of the signatures of the dyes it carries, each weighted by the amount of that dye. With more detectors than dyes and noisy readings, there is in general no exact solution. Unmixing finds the amounts whose combined signatures fit the readings best, usually by the method of least squares. In a 2022 comparison, the founder of an analysis-software company describes conventional compensation as a special case of the same mixture model: the square case, in which the number of detectors equals the number of dyes.

28 — Unmixing is the same arithmetic
SIGNATURES ACROSS 16 DETECTORS DYE 1 DYE 2 DYE 3 similar signatures amplify spread CELL READINGS 1 16 detector cell readings = a₁ × dye 1 + a₂ × dye 2 + a₃ × dye 3 CONVENTIONAL 3 detectors × 3 dyes: square → compensation SPECTRAL 3 dyes × 16 detectors: more detectors than dyes → least-squares fit rows: dyes · columns: detectors
FluorescenceReadoutFocal detail
Plate 28 — A spectral cytometer records each dye as a signature across many detectors and finds the amounts whose signatures best fit a cell's readings. Compensation is the square case of the same model, with as many detectors as dyes.

Unmixing inherits both limits of compensation: it restores the averages and leaves the counting noise. It also makes common a third limit, which compensation meets only when two dyes spill heavily into each other. The divisor of the worked example, 0.997 there, then becomes small, and dividing by it magnifies every fluctuation. When two signatures are similar, small fluctuations in the readings can be assigned to either dye, and that amplifies the spread. A 2026 study measured this unmixing-dependent spreading on four spectral instruments from three manufacturers. An engineer at one manufacturer led the study, with academic co-authors. The authors found that the spreading is not new noise but a magnification of uncertainty already present in the raw data.

Plain least squares also assumes that every detector is equally noisy, which photon counts are not. In a 2013 analysis, the same software developer and academic colleagues argued that photon-count data violate the assumptions of plain least squares. They linked the violation to spreading and negative values, and they proposed a model built on photon statistics. Cells also glow faintly without any dye, which is called autofluorescence (Chapter 11). Unmixing can treat that glow as one more signature and subtract it the same way. The similarity indices that software reports for pairs of dyes have no peer-reviewed formula, and Chapter 14 weighs when a spectral instrument is the better choice.

The matrix is only as good as its controls

Every spillover value comes from a single-stain control, so the controls decide whether compensation is right. A 2006 guideline by staff of one manufacturer asked that each control be stained with one of the panel's own reagents and be at least as bright as the test samples. A later guideline for spectral cytometry added that controls use "the same antibody lot" and be treated like the samples, because fixation and pH can change a dye's spectrum. A manufacturer's staff were among that guideline's authors. Tandem dyes need controls from the same vial and lot, because their spillover changes as they degrade (Chapter 5).

EuroFlow is a European consortium that standardized cytometry panels and procedures for blood cancers such as leukemia, and its protocol puts these rules on a fixed schedule. Its leukemia panels return in Chapter 21. Its protocol sets compensation with samples each stained with a single antibody, by default once a month. For the protocol's two tandem dyes, the values are specific to each conjugate. In a test of eight laboratories, the compensation matrices of the seven instruments compared were similar, which is part of what lets a pattern read in one laboratory mean the same in another.

Treat the matrix as part of the result

In an assay specification, define the single-stain controls by reagent, lot, cell or bead type and brightness relative to the samples. State how often the matrix is recalculated and its acceptance limits. Keep the uncompensated data and the matrix used for each result. Design panels against a spillover spreading matrix measured on the instrument at its settings, and recalculate after a change of reagent lot, detector voltage, filter or laser.

+ What this chapter established
  • Dye emission is broad, so each detector receives light from several dyes; spillover is linear and depends on dyes, filters and settings, not on the cell.
  • Compensation inverts the mixing with spillover values, one for each dye in each detector other than its own, measured on single-stain controls, and the FCS standard requires data to be stored uncompensated.
  • Compensation restores averages but not precision: spread grows with the square root of the spilled light and limits dim markers in receiving detectors.
  • Spectral unmixing is the same model with more detectors than dyes; it magnifies the spread already present in the data when signatures are similar, as compensation does when two dyes spill heavily into each other, and depends just as much on its controls.
11 — Controls

Where a positive signal begins.

+ The questionEvery cell gives some light in every detector, stained or not. Which comparison decides that a cell carries a marker, and why do some widely used controls answer the wrong question?

Positive is a comparison, not a value

In 1998 an editorial on counting lymphocytes and CD34-positive cells carried the subtitle "time to let go!" Its target was the isotype control, then in widespread use in clinical cytometry: an antibody made to bind nothing on the cells, so that its signal stands for the test antibody's nonspecific binding.

No detector reads zero for an unlabeled cell. Cells glow faintly by themselves, which is called autofluorescence. The glow comes from flavins, small molecules made from vitamin B2, and from other molecules inside the cells. Light from the panel's other dyes spills into the detector and leaves its spread behind after compensation (Chapter 10). Antibodies also stick weakly where their target is absent: to Fc receptors on some white cells, to dead cells, and to other cells through simple stickiness (Chapter 5). The authors of a 2009 review grouped these sources of background into three kinds: autofluorescence, spectral overlap and undesirable antibody binding.

A cell is therefore never positive in an absolute sense. It is positive when its signal in one detector is higher than that of comparable cells that differ only in lacking the specific binding being tested. A control is the sample, or the population within a sample, that supplies that comparison. Each kind of control leaves out a different source of background, so the choice of control decides what the boundary between positive and negative actually measures.

29 — What a detector reads for a stained cell
ONE DETECTOR autofluorescence spillover spreading nonspecific binding specific signal STAINED CELL UNSTAINED autofluorescence only FMO + spillover spreading ISOTYPE another antibody's binding, no spread INTERNAL NEGATIVE same tube: all but specific binding, if cells are alike schematic; layer sizes illustrative
ParticlesFluorescenceReadoutFocal detail
Plate 29 — A detector's reading for a stained cell stacks autofluorescence, spillover spreading, nonspecific binding and the specific signal. Each control removes different layers, so the choice of control decides what the positive boundary measures.

The boundary matters most where a marker is dim. A bright marker separates from its negatives on almost any reasonable control. A dim one lies within a few multiples of the background, and moving the boundary by the width of the negative population can change the fraction of positive cells severalfold. Leukemic cells, whose markers are often abnormally dim, have to be read in that region, and so do vesicles, whose labels sit close to the background (Chapter 5).

The unstained cell is the wrong reference

The simplest control is a sample of the same cells with no stain at all. It measures autofluorescence and nothing else. In the 2001 review of Chapter 10, Mario Roederer explained why that is not enough for a multicolor panel. He wrote that on compensated data "any gate based on a completely unstained sample" would give wrong results, because at high intensities the negatives spread upward into the positive region. An unstained sample has no spillover, so it has no spillover spreading, and a boundary set on it is too low for the stained tube.

The same review gave the alternative a name. A fluorescence-minus-one control, or FMO, contains every antibody of the panel except the one whose positive boundary is being set. It carries all the spillover into that detector, with all its spread, and none of the specific signal. One manufacturer's staff wrote the 2006 guideline of Chapter 10. The guideline defined the FMO as a sample with all the conjugates "except one" and noted its limit: an FMO does not measure the background binding of the missing antibody itself, because that antibody is absent.

A boundary set on the wrong control

Suppose 99 % of unstained cells fall below 300 in the phycoerythrin detector, and a boundary is set there. In the FMO tube, where the other dyes are present but phycoerythrin is not, spillover spreading pushes the upper edge of the negatives higher, and 8 % of cells now lie above 300. Those cells carry no phycoerythrin, so in the fully stained tube the same 8 % appear positive for a marker they lack. A boundary set on the FMO at 1,200, below which 99 % of its cells fall, leaves only 1 % of the FMO's cells above it. The values are illustrative, chosen for this guide.

30 — A boundary set on the wrong control
UNSTAINED FMO FULL STAIN 0 300 1,200 10⁴ 10⁵ PE, LOG-LIKE DISPLAY illustrative values boundary on unstained: 99 % below boundary on FMO: 99 % below 8 % above 300: cells that carry no PE, called positive
ReadoutFocal detail
Plate 30 — A boundary set on unstained cells is too low for a stained tube: here 8 % of cells that carry no phycoerythrin lie above it because of spillover spreading. A boundary set on the fluorescence-minus-one control leaves only 1 % of such cells above it.

FMO controls are needed most for dim markers, for markers whose level varies continuously from cell to cell, and for detectors that receive heavy spread. They are needed least where positive and negative cells form clearly separated groups, which is why laboratories choose them channel by channel rather than for every marker of every panel.

Why isotype controls usually fail

Antibodies come in structural classes and subclasses, which differ in the part of the molecule that does not bind the target; an antibody's class and subclass are its isotype. An isotype control is an antibody of the same class and subclass as the test antibody, carrying the same dye, but made to bind a target that the cells do not have. The idea is that it binds nonspecifically as the test antibody does, so its signal shows how much of the test signal is background. The 2006 guideline stated the intent: such controls "are meant to account for nonspecific staining" of a given isotype conjugated to a given dye.

In practice the match is poor. Two antibodies of the same subclass differ in structure, in the number of dye molecules attached and in how they were purified, and each conjugate has its own background. The authors of the 1998 editorial reported that isotype controls do not stain the same number of events as the test antibody stains nonspecifically, and they argued that the widespread use of isotype controls should be questioned. The 2006 guideline added that, on their own, isotype controls "do not account for fluorescence spillover from other channels."

The evidence against isotype controls is a guideline and an editorial with observations, not a controlled study, and some reagent suppliers still recommend isotype controls from the same supplier. Their remaining use is narrow. The 2006 guideline describes one case: an isotype control in the channel of interest, together with all the panel's other antibodies. That combination takes care of spillover but still does not match the test antibody's own background, and it does not set a positive boundary by itself.

A percentage positive depends on the boundary

A result such as "12 % CD38-positive" is a property of the cells, the reagent and the boundary together. If the boundary was set on an unstained or isotype sample, the figure includes spillover spreading and nonspecific binding of unknown size. Without the control named, a percentage of dim positive cells cannot be compared with another laboratory's.

Biology often gives the best negative

The most faithful control is often inside the tube. Some cells in the same sample belong to a type known not to carry the marker, and they have experienced the same staining, the same spillover, the same antibody and the same instrument settings. T cells do not carry CD19, the B-cell protein of Chapter 5, so in a tube that stains B cells for CD19 the T cells give the negative directly. The 2006 guideline made the same point for stimulation assays, which measure how cells respond to a deliberate stimulus. In such an assay, the unstimulated sample "usually provides the best means" of telling positive from negative.

Clinical immunophenotyping reads markers this way. ICSH and ICCS are international bodies for standardization in hematology and for clinical cytometry, and their 2013 recommendations describe abnormal intensity, bright or dim, relative to the normal counterpart of the abnormal cells. The 2018 international guidelines for chronic lymphocytic leukemia describe three markers as characteristically dim compared with normal B cells: surface immunoglobulin, the antibody that a B cell carries on its own surface, and the proteins CD20 and CD79b. That judgment is easiest when normal B cells are present in the same sample. Chapter 21 shows how a report states such patterns. Dead cells, which bind many antibodies nonspecifically, are excluded beforehand with a viability dye (Chapter 12).

For vesicles, the first question is whether an event is a vesicle at all, and the controls change accordingly. The reporting framework for vesicle cytometry lists controls for this question. Buffer is the salt solution, held at a steady pH, in which the sample is diluted. The controls include buffer alone and buffer with the labeling reagents, because antibodies and dyes form small aggregates that cross the threshold like particles. They also include a detergent step that dissolves membranes, so that events which survive it cannot be vesicles. Chapter 20 takes these controls further.

Titration sets how far positive sits from negative

How much antibody to add is itself a control on the boundary. Too little leaves binding sites empty, so positive cells are dim and their brightness depends on how many cells are in the tube. Too much raises nonspecific binding, so the negatives brighten and spread. Between the two lies an amount at which positives are well separated from negatives, and titration finds that amount by staining the same cells with a series of antibody amounts and measuring the separation at each.

31 — Titration chooses separation, not brightness
10² 10³ 10⁴ 0 50 100 150 MEDIAN FLUORESCENCE (LOG) STAIN INDEX 1/32 1/16 1/8 1/4 1/2 1 2 ANTIBODY AMOUNT, × A REFERENCE (DOUBLING STEPS) POSITIVE MEDIAN STAIN INDEX, RIGHT AXIS NEGATIVE MEDIAN too little: dim, depends on cell number too much: negatives brighten best separation schematic
ReadoutFocal detail
Plate 31 — As antibody is added, positive cells brighten and plateau while negatives brighten at high amounts. The stain index peaks before the brightest staining, and that amount is the one to use.

The measure of separation is the stain index of Chapter 5, which rewards a narrow negative population as much as a bright positive one. The best concentration is therefore not always the one that makes positive cells brightest. A titration holds only for the reagent lot, cell type, staining volume and instrument it was done on. The spectral guideline of Chapter 10 advised that new lots of tandem dyes be titrated again, and a manufacturer's staff were among that guideline's authors.

Name the control for every boundary

In an assay specification, state for each marker which control sets its positive boundary, with acceptance limits for that control. The control may be an FMO, an internal negative population, an unstimulated sample or, for bright and well-separated markers, the stained tube itself. Record titration data for each reagent and repeat it after a change of lot, staining volume or cell type. For vesicles, include buffer-only, reagent-only and detergent controls in every run.

+ What this chapter established
  • Background comes from autofluorescence, spillover spreading and nonspecific binding, so a positive signal is always a comparison with a control.
  • An unstained sample sets the boundary too low for a stained tube; a fluorescence-minus-one control includes the spillover spreading and so accounts for it, though not for the missing antibody's own background.
  • Isotype controls rarely match the test antibody's background and do not account for spillover; cells known to lack the marker, in the same tube, are often the best negative.
  • Titration chooses the antibody amount that maximizes separation, not brightness, and must be repeated for new lots, especially of tandems.
12 — Gating

How a population is drawn from a cloud of events.

+ The questionA file holds a million events and a report gives a handful of percentages. Who draws the boundaries between them, how much does the display decide, and how many events make a result?

A gate is a decision about a cloud

After compensation, each event is a point in a space with one axis for every detector and pulse measurement. Cells of one kind form a cloud in that space, because they carry similar amounts of each marker and scatter light similarly, and the job of analysis is to say which events belong to which cloud. The traditional tool is the gate: a boundary drawn on a plot of two parameters, which keeps the events inside it and passes them to the next plot.

A sequence of gates is called a gating hierarchy. A typical analysis first plots time against a scatter or fluorescence signal and removes stretches where the flow was disturbed; a 2021 set of guidelines describes removing "possible clogs" this way. The analysis then removes doublets with a plot of area against height (Chapter 9). Next it removes dead cells with a viability dye and selects a lineage, a major family of related cell types such as T cells, before dividing that lineage into subsets. Every percentage in a report is a fraction of some parent gate, so "8 % of CD4 T cells" and "8 % of lymphocytes" describe very different numbers of cells.

32 — A gating hierarchy
SSC TIME clog removed FSC-A FSC-H VIABILITY CD45 SSC CD3 CD8 CD4 STABLE FLOW % of parent SINGLETS % of parent LIVE LEUKOCYTES % of parent T CELLS % of parent CD4, CD8 SUBSETS % of parent 8 % of CD4 T cells ≠ 8 % of lymphocytes schematic
ReadoutFocal detail
Plate 32 — Gates are applied in sequence, from stable flow and single cells through live cells and a lineage to subsets. Every reported percentage is a fraction of a parent gate, so the denominator must be stated.

The early gates are not formalities. As Chapter 9 showed, the doublet gate works only for particles comparable to or larger than the height of the beam, and the sorting guide of Chapter 6 names bacteria, yeast and platelets as exceptions. Vesicles are all far smaller than the beam, so for them the doublet gate is unavailable, and the problem it solves for cells reappears as the swarm detection of Chapter 19.

The display can move the boundary

A gate is drawn on a picture, and the picture depends on how the axis is scaled. Compensated data contain values near zero and below it, which a logarithmic axis cannot show (Chapter 10). Chapter 9 quoted the 2006 paper on the log artifact: the false peak and the pile-up of events at the baseline that log displays produce. The same paper described how log displays make compact populations look split in two. The paper's remedy is the logicle transform: a function that maps each value to a position on the axis, linear around zero and logarithmic at high values, with a parameter that sets the width of the linear region. Many analysis packages use the arcsinh transform, and so does mass cytometry, which tags antibodies with metal atoms instead of dyes and detects the metals by their mass (Chapter 24). The arcsinh transform has the same shape as the logicle, linear near zero and logarithmic at high values. Its parameter, called the cofactor, sets roughly where the linear region ends, in the data's own units, and is conventionally 150 for fluorescence and 5 for mass cytometry.

One file, two displays, two answers

For the material behind this guide, one exercise used a public data set of stained control blood cells that is distributed with open-source analysis software. A single file of 61,832 events was displayed with two logicle transforms that differed only in the width of the linear region. A gate was placed at the same position on the screen in each. Above it lay 2.413 % of events in one display and 0.996 % in the other: a 2.4-fold difference in a reported percentage, with no change to a single measurement. The figures come from one file; the size of the effect depends on where a population sits relative to zero.

33 — One file, two displays, two answers
NARROW LINEAR REGION 0 10² 10³ 10⁴ 10⁵ 2.413 % ABOVE WIDE LINEAR REGION 0 10³ 10⁴ 10⁵ 0.996 % ABOVE × 50 gate at the same screen position 1 10² 10⁴ log display: pileup at the baseline 2.4-fold, with no change in the data schematic histograms; percentages from one public file of stained control cells, 61,832 events
ReadoutFocal detail
Plate 33 — The transform does not change the data, but it moves where a boundary drawn on screen falls. In one file of 61,832 events, a gate at the same screen position caught 2.413 % on one display and 0.996 % on the other.

The transform does not change the data, but it changes where a person's eye places a boundary. A boundary placed in display coordinates therefore moves with the display. In a 2010 study, transforms with parameters fitted to the data reduced the misclassification of events compared with default settings. The transform and its parameters are therefore part of the analysis and must be recorded with it, as MIFlowCyt asks.

A gate drawn on screen moves with the display, the transform and the scale

A gate set by eye on one display, at one transform setting, on one instrument's scale moves when any of the three changes. Copying a gate template from one file to another without checking that the populations sit in the same place can cut through a population or include part of its neighbor. The error then appears in the report as a change in biology.

People gate differently

Manual gating is skilled judgment, and judgments differ. Staff of one manufacturer led a 2005 study that sent the same samples to many laboratories, and the manufacturer also supplied the reagents. For a measurement of responding T cells, the coefficients of variation between laboratories ranged from 17 to 44 %, and the authors concluded that analysis, "particularly gating," is a significant source of variability. Analyzing all the files centrally reduced the inter-laboratory variation by 5 to 20 %. The variation depended on how rare the population was: 18 to 24 % for samples with more than 0.5 % of cells responding, and 57 to 82 % for samples with fewer than 0.1 %.

Standardized panels and central analysis narrow the spread. A 2016 study used five standardized eight-color panels across nine laboratories, and one manufacturer's staff were among its authors. The study's authors found variation below 10 % across sites for large, easily identified subsets such as CD4 T cells, and higher variation for dim subsets and for those reached through many gates. Software itself is a variable as well. In the exercise described in the note on displays, two programs were given the same workspace, a saved analysis with its gates already drawn. They gave different counts for 44 of 48 combinations of population and sample, by up to 3.8 %, for a reason not yet traced.

Algorithms, clusters and maps

Automated methods replace hand-drawn boundaries with rules applied identically to every file. In a 2013 community benchmark, 14 groups submitted 36 sets of results. Many algorithms agreed with expert gating at a level the organizers judged sufficient for reliable use, and combining several algorithms scored better than any single one. In the benchmark's sample-classification part, 12 submissions classified all 359 samples of an acute myeloid leukemia data set correctly; half of the samples had been supplied with their known classes for training. The authors of the 2016 nine-laboratory study found that automated gating matched central manual analysis "for all tested panels." Benchmarks of this kind score algorithms against expert manual gates, so they measure agreement with people rather than truth.

Clustering goes further and groups events without predefined gates. The authors of a 2016 comparison of 18 clustering methods found one of them, FlowSOM, best or near best on every data set, and given its speed they recommended it as a first choice. Clusters are often shown on two-dimensional maps made by the methods called t-SNE and UMAP, which place similar events near one another. Such maps distort. A 2019 analysis found that the relative position of clusters on a t-SNE plot is "almost arbitrary" and depends mostly on random initialization, the random layout from which the method starts. A 2023 study showed that reducing many dimensions to two inevitably distorts distances. Both studies come from single-cell genomics, and the point carries over by analogy: a map shows which events are similar, not how far apart populations are.

What n is

A tube may contain a million events, but they come from one sample of one donor, processed once. The events measure that sample precisely, but they cannot show how a second donor, or a second preparation from the same donor, would differ. Treating events as independent replicates is called pseudoreplication. A 1984 paper defined it as using statistics to test for effects when the replicates are not independent, and the same paper reported it in about a quarter of 176 ecological studies. In cytometry the replicate is the donor, the patient or the independent preparation, and the events within a tube decide only how precisely each sample's frequency is known.

That within-tube precision follows the counting statistics of Chapter 8, applied to events rather than photoelectrons. What matters is the number of events in the population of interest, not the total.

How many events a rare population needs

A frequency estimated from r events of interest has a counting spread of about 1 ÷ √r. One hundred events give about 10 %, four hundred about 5 %. For a population at 1 in 10,000 cells, collecting 100 of them takes 1,000,000 events; at 1 in 100,000, it takes 10,000,000. That is why tests for residual disease, which look for the few abnormal cells left after treatment, acquire millions of cells per sample (Chapter 22). The arithmetic is derived for this guide and assumes events arrive independently.

34 — How many events a rare population needs
0 10 % 20 % 30 % 10 100 1,000 10,000 COUNTING SPREAD EVENTS IN THE POPULATION (LOG) 32 % 5 % 1 % 1 ÷ √r 10 % count the population, not the total TOTAL EVENTS TO COLLECT 100 OF THE POPULATION 1 in 10,000 → 1,000,000 events 1 in 100,000 → 10,000,000 events derived; events assumed independent
ReadoutFocal detail
Plate 34 — A frequency estimated from r events has a counting spread of about 1 ÷ √r: 100 events give 10 %. Collecting 100 events of a population at one in 10,000 takes a million events; at one in 100,000, ten million.

The 2005 study's figures make the same point from the other side: the rarest populations were the least reproducible between laboratories. Raw intensities are no easier to compare between instruments than the percentages of rare populations are between laboratories. In the 2024 study of Chapter 5, scientists at the US National Institute of Standards and Technology found that the raw fluorescence intensities of the same cells varied widely between four instruments, while values converted to antibodies bound per cell agreed closely. That contrast is the case for calibration made in Chapter 17.

Write the analysis down as a specification

For an assay, document the gating hierarchy with example plots, and name the control that sets each boundary (Chapter 11). Record the transform and its parameters, the minimum number of events in the reported population, and the software and its version. Validate the software as part of the assay, and treat a change of template, transform or version as a change to be verified. In a study design, count donors or independent preparations as n, never events.

+ What this chapter established
  • Gates select events in sequence, from time and doublets through viability and lineage to subsets, and every percentage is a fraction of a parent gate.
  • The transform changes how populations look and where a boundary drawn by eye falls: one file gave 2.413 % or 0.996 % with no change in the data.
  • Gating is a major source of variation between laboratories; standardized panels, central analysis and automated gating reduce it, measured against expert gates.
  • Events are not replicates: n is the number of donors or preparations, and a rare population's precision depends on how many of its own events were counted, and 100 events give a counting spread of about 10 %.

+ Part V · The cytometer as a system

Engineering the whole.

One core facility found a laser delay set two microseconds wrong. A population that should have been almost entirely positive for two markers read 89.4 % double-positive; after the correction it read 97.6 %. No single part had failed: the error lay in how two of them were timed against each other. Chapters 13 to 18 put the instrument back together as a systems engineer would. They show where the parts meet and fail, how two architectures compare in a trade study, how a stated need becomes a verifiable specification, how an instrument is kept stable and made to agree with others, how its scales are tied to physical units, and what the data file keeps. Together they give the engineering half of the answer to when a count can be trusted.

13 — Interfaces

Where the parts of a cytometer meet.

+ The questionWhy do so many of a cytometer's failures happen between its parts rather than inside them, and what does each one look like in the data?

No part knows what a cell is

Drawn as a block diagram, a flow cytometer is a chain of subsystems, each with a single job. Sample handling delivers a suspension of the right concentration, free of clumps, at a steady rate. The fluidics of Chapter 6 bring each particle to the same point of the beam. The excitation optics of Chapter 7 deliver light of known color, power and shape to that point, at the right place along the stream. The collection optics and detectors of Chapter 8 turn the light that comes back into currents, and the electronics of Chapter 9 turn currents into numbers. Software applies compensation, transforms and gates, and it writes the file.

None of these parts knows anything about cells. The fluidics move water, and the detectors count photons. How the parts work together decides whether the instrument reports the right fraction of leukemic blasts, the immature cancerous cells of leukemia. The most consequential engineering decisions therefore concern the boundaries between the parts.

35 — The cytometer as a system
SAMPLE HANDLING FLUIDICS EXCITATION OPTICS COLLECTION OPTICS DETECTORS ELECTRONICS SOFTWARE & FILE suspension, concentration stream speed, core position beam position, power interrogation point photons currents samples, events compensated, gated data the laser delay belongs to one side and depends on the other stream speed → laser delay DAILY BEADS back to settings: voltages, delays no part of the instrument knows what a cell is
ParticlesFluidExcitation lightFluorescenceScattered lightReadoutFocal detail
Plate 35 — No part of a cytometer knows what a cell is. Results emerge from how sample handling, fluidics, optics, detectors, electronics and software work together, and the most consequential engineering lives at the interfaces between them.

The cytometry community has published a decomposition of the instrument, though not for design. The reporting standard MIFlowCyt groups the details an experiment must report by subsystem: the flow cell and fluidics, the light sources, the excitation optics, the filters, the detectors and the optical paths, with a final item for "other relevant instrument details" such as agitation and temperature control. The standard's preamble states that the system and its configurations "have significant impact on experimental results." This guide found no peer-reviewed treatment that describes a cytometer in systems-engineering terms, with an architecture, interface definitions and a failure analysis. The closest published decomposition is a list of what to report.

The interfaces that are clocks

Several of the most important interfaces in a cytometer are timings. The speed of the stream, the height of the beam and the size of the particle set the duration of a pulse (Chapter 9). The distance between beams and the speed of the stream set the laser delay (Chapter 7). The processing window decides how close two particles can pass before one is aborted (Chapter 6). The converter's sampling rate decides how many samples describe each pulse, and in a sorter the drop delay decides which droplet carries a chosen cell (Chapter 24).

Several of these clocks belong to one subsystem and depend on another: the stream speed belongs to the fluidics, but the laser delay that depends on it belongs to the electronics. A change on one side of that boundary that is not matched on the other produces an error that no single subsystem detects.

A small change in speed, a large change in timing

Every delay between beams is a distance divided by a speed. If the stream slows by 5 %, because the sheath pressure dropped or the sheath filter began to clog, every delay grows by about 5 % (1 ÷ 0.95). A delay of 40 microseconds becomes about 42. That error of about 2 microseconds is the size of the error that turned 97.6 % double-positive cells into 89.4 % in Chapter 7. The figures are illustrative and derived for this guide; real delays and speeds are properties of each instrument.

36 — The interfaces that are clocks
NOMINAL converter samples pulse ≈ 5 µs laser delay 40 µs processing window STREAM 5 % SLOWER illustrative delays +2 µs from a 5 % change in speed +4 µs the window misses part of the pulse 0 10 20 30 40 50 60 70 80 90 µs
ReadoutFocal detail
Plate 36 — Every delay between beams is a distance divided by a speed. If the stream slows by 5 %, a 40-microsecond delay becomes 42, an error the size of the one that turned 97.6 % into 89.4 % in Chapter 7.

These timings are set when data are acquired. The standard data file has nowhere to keep most of them. FCS 3.1, the version this guide describes (Chapter 18), has keywords for each detector's voltage, gain and filter, for the excitation wavelength and power, for the trigger and for the spillover matrix. It has none for sheath pressure, laser delay, processing window, drop delay, baseline restoration or detector temperature.

Failures live at the boundaries

Many failures of a cytometer in use can be traced to one interface. Like the failures inside a single part, each leaves its own signature in the data. At the boundary between sample preparation and fluidics, a partial clog appears as steps in event rate and signal over time. Between fluidics and data, a surge of flow or a bubble appears as a shift in the median signal for a few seconds. Between fluidics and optics, a core widened by a high sample flow rate appears as broader populations (Chapter 6). Between fluidics and electronics, a wrong or drifting laser delay appears as lower values on the downstream lasers only.

On the optical side, a laser that has drifted in alignment or power appears as a wider and dimmer bead peak in daily quality control. The width of a peak is measured as its coefficient of variation (Chapter 6). The EuroFlow consortium of Chapter 10 requires the coefficient of variation of the brightest bead peak to stay below 4 % on the blue and violet channels and below 6 % on the red channels and the PE–cyanine 7 channel (Chapter 16).

A filter whose coating has aged appears as a slow loss of detection efficiency in one color band. A defective detector appears as low Q and high B on one channel, and the 2018 study of Chapter 8, which tested 23 instruments, found channels in need of service this way. The study's authors included staff of a cytometer manufacturer and of an analysis-software company. In the electronics, the baseline is the signal level between pulses, which is measured and subtracted from each pulse. One manufacturer's patent describes how the circuit that restores the baseline can add a constant bias and distort pulses. A bias of that kind shifts every dim value. As the event rate rises, pulses overlap more often, and counts fall short of the true number.

37 — Failures live at the boundaries
FAILURE INTERFACE SIGNATURE IN DATA CHECK partial clog sample ↔ fluidics steps in rate and signal over time time plot flow surge, bubble fluidics ↔ data median shifts for seconds time plot wide core fluidics ↔ optics broader populations at high rate fixed rate, bead CV laser delay drift fluidics ↔ electronics lower values on downstream lasers daily beads laser drift optics ↔ QC wider, dimmer bead peak daily beads filter aging optics over time slow loss of Q in one band Q and B trend defective detector detector ↔ QC low Q, high B on one channel Q and B baseline bias detector ↔ electronics dim values shifted linearity at low end pulse overlap rate ↔ electronics counts fall short at high rate dilution series looks like biology, not like an error
FluidExcitation lightFluorescenceReadoutFocal detail
Plate 37 — Many failures of a cytometer in use sit at one interface and leave a recognizable signature in the data. Each signature points to a routine check: a time plot, daily beads or a dilution series.

Each signature in this list points to a test, which is what makes the list useful. A failure that shows up in event rate over time is checked by plotting signals against time, one that shows up in bead peaks by daily quality control, and one that shows up only at high rates by running a dilution series.

A failure at an interface looks like biology

A drifting laser delay lowers the fraction of double-positive cells. A partial clog dims or shifts signals for part of the run, and overlapping pulses at high rate inflate apparent doublets and brighten populations. None of these failures produces an error message. The data look like a plausible sample with a different composition, so interface checks must be part of every run rather than a response to suspicious results.

Time is a measurement too

A cytometry file can record when each event occurred, in a time parameter that FCS 3.1 names but does not require. Where it is recorded, the time parameter is the simplest tool for finding interface failures. A plot of time against a scatter or fluorescence signal shows clogs, bubbles and drifts as steps, gaps and slopes in what should be a steady band. The 2021 guidelines for cytometry in immunology describe removing possible clogs this way. The analysis package flowAI automates the check. It was released in 2016, and it looks for surges in flow rate, shifts in median signal and events piled at the limits of the scale.

The time plot also matters for extracellular vesicles, the guide's hard measurement. When particles are far smaller than the beam, a count that rises or falls during a run can mean that the sample is settling or sticking to the tubing, not that the particles changed. Chapter 19 adds the dilution series as the check that each event is one particle: the series tests whether counts fall in proportion to dilution.

Sample preparation is part of the instrument

Most failures at the first interface begin before the sample reaches the instrument. Clumped cells block the flow cell and form doublets, and dead cells release DNA, which makes cells stick together. The sorting guide of Chapter 6 recommends filtering through a 30-micrometer mesh "at each step" and adding DNase and EDTA to reduce clumping. DNase is an enzyme that breaks down DNA, and EDTA binds the calcium and magnesium that cells need to stick to one another. The age of a blood sample and its anticoagulant change some markers more than others, and the clinical recommendations of Chapter 22 turn these effects into stability limits.

The EuroFlow consortium standardized sample preparation together with the instrument settings for this reason. A lysing reagent bursts the red cells in a blood sample so that the white cells can be measured. The consortium's protocol fixes the lysing reagent, the volume of blood per tube and the stain–lyse–wash sequence, because instrument settings agreed to the last volt would not make results agree if each laboratory prepared its samples differently.

Write the interface list for the instrument and the assay

Write down every boundary between subsystems: the quantity that crosses it, its units and limits, and the owner on each side. For a cytometer the list includes sample concentration and filtering, sheath pressure and stream speed, beam spacing and laser delays, processing window, trigger and threshold, detector voltages, compensation matrix, transform and gating template, and software version. For each boundary, name the check that detects a failure, such as a time plot, daily beads or a dilution series. Record the settings that the file cannot hold.

+ What this chapter established
  • A cytometer is sample handling, fluidics, excitation, collection, detection, electronics and software; none knows what a cell is, and results emerge from how they work together.
  • Several key interfaces are clocks, such as pulse duration, laser delay, processing window and drop delay; a 5 % change in stream speed shifts a 40-microsecond delay by about 2 microseconds.
  • Each interface failure leaves a signature in the data, from steps over time to wider bead peaks, and most look like biology rather than like errors.
  • Sample preparation is part of the system; EuroFlow standardized preparation together with instrument settings so that results would agree between laboratories.
14 — Architectures

One detector per dye, or the whole spectrum.

+ The questionA conventional cytometer gives each dye its own detector behind its own filter, while a spectral one spreads every particle's light across dozens of detectors. What does each architecture buy, what does it cost, and when is the older design the right one?

Two ways to divide the light

In 1979 a group at the University of Texas and the Lawrence Berkeley Laboratory passed the light from cells in a flow cytometer through a grating, a finely ruled surface that spreads light by wavelength. The grating cast the spectrum onto a vidicon, a television-type detector with 500 channels, and the group reported what it called the first complete emission spectra of cells in flow.

A conventional cytometer divides the collected light with a cascade of dichroic mirrors and gives each dye a detector behind a bandpass filter chosen to pass its peak (Chapter 8). The number of detectors roughly equals the number of dyes, and the overlap between the dyes is corrected by compensation with a square spillover matrix (Chapter 10). The FCS file stores that matrix as a single keyword. Each value in it is the ratio of a dye's signal in another detector to its signal in its own.

A full-spectrum cytometer instead spreads the light from each laser over many detectors, with a prism, a grating or a long cascade of narrow filters, and it records the whole shape of each particle's emission. Each dye is identified by its signature across all the detectors, and the amounts are found by unmixing (Chapter 10). Manufacturers state 48 fluorescence channels on one instrument, 64 on another and up to 186 detectors on a third. After the 1979 vidicon instrument, a 32-channel instrument was described in 2012, and the first commercial spectral cytometer was launched by its maker in 2013 (Chapter 2).

38 — Two ways to divide the light
same fluidics, lasers and collection CONVENTIONAL one detector per dye → square matrix, compensation dichroic filter detector SPECTRAL prism or grating detector array the colors separated in arithmetic many detectors → signature per dye → unmixing schematic
ParticlesFluorescenceFocal detail
Plate 38 — A conventional cytometer separates dyes in hardware, one detector per dye behind its filter; a spectral one spreads the light across many detectors and separates dyes in arithmetic. Everything upstream of the collection lens is the same.

The two designs share everything upstream of the collection optics: the same fluidics, lasers and beams, and the same physics of detection. They differ in how the colors are separated, in hardware or in arithmetic. That difference decides what each design is good at.

What the whole spectrum buys

The first gain is the number of dyes. Two dyes whose emission peaks are too close to be split by filters can still differ in the shape of their spectra, or in how strongly each laser excites them, and a spectral instrument can tell them apart by the whole pattern. Authors mostly from one manufacturer published the forty-color panel of Chapter 2 in 2020. An engineer at one manufacturer led the 2026 study of Chapter 10, which noted that measurements of fifty fluorescent analytes at once had been reported. Changing a panel also needs no change of filters, because the detectors record the whole spectrum whatever dyes the panel uses.

The second gain is in handling autofluorescence, the faint glow of cells themselves (Chapter 11). A conventional instrument sees it only as background in each detector. A spectral instrument can record its signature and treat it as one more component to unmix, which removes it from the other dyes. Because different cell types glow differently, the instrument can even use autofluorescence as a parameter. A 2026 study of liver cells showed both the gain and its conditions: several autofluorescence signatures pooled across conditions worked, while a single default signature silently underestimated the number of macrophages, the immune cells that engulf debris and microbes.

What it costs

The cost is paid in spread and in controls. Chapter 10 showed that unmixing magnifies the spread already in the data when two signatures are similar, because small fluctuations in the readings can be assigned to either dye. The similarity of two signatures can be measured as a number between 0, for signatures with no overlap, and 1, for identical ones. The closer it is to 1, the more noise unmixing amplifies.

How similarity amplifies noise

Take the simplest case: two dyes, measured in detectors that all carry equal, independent noise. Let s be the cosine similarity of their signatures, 0 for no overlap and 1 for the same shape. Compared with two signatures that do not overlap, least-squares unmixing multiplies the spread of each dye's estimated amount by 1 ÷ √(1 − s²). At a similarity of 0.5 the factor is about 1.15; at 0.9 it is about 2.3, and at 0.98 about 5. A pair of dyes that looks acceptably distinct on a spectrum plot can still multiply the spread fivefold. The arithmetic is derived for this guide; real instruments have unequal noise between detectors, and real panels have more than two dyes.

39 — How similarity amplifies noise
SIMILARITY 0.5 dye 1 dye 2 SIMILARITY 0.98 the same 16 detectors 1 2 3 4 5 6 0.0 0.2 0.4 0.6 0.8 1.0 SPREAD MULTIPLIER SIMILARITY s 1 ÷ √(1 − s²) 1.15 at 0.5 2.3 at 0.9 ≈ 5 at 0.98 a pair that looks distinct can spread fivefold derived: two dyes, equal noise in every detector
FluorescenceReadoutFocal detail
Plate 39 — When two dyes' signatures are similar, unmixing cannot tell their light apart and multiplies the spread of each estimate by 1 ÷ √(1 − s²): about 1.15 at a similarity of 0.5, 2.3 at 0.9 and 5 at 0.98.

Pairs are not the whole story. The 2026 study of Chapter 10 measured unmixing-dependent spreading on four spectral instruments and found that the similarity of pairs predicts it only loosely, because spread can come from combinations of three or more dyes. Its authors proposed a matrix that shows where in a panel the spread concentrates. The cosine similarity of the note above has a standard formula, but the similarity indices that instrument software reports have no peer-reviewed formula (Chapter 10), and the only explicit formulas this guide found are in a patent assigned to one manufacturer.

The second cost is the reference library. Every signature used for unmixing comes from a single-stain control, as every spillover value does in compensation, but a spectral panel of thirty dyes needs thirty controls, plus unstained cells for each tissue, and each control must meet the rules of Chapter 10. One clinical review described unmixing as dependent on "rigorously maintained" single-color and autofluorescence controls. That review was not peer-reviewed.

The third cost is dependence on the algorithm. Plain least squares, least squares weighted by each detector's noise, and models built on photon-counting statistics can give different results from the same raw data. The algorithm is part of the instrument's software, and the user does not always see the choice.

When the conventional design is right

The trade study does not always favor more detectors. A panel small enough that filters separate its dyes cleanly gains nothing from unmixing, and it avoids the magnified spread of similar, or collinear, signatures. The same clinical review stated that a laboratory with panels already validated on conventional instruments, a stable high-throughput workflow or no capacity for expanded training or software infrastructure may see no net benefit.

Standardization across laboratories is the strongest case for the conventional design. The EuroFlow consortium built its leukemia panels on instruments with three lasers at about 405, 488 and 633 nanometers and with filter configurations identical apart from listed exceptions, and its quality program covered 14 instruments in 11 laboratories (Chapter 16). A spectral instrument could reproduce the panels, but it could not join that system without re-deriving the system's targets and checks. Regulatory status also differs by instrument and country. A 2023 review stated that spectral cytometry had been approved for diagnostic use in China and Europe. In the United States, the clearances found for this guide are for conventional analyzers. A clearance is the US regulator's permission to market a device shown to be substantially equivalent to one already on the market. This guide did not confirm a US clearance of a spectral analyzer as of October 2026 (Chapter 23).

40 — A trade study, not a ranking
CRITERION CONVENTIONAL SPECTRAL dyes per panel limited by filters 40 published (2020), 50 reported panel change new filters may be needed no hardware change autofluorescence background only unmixed as its own signature spread spillover spreading; collinearity only if two dyes overlap heavily spillover + collinearity spread, met far more often controls one per dye one per dye + unstained per tissue, library kept algorithm fixed matrix depends on unmixing method and version cross-lab standardization EuroFlow: identical filters apart from listed exceptions; 14 instruments in 11 labs targets must be re-derived the strongest case for the older design US clearance (Oct 2026) conventional analyzers cleared not confirmed by this guide
Focal detail
Plate 40 — Neither architecture wins every row. Spectral instruments buy more dyes and autofluorescence handling; conventional ones keep small panels free of unmixing spread and fit networks such as EuroFlow and existing clearances.

For vesicles the choice turns on a different question. A particle whose label is equivalent to a few tens of dye molecules can rarely support many colors at once. What matters for such a particle is how dim a signal each channel can see, measured by Q and B (Chapter 8), rather than how many channels the instrument has. Either architecture can be good or poor at seeing dim signals.

A spectral result depends on the reference library used to unmix it

The same raw data unmixed with a different set of reference signatures give different amounts and different spreads, and the 2026 study of Chapter 10 defined unmixing-dependent spreading by exactly that comparison. A changed reference control, a missing autofluorescence signature or an updated algorithm can change a result without any change in the sample or the instrument.

Run a trade study, then specify what each architecture depends on

Compare candidate instruments against the panels they must run: number of dyes, the spread each panel will carry, autofluorescence of the target tissues, control burden, throughput, standardization with existing panels and regulatory status in the target markets. For a spectral instrument, specify the reference library, how often it is renewed, the unmixing algorithm and its version, and a spread check for every panel. For a conventional one, fix the filter configuration and treat any change of it as a change to every assay that uses it.

+ What this chapter established
  • Conventional instruments separate dyes with filters and one detector per dye; spectral instruments record each particle's whole emission and separate dyes by unmixing.
  • The spectrum buys more dyes, panel changes without new filters, and autofluorescence handled as a component of its own.
  • It costs spread when signatures are similar, about fivefold at a similarity of 0.98 for two dyes with equal detector noise, as well as a larger library of reference controls and dependence on the unmixing algorithm.
  • Small validated panels, cross-laboratory standardization such as EuroFlow's and regulatory status can make the conventional design the right choice.
15 — Specification

Turning performance words into numbers.

+ The questionSensitive, precise and linear are words on a datasheet. How does each become a number that can be measured, what does a test of it look like, and which standards set the instrument's electrical safety, laser safety and electromagnetic compatibility?

From a need to a number

A systems engineer starts from what the instrument must do for its user, stated as a need: count blasts at one in ten thousand cells, measure CD4 T cells in blood, detect vesicles of 150 nanometers. Each need is then broken into requirements for the instrument, written so that a test can show whether they are met. A requirement that says "highly sensitive" cannot be tested; one that names a quantity, a value, a method and a condition can.

The performance of a cytometer comes down to a short list of such quantities. Each has a definition and a way of measuring it. On a datasheet, each also has a value claimed by the manufacturer under the manufacturer's own method. The rest of this chapter takes the quantities in turn and then moves to the standards that govern safety rather than performance.

41 — Performance words become numbers
QUANTITY DEFINITION HOW TESTED EXAMPLE CLAIM Q and B photoelectrons per unit of dye; background multilevel beads or calibrated light per channel dimmest signal 4 × (1 ÷ Q + background spread) derived from Q and B ≈ 144 units (Ch. 8) robust CV 100 × 0.7413 × IQR ÷ median named bead 7.4 % (worked) linearity deviation from proportional bead ratios across range ±2 % or R² ≥ 0.995 carryover blank ÷ sample × 100 sample then buffer < 0.01 % to < 1 % event rate maximum rate with coincidence fraction 10,000 to 40,000 /s scatter sensitivity smallest bead from noise polystyrene beads 80 nm bead ≈ 135 nm vesicle a bead size is not a vesicle size example claims are manufacturer figures; ≈ and (worked) values are derived
Focal detail
Plate 41 — Each performance word on a datasheet becomes testable only as a quantity with a value, a method and a condition: Q and B per channel, a robust CV, a linearity deviation over a range, carryover, an event rate with its coincidence fraction.

Sensitivity and precision

Sensitivity is how dim a signal the instrument can separate from nothing. Chapter 8 gave the measurable form: the detection efficiency Q and the background B of each channel, which together set the dimmest resolvable signal. Datasheets more often quote a single figure in molecules of equivalent soluble fluorochrome, a calibrated unit of brightness (Chapter 17). In the 2012 study of Chapter 8, the US National Institute of Standards and Technology and four bead manufacturers assigned values to the same beads, in this unit for some dyes and in a related unit for others. Their values varied by orders of magnitude in most cases. A sensitivity requirement is therefore best written per channel, as Q and B measured by a stated method.

Precision is how narrow a population of identical particles appears. It is measured as a coefficient of variation, or CV, often in a robust form that ignores outliers. One manufacturer's quality-control system defines the robust CV as 100 × 0.7413 × the distance between the 25th and 75th percentiles, divided by the median. The factor 0.7413 converts that distance into the equivalent of a standard deviation for a bell-shaped population. A peak whose quartiles lie at 9,500 and 10,500 around a median of 10,000 has a robust CV of about 7.4 %. For DNA measurements, manufacturers state precision as the CV of nuclei from chicken red blood cells stained with a DNA dye, typically below 3 %.

Linearity, range and carryover

Linearity is the proportionality of the output to the input: twice the light should give twice the number. One quality-control system reports the range over which the deviation stays within ±2 %; another manufacturer claims a fit with R² of at least 0.995 for two dyes. The two are not equivalent. A straight-line fit over five decades can reach a very high R² while the bottom decade, where dim populations lie, deviates by far more than 2 %, so a useful requirement states the permitted deviation and the range over which it holds. The dynamic range is the span from the dimmest to the brightest signal measured within that deviation. It is not the same as the converter's bit depth (Chapter 9).

Carryover is the fraction of one sample that appears in the next. It is measured by running a sample and then particle-free buffer, and dividing the concentration found in the buffer by the concentration in the sample. Manufacturers claim values from below 0.01 % to below 1 % on different instruments. In clinical use the figure matters most when a heavily diseased sample is followed by one being tested for residual disease (Chapter 12).

Carryover meets residual disease

Suppose an instrument carries over 0.1 % of each sample, and a marrow sample in which half the cells are leukemic blasts is followed by a sample tested for residual disease. If the two have similar cell concentrations, the second sample receives blasts amounting to 0.05 % of its cells, five times a residual-disease threshold of 0.01 %. A carryover of 0.01 % would still contribute 0.005 %, half the threshold. The figures are illustrative and derived for this guide. The cure is a low-carryover specification, rinses between samples and a run order that does not place high-burden samples before residual-disease tests.

Throughput is specified as a maximum event rate. Manufacturers state rates from 10,000 events per second with eight parameters on an older analyzer to 35,000 or 40,000 on spectral instruments. A rate is only half a specification: Chapter 6 showed that coincidence rises with rate, so a useful requirement states the abort or coincidence fraction at that rate as well.

Verification is a test with a method

Verification shows that the instrument meets its specification. It is different from the validation of Chapter 22, which shows that an assay run on the instrument serves its clinical or scientific purpose. A 2006 protocol described a three-part program to optimize, calibrate and monitor cytometers for panels of five or more colors. The program used beads with eight levels of brightness, measured over a series of detector voltages. Its 2012 successor stated that the complete process takes 3 to 4 hours, with a subset repeated routinely.

Every verification result carries its method. The same quantity measured with different beads, lots, voltages or software gives different numbers, and a buyer cannot repeat a claim that comes without its method. The trap is sharpest for small particles, because scatter sensitivity is almost always specified with polystyrene beads. One manufacturer states that its instrument separates 80-nanometer polystyrene beads from noise, another states sensitivity to 200-nanometer beads, and a third gives below 200 nanometers. Chapter 4 showed why none of these is a vesicle size.

What a polystyrene bead specification means for vesicles

With the scatter arithmetic of Chapter 4, an 80-nanometer polystyrene bead sends about as much side scatter at 488 nanometers as a vesicle of about 135 nanometers with a refractive index of 1.40. A 100-nanometer bead matches a vesicle of about 175 nanometers, as Chapter 4 showed, and a 200-nanometer bead matches one of about 750 nanometers, because a vesicle's side scatter levels off between about 300 and 600 nanometers and climbs again only above that. The figures are derived for this guide for side scatter collected between 45 and 135 degrees in water. Real instruments collect over different angles, and vesicles vary in refractive index from about 1.37 to 1.45.

42 — What a bead specification means for vesicles
1 10² 10⁴ 10⁶ 50 100 200 500 1,000 SIDE SCATTER, RELATIVE (LOG) DIAMETER, nm 80 → 135 100 → 175 200 → 750 an 80 nm bead spec ≈ a 135 nm vesicle polystyrene, n 1.605 vesicle, n 1.40 derived (Mie), side scatter 45–135°, 488 nm, in water; vesicle index 1.37–1.45 in reality
Scattered lightFocal detail
Plate 42 — Polystyrene scatters far more than a vesicle of the same size. An 80-nanometer bead sends about as much side scatter as a vesicle of about 135 nanometers, a 100-nanometer bead as much as one of about 175, and a 200-nanometer bead as much as one of about 750.

Safety and electromagnetic compatibility

Performance is a matter between maker and buyer; safety is a matter of law. A cytometer sold as a laboratory or diagnostic instrument is designed and tested to international standards, and the editions of those standards change. The standards named here come from the International Electrotechnical Commission, IEC, the body that sets international standards for electrical equipment. The general safety standard for laboratory equipment is IEC 61010-1. As of October 2026 it is in its third edition of 2010, with a first amendment of 2016 and a second close to publication. A particular part, IEC 61010-2-101, covers in vitro diagnostic equipment, which tests samples taken from the body. That part is in its third edition of 2018.

As of October 2026, electromagnetic compatibility is covered by IEC 61326-1, in its third edition of 2020. For diagnostic equipment it is covered by IEC 61326-2-6, whose fourth edition of 18 June 2025 replaced the 2020 edition with changes to test levels and documentation. Lasers have their own standard, IEC 60825-1, in its third edition of 2014. Manufacturers declare enclosed cytometers Class 1 laser products, the least hazardous class, even though the lasers inside deliver tens to hundreds of milliwatts. The class describes what a user can reach with covers and interlocks in place, so servicing an instrument with its covers removed is a different hazard. In the United States, the Food and Drug Administration, FDA, stated in a notice of 8 May 2019 that it does not intend to enforce its own comparable laser rules for manufacturers that comply with the IEC standard's third edition. The FDA reissued that notice on 21 February 2023 with the same position, and as of October 2026 it was still listed as final guidance.

43 — Safety standards by subsystem
FLUIDICS COMPUTER LASER ENCLOSURE POWER & ELECTRONICS Class 1 only with covers on interlock ELECTRICAL SAFETY IEC 61010-1 Ed. 3 (2010) + AMD1:2016; AMD2 near publication DIAGNOSTIC EQUIPMENT IEC 61010-2-101 Ed. 3 (2018), IVD equipment LASER SAFETY IEC 60825-1 Ed. 3 (2014): product Class 1 with covers and interlocks US: FDA Laser Notice 56, 8 May 2019 ELECTROMAGNETIC COMPATIBILITY IEC 61326-1 Ed. 3 (2020) + IEC 61326-2-6 Ed. 4 (18 June 2025) editions as of October 2026
Excitation lightFocal detail
Plate 43 — Safety is a matter of law, not specification: electrical safety under IEC 61010-1 and its diagnostic part, laser safety under IEC 60825-1, and electromagnetic compatibility under IEC 61326-1 and 61326-2-6, each in an edition that changes.
A specification without its test method cannot be verified

A sensitivity figure from one maker's beads, a linearity R² over five decades, a scatter limit in polystyrene and a maximum event rate with no coincidence fraction each describe a test that the buyer cannot repeat or compare. Accepting such figures as requirements moves the risk from the specification to the first assay that fails.

Write each requirement with its value, method and condition

For each performance quantity, write the value, the test method, the reference material and lot, the settings and the acceptance criterion. The list covers Q and B per channel, robust CV of a named bead, linearity deviation over a stated range, carryover with the rinse procedure, event rate with its coincidence fraction, and scatter sensitivity in both bead size and the estimated vesicle size it implies. List the safety, laser and electromagnetic standards by edition, and recheck the editions before each design review.

+ What this chapter established
  • A need becomes a requirement only when it names a quantity, a value, a method and a condition; performance words on a datasheet do not.
  • Sensitivity is best specified per channel as Q and B; precision as a robust CV; linearity as a permitted deviation over a range rather than an R².
  • A carryover of 0.1 % from a sample in which half the cells are blasts would put blasts into the next sample at five times a residual-disease threshold of 0.01 %.
  • Safety rests on IEC 61010-1 and its diagnostic part, laser safety on IEC 60825-1 and electromagnetic compatibility on IEC 61326, with editions that change.
16 — Stability

Keeping one instrument the same, and two alike.

+ The questionA cytometer's lasers age, its filters fade and its detectors drift. How is one instrument kept the same from day to day, and how far can laboratories go toward making different instruments give the same numbers?

Every instrument drifts

A cytometer that met its specification on the day it was installed will not meet it unchanged a year later. Laser output and alignment drift, filter coatings age (Chapter 8), detectors lose efficiency, and the fluidics wear. Each change shifts the numbers a sample produces, and Chapter 13 showed that most shifts look like biology rather than like faults. Stability therefore has to be measured with something that does not change, on every day the instrument is used.

That something is a set of quality-control beads: plastic particles dyed with fixed amounts of fluorescent dye, run before samples to check that each channel reads where it should, with the spread it should have. One manufacturer's system uses beads at three levels, and the manufacturer explains the choice. In its bright beads, counting statistics contribute negligibly to the spread. In its mid beads they contribute a large part, and in its dim beads the background contributes significantly. Spread has three sources: the beads' own variation, the counting statistics of Chapter 8 and the background. Because the three levels expose them separately, a system of this kind can report relative values of Q and B for each channel, along with detector voltages and laser delays.

Each day's results are plotted against time, often on a Levey–Jennings chart with limits drawn around the expected value, so that a slow trend becomes visible before it crosses a limit. This guide found no peer-reviewed data set that follows many instruments over years. The published evidence on drift comes mostly from the daily logs of standardization programs, such as the one described below.

Choosing the detector voltage

Before an instrument can be kept the same, its detector settings have to be chosen. The voltage on a photomultiplier sets its gain. Too low, and dim signals are lost in the electronic noise of the amplifier and converter. Too high, and bright signals run off the top of the scale. Between the two lies a range in which raising the gain no longer improves the spread of a dim population, because counting statistics, not electronics, now dominate.

44 — Choosing the detector voltage
bright beads run off the top 300 400 500 600 700 800 900 999 rCV of the second-dimmest bead peak (schematic) DETECTOR VOLTAGE, STEPS OF 50 electronic noise dominates counting statistics dominate chosen voltage schematic; EuroFlow procedure with eight-peak beads
ReadoutFocal detail
Plate 44 — As gain rises, a dim bead's spread falls out of electronic noise until counting statistics dominate and the curve flattens. EuroFlow chose the voltage at the beginning of that plateau; more gain only loses room at the top of the scale.

The EuroFlow consortium found that range with beads of eight brightness levels. On a reference instrument, the second-dimmest bead population was measured at voltages from 300 to 999 volts in steps of 50 volts, and its robust CV was calculated at each. The chosen voltage was the one "at the beginning of the plateau phase of the curve." Manufacturers' systems use related rules, such as placing a dim bead at ten times the spread of the electronic noise. One core-facility protocol aims for electronic noise to contribute only 10 to 20 % of the measured variance. Above the plateau, extra gain buys nothing at the bottom of the scale and loses room at the top.

Target values make instruments alike

Keeping one instrument stable is not enough when results from many laboratories must mean the same thing. EuroFlow addressed that problem for the leukemia panels of Chapter 21, and in 2012 it described its instrument settings, the product of six years of joint experiments. Its laboratories used instruments with three lasers at about 405, 488 and 633 nanometers and a fixed set of eight dyes. The filter configurations were identical, apart from exceptions that the description lists.

The method turned one instrument's settings into targets for all. After the voltages were chosen on the reference instrument, the brightest bead peak was measured in every channel. Those values became the target values, which every other instrument had to reach by adjusting its own voltages. One master lot of beads was used throughout. Each day, an instrument had to pass two checks: its bead values had to lie within 15 % of target, and the spread of its brightest peak had to be below 4 % on the blue and violet channels and below 6 % on the red channels and the PE–cyanine 7 channel.

45 — Target values make instruments alike
BEFORE A B B reads low AFTER target ±15 % A B bead intensity, log scale brightest-peak CV < 4 % (blue, violet), < 6 % (red, PE-Cy7) beads across 8 instruments: < 5.5 % cells across 11 labs: about 30 % beads test instruments; cells test everything else 0 % 10 % 20 % 30 % EuroFlow 2012 and quality rounds 2010–2013
ParticlesReadoutFocal detail
Plate 45 — EuroFlow set every instrument so that one bead lot read its target values, within ±15 % each day. Bead values then agreed within 5.5 % across eight instruments, while cell intensities across laboratories still varied by about 30 %.

The approach worked on beads. Across the eight instruments of the 2012 evaluation, the variation of the brightest peak's value was "systematically lower than 5.5%." The instruments were not identical, but they had been made to read the same reference material the same way, and that property can be checked every day.

How far standardization reaches

Beads are the easy part. Between 2010 and 2013, EuroFlow ran four annual rounds of quality assessment on 123 blood samples from healthy donors, measured on 14 instruments in 11 laboratories in nine countries with uniform gating. The average median fluorescence in each round ranged from 86 to 125 % of the overall median, and for 7 of 11 markers the variation stayed below 30 %. The authors who reported the rounds described the scheme as a complement to established proficiency tests, not a replacement. In a proficiency test, an outside organizer sends the same samples to many laboratories and compares their results.

A 2019 study transferred the method to 10 clinical laboratories in Switzerland, six with instruments of one manufacturer and four with another's. Over three rounds, the average variation across 11 markers was 30.3 %, 32.9 % and 27.8 %, comparable with EuroFlow's own laboratories. Median fluorescence did not differ significantly between the two makes. By the third round, 89 % of participants had at least nine in ten of their measurements within the acceptance criteria.

Why beads agree within 5.5 % and cells within about 30 %

A bead is the same particle in every laboratory, measured with the same dye, so its value tests only the instrument. A cell population measured in a quality round carries everything else as well: blood from different donors, reagents from different vials and lots, staining by different people, and gating by different analysts. The bead figure is the floor set by the instruments. The cell figure stays near 30 % even after full standardization, and it is the realistic spread for intensities compared between sites. The comparison of the two published figures is made for this guide.

Without a shared scheme, beads alone spread more widely than EuroFlow's 5.5 %. The 2012 study of Chapter 8, which covered 133 cytometers, found that cross-calibration with hard-dyed beads, which carry dye through their whole volume, varied by typically 20 % or more, with variation between instrument models often greater than within one. The 2018 study of Chapter 8 found that detection efficiency varied between analyzers of the same model by about a factor of two in some channels and by more than an order of magnitude in others. Its authors included staff of a cytometer manufacturer and of an analysis-software company. No shared settings exist for vesicles, and Chapters 17 and 20 show how calibration in physical units narrows a spread that is far larger still.

What standardization buys is that populations land in the same place. A pattern of markers read in one laboratory can then be compared with another laboratory's and with reference databases of normal and malignant cells. EuroFlow's panels were designed for that automated comparison.

Daily quality control covers the instrument, and only the instrument

Bead checks show that the instrument reads beads as it did yesterday. They do not detect a degraded tandem dye in a reagent vial, a wrong compensation matrix, a sample prepared differently, or a gate moved by hand. Quality control of the instrument is necessary for a trustworthy result and is not sufficient for one.

Treat targets, limits and logs as controlled records

For an instrument used in a regulated or multi-site setting, define how detector voltages are chosen, the bead material and lot that carries the targets, the daily acceptance limits for value and spread, and what happens when a limit is crossed. Keep the charts as records, review trends at fixed intervals, and repeat the voltage and target procedure after any service that touches lasers, filters or detectors. Join an external quality assessment, a scheme of regular proficiency tests, for each panel in routine use.

+ What this chapter established
  • Lasers, filters and detectors drift, so stability is measured daily with dyed beads and tracked on charts, with Q and B where the bead system allows.
  • Detector voltages are chosen at the start of the plateau where a dim population's spread stops improving with gain.
  • EuroFlow made instruments alike by setting each to target bead values with one bead lot, reaching variation below 5.5 % on beads across eight instruments.
  • Cell intensities still varied by about 30 % between standardized laboratories, enough for populations to land in the same place, not at identical values.
17 — Calibration

Turning channels into units.

+ The questionHow can a channel, whose meaning differs from one instrument to the next, be tied to a number of molecules, a diameter or a volume, and what does each conversion assume?

Channels have no units

The number a cytometer records for a particle depends on the detector voltage, the gain of the electronics, the efficiency of the optics and the converter's scale. Two instruments can give the same particle values that differ tenfold, and so can one instrument on two days with different settings. Chapter 16 showed how laboratories make instruments read the same reference material alike. That is standardization: agreement on a scale, without saying what the scale means.

Calibration goes further. A 2023 review of vesicle cytometry defined it as "a procedure to relate the arbitrary units of measured data to comparable standard units, preferably SI units." A calibrated value says how many dye molecules' worth of light a particle gave, how large it is, or how many particles were in a milliliter. The conversion needs a reference material whose value is known with a stated uncertainty, and it needs a model of how the reference and the sample behave alike. Every calibration is only as good as that model.

Fluorescence in molecules

The oldest fluorescence unit is MESF, molecules of equivalent soluble fluorochrome: the number of free dye molecules in solution that would give the same fluorescence as the particle. For establishing the MESF scale, the US National Institute of Standards and Technology, or NIST, issues a standard reference material: a fluorescein solution certified at 60.97 ± 0.40 micromoles per kilogram. Bead manufacturers assign MESF values to beads of several brightness levels. Running those beads gives a line that converts each channel of the instrument into molecules.

A calibration line

Suppose beads assigned 1,000, 10,000 and 100,000 MESF read 210, 2,100 and 21,000 in a channel. The line through them gives about 4.8 MESF for every channel unit, so a stained population reading 630 carries about 3,000 MESF. Real bead sets rarely fall on a line through zero: the dimmest beads often sit above it because of background, and the fit then has an intercept as well as a slope. The values are illustrative, for this guide.

46 — A calibration line
100 1,000 10,000 100,000 1,000,000 10 100 1,000 10,000 100,000 CHANNEL (LOG) ASSIGNED VALUE, MESF (LOG) reads 210 reads 2,100 reads 21,000 the dimmest bead (open circle) sits above the line: background lifts it, so a real fit needs an intercept as well as a slope channels become molecules population at 630 ≈ 3,000 MESF illustrative values; slope ≈ 4.8 MESF per channel
ReadoutFocal detail
Plate 46 — Beads with assigned values give a line that converts channels into molecules of equivalent soluble fluorochrome. Here about 4.8 MESF per channel turns a population reading 630 into about 3,000 MESF; real lines often need an intercept.

MESF assumes that the bead and the stained cell carry the same dye in equivalent surroundings. Beads dyed through their bulk are generally not spectrally matched to the dyes used on cells, and each instrument's filters respond differently to the mismatch. The 2012 study of 133 cytometers of Chapters 8 and 16 concluded that any spectrally unmatched bead used as a general calibrator "must be verified and characterized for every particular instrument model."

NIST's answer to the mismatch is ERF, equivalent reference fluorophore, a unit that it had defined in 2011 and that the 2012 study applied channel by channel. It is the number of molecules of a stated reference dye in solution that give the same signal as one bead. Each channel has its own reference dye: fluorescein for the green channel, Nile Red for phycoerythrin's channel, allophycocyanin for its own and coumarin 30 for the violet channel. Assigning ERF values to beads carries an uncertainty of about 12 to 15 %.

Antibodies bound per cell

For immunophenotyping, the quantity of interest is often not dye but protein. A calibration in antibodies bound per cell uses a biological standard instead of a dye: a protein whose number of bound antibodies is known on a well-characterized cell. The usual choice is CD4 on T cells, taken as about 40,000 antibodies bound per cell with one reagent (Chapter 5). The 2024 NIST study of Chapter 12 found that raw fluorescence of the same cells varied widely between four instruments, while values in antibodies bound per cell agreed closely, with coefficients of variation below 2 %. When two laboratories prepared their own antibody cocktails, the variation rose to about 5 to 11 %.

Antibodies bound are not proteins present. A 2018 study at NIST estimated about 132,000 CD4 molecules per lymphocyte. It also found that the number of antibodies bound differed about twofold between two labeled forms of anti-CD4, the antibody against CD4, because an antibody can bind one or two copies of its target. The unit is therefore tied to the reagent and its clone, and a calibrated value should name them.

Scatter in nanometers

Scatter calibration is the hardest, because scatter depends on refractive index and collection angle as well as size (Chapter 4). The method published in 2012 starts by measuring beads of known size and refractive index. It then uses the physics of scattering by spheres, Mie theory, to compute how much light each bead sends into the instrument's detector. From the measured and the computed values, it derives the factor that converts channels into a physical quantity of scattered light: a cross-section, the area of the beam whose light the particle in effect sends into the detector, in square nanometers. A software tool published in 2020 does the same from bead data, wavelength and collection angles. The tool fitted the collection angles of several commercial instruments to within 0.05 to 2.6 degrees of their specifications.

The cross-section is a property of the measurement; the diameter is an inference from it. Converting scatter into a vesicle diameter requires assuming the vesicle's refractive index, which varies from about 1.37 to 1.45 (Chapter 4). That assumption dominates the uncertainty.

How much the refractive index moves the diameter

A side-scatter signal that a model assigns to a 150-nanometer vesicle of refractive index 1.40 fits a vesicle of about 120 nanometers if the index is 1.45, and about 200 nanometers if it is 1.37. For a signal assigned to 200 nanometers, the range is about 150 to 300. The figures are derived for this guide for side scatter collected between 45 and 135 degrees at 488 nanometers in water.

47 — Scatter calibrates to a cross-section
MEASURED BEADS CHANNEL (LOG) 100 nm 150 nm 200 nm 300 nm beads of known size and index fit one factor MIE MODEL OF THE INSTRUMENT cross-section, nm² 1 10 100 10³ 10⁴ 100 200 300 bead diameter, nm polystyrene n 1.605 assume an index VESICLE DIAMETER cross-section, nm² 1 10 100 10³ 10⁴ 100 150 200 250 300 vesicle diameter, nm n 1.37 n 1.40 n 1.45 one signal: 120–200 nm the refractive index decides the diameter derived (Mie): side scatter 45–135°, 488 nm, in water a signal read as 200 nm at n 1.40 fits 150–300 nm
ParticlesScattered lightReadoutFocal detail
Plate 47 — Beads of known size and index, with Mie theory, convert channels into a scattering cross-section. Turning that into a vesicle diameter needs an assumed refractive index: a signal read as 150 nanometers at 1.40 could be 120 to 200 nanometers.

Chapter 4 showed that a bead and a vesicle of the same size scatter very differently, and the reporting framework for vesicle cytometry concludes that a gating strategy based on polystyrene beads alone is not a sound standardization methodology. Gates and thresholds should be stated in calibrated scatter, with the model used to convert them into diameters.

Volume, the forgotten calibration

A concentration is a count divided by a volume, and the volume is easy to take for granted. Many cytometers infer the analyzed volume from the set flow rate and the run time. A 2018 interlaboratory study of vesicle cytometry, described in Chapter 20, found flow rates that differed sixfold between instruments set to the same value, so concentrations reported from set rates could differ by the same factor before any optical difference was considered. FCS 3.1 has a keyword for the analyzed volume, in nanoliters, but it is optional.

Clinical absolute counts report cells per microliter of blood rather than as a percentage, and they solve the problem a different way. A known number of counting beads is added to a known volume of sample, and cells are counted relative to the beads, so the instrument's flow rate drops out (Chapter 21). For vesicles no such reference was available in 2023, when the review noted that submicrometer reference materials with a traceably determined concentration were not commercially available. Chapter 20 shows how much calibration of flow rate, fluorescence and scatter together narrowed the spread of vesicle counts between laboratories.

A calibrated value carries the assumptions of its model

An MESF value assumes spectral matching between bead and dye. A value in antibodies bound per cell assumes a reagent and its binding, and a vesicle diameter assumes a refractive index. A calibrated number is more comparable than a channel value, but it is not model-free, and the model and the reference material used must travel with it.

Calibrate the quantities the result depends on, and record how

For each reported quantity, state the unit, the reference material and lot, its assigned values and uncertainty, the fitting model, and for scatter the refractive indices and collection angles assumed. Calibrate the analyzed volume directly rather than trusting the set flow rate. Record calibration factors with the data. FCS 3.1 stores one multiplying factor per parameter, so document a fit with an intercept outside the standard keyword.

+ What this chapter established
  • Channel values have no units; standardization agrees on a scale, while calibration converts it into molecules, diameters or volumes with a reference material and a model.
  • MESF ties fluorescence to a NIST fluorescein standard but assumes spectral matching; ERF names a reference dye per channel, with uncertainties of about 12 to 15 %.
  • Values in antibodies bound per cell varied by less than 2 % across four instruments where raw intensities did not, but they count bound antibodies, not proteins.
  • Scatter calibrates to a cross-section; the diameter depends on an assumed refractive index, so a signal read as 150 nanometers can mean 120 to 200.
18 — The file

What the file keeps, and what it drops.

+ The questionWhat does the standard data file record about how its numbers were made, what is lost on the way to a report, and when does the file itself become the record that matters?

Three segments and a list of keywords

Cytometry data have had a standard format for four decades. The first Flow Cytometry Standard, FCS 1.0, was adopted in 1984, and revisions followed in 1990 and 1997. Version 3.1 was published in 2010, and a version 3.2 followed in 2021. As of October 2026, the data-standards page of the International Society for Advancement of Cytometry lists the full specification of 3.1 but not of 3.2, so this guide describes 3.1. The format's stability is a large part of why files from different instruments and decades can still be opened by the same software.

An FCS file has three main segments. A short header says where the others begin. The text segment holds keywords, each a name and a value, such as the number of events, the number of parameters, and each parameter's name, range and detector settings. The data segment holds the measurements in list mode: one row per event and one column per parameter. Each parameter carries a short name for the detector, such as FL1-A, and may carry a long name for the axis label, such as "CD45 FITC Fluorescence - Area," so that the file can tell the detector from the marker it measured.

48 — Inside an FCS file
HEADER TEXT DATA ANALYSIS CRC FCS3.1 version, offsets $PAR 24 $TOT 1,000,000 $P3N FL1-A $P3S CD45 FITC $P3V 520 $SPILLOVER … P1 P2 P3 P4 P5 P6 P7 P8 … P24 one row per event, one column per parameter optional optional; zeros if absent offsets in the header say where each begins 1,000,000 events × 24 parameters × 4 bytes ≈ 96 million bytes data stored uncompensated; one spillover matrix the only integrity check is optional
ReadoutFocal detail
Plate 48 — An FCS file holds a short header, a text segment of keywords and a data segment with one row per event and one column per parameter. One million events with 24 parameters fill about 96 million bytes.
How large a file is

A file stores each measurement in 4 bytes when it uses 32-bit numbers. One million events with 24 parameters therefore need about 96 million bytes of data. A test for residual disease that acquires 10 million events produces a file of nearly a gigabyte. The header gives the start and end of each segment as byte positions in eight-digit fields, so once a segment ends beyond byte 99,999,999, its positions move into keywords in the text segment. The sizes are derived for this guide.

The data can be stored as unsigned integers, as 32-bit floating-point numbers or as 64-bit ones. The choice matters wherever values near and below zero occur, as they do in files that software exports or re-saves after compensation, even though the standard expects stored data to be uncompensated (Chapter 10). Such values survive in floating point, while unsigned integers cannot hold negative numbers at all.

What the file records

FCS 3.1 has keywords for much of the acquisition. For each parameter it can record the detector type, voltage, gain and filter, and the wavelength and power of the light that excited it. It can record one trigger channel and its threshold (Chapter 9), the volume analyzed, and the spillover matrix, which the standard calls "the only standardized way to specify compensation." The standard states that "the stored data is always uncompensated," so software applies compensation from the matrix, and only one matrix can be stored for each data set.

Three keywords added in version 3.1 matter for calibration, display and record-keeping. One carries a calibration factor per parameter that converts channel numbers into units such as MESF (Chapter 17); it is a single multiplier and is usually absent. A second recommends a display scale but recognizes only linear and logarithmic scales, so a logicle or arcsinh display cannot be recorded there. A third records the file's originality, from Original to DataModified. The standard advises that modifying data sets is bad practice and that "the original file should always be kept." The file can end with a checksum over the whole data set, but the checksum is optional, and software that skips it when writing the file fills the space with zeros.

What the file does not record

The list of what FCS 3.1 has no keyword for is as instructive as what it has. It does not record the name or version of the acquisition software, only the computer and operating system. It has no keyword for laser delays, processing window, sheath pressure, baseline restoration or detector temperature (Chapter 13), none for the daily quality-control results of Chapter 16, and none for any trigger more elaborate than one channel above one level. Manufacturers write some of these into their own keywords, in units the standard does not define.

49 — What the file keeps, and what it drops
RECORDED IN FCS 3.1 NOT RECORDED detector type, voltage, gain, filter excitation wavelength and power one trigger and threshold ($TR) analyzed volume ($VOL) spillover matrix (uncompensated data) calibration factor (optional) display scale: linear or log only originality acquisition software version laser delays processing window sheath pressure baseline restoration detector temperature daily QC results triggers beyond one channel gates (beyond legacy regions) logicle or arcsinh parameters manufacturers write some missing settings into their own keywords, in units the standard does not define decides validity, kept nowhere in the standard
ReadoutFocal detail
Plate 49 — FCS 3.1 records much of the optical configuration but not several settings that decide whether its numbers are valid. A file alone cannot reproduce an acquisition.

The consequence is that a file alone cannot reproduce an acquisition. The file holds the measurements and much of the optical configuration, but several settings that decide whether those measurements are valid live only in the instrument, its log or its software. A data set exchanged between laboratories arrives without those settings unless they are documented separately.

What export and analysis drop

Further losses happen after acquisition. Some exporting software converts data to a linear scale, and the standard gives that as the reason for the display keyword. The reporting standard MIFlowCyt permits a spreadsheet export of list-mode data, and such an export keeps the numbers and loses every keyword: the detector settings, the matrix and the provenance. Gates and transforms with their parameters are not part of FCS 3.1 at all, apart from crude legacy region keywords. They are kept in the analysis software's workspace or in a separate standard, Gating-ML 2.0, which was published in 2015 and can describe logicle and arcsinh transforms and gate boundaries exactly. A compensation matrix edited at analysis time is also kept outside the file.

MIFlowCyt was published in 2008 and is still the community's reference. It asks for what the file cannot hold. A report "shall" state the denominator of every gate percentage, give the compensation matrix and say whether it is a spillover or a compensation matrix, and describe transforms by an open specification, while the software name and version are only recommended. Chapter 20 shows how MIFlowCyt's extension for vesicles, MIFlowCyt-EV, adds the flow rate and calibrations in standard units, and asks for the trigger channel and threshold preferably in calibrated units. MIFlowCyt also asks that a report provide its list-mode files or say how to obtain them. FlowRepository is a public archive where researchers deposit cytometry data. As of 6 October 2026 it had temporarily stopped accepting new experiments for lack of storage, while downloads continued.

50 — Where the information lives
INSTRUMENT settings, log, QC FCS FILE measurements, keywords, matrix ANALYSIS WORKSPACE or Gating-ML gates, transforms, edited matrix REPORT percentages with denominators RECORD US clinical lab: CLIA, at least 2 years FDA-regulated records: Part 11 audit trail INTEGER EXPORT negatives lost CSV EXPORT keywords lost the numbers survive; the means to check them do not
ReadoutFocal detail
Plate 50 — The information needed to check a result is spread across the instrument log, the file, the analysis workspace and the report. Exports to spreadsheets or integers can strip what makes the file interpretable.
Re-saving or exporting a file can strip what makes it interpretable

A file can lose the spillover matrix, the scale, negative values and its originality status when it is exported to a spreadsheet, converted to integers, re-saved after editing or passed through software that rewrites keywords. It still opens normally. The numbers look the same, but the information needed to check them is gone.

The file as a record

In regulated settings the file becomes evidence. The US rule on electronic records, 21 CFR Part 11, applies to records kept under the FDA's own record requirements, such as those of a device manufacturer. It requires validated systems, accurate and complete copies, protected retrieval and "secure, computer-generated, time-stamped audit trails." Clinical laboratories in the United States keep their records instead under the Clinical Laboratory Improvement Amendments, CLIA, the federal rules for laboratories that test human samples. These rules require quality-control and patient test records, "including instrument printouts," to be kept for at least two years, and pathology reports for ten.

The file is also becoming the test object. EuroFlow runs an external quality assessment for residual disease in myeloma, a cancer of the antibody-producing cells of the bone marrow. The program sends participants FCS files rather than samples, so that laboratories are compared on analysis alone, with the variation of the instrument and the sample removed. For that comparison to mean anything, the files must arrive with their keywords intact.

Keep the original, and record what the file cannot hold

Archive the original FCS files unchanged, with a checksum computed on arrival. Store the analysis workspace or Gating-ML file, the compensation matrix used, the transform parameters and the software version with each result. Record laser delays, sheath pressure, threshold and quality-control results in an instrument log linked to the files. Use MIFlowCyt as the checklist for reports, and set retention by the rules that apply: CLIA for a US clinical laboratory, and, for records kept under FDA requirements, the retention period of the governing FDA rule, with Part 11 controls on the electronic records.

+ What this chapter established
  • FCS files hold a header, keyword text and list-mode data; version 3.1 is the version this guide describes, and the standard requires data to be stored uncompensated, with at most one spillover matrix.
  • The file records detector settings, excitation, one trigger, volume and an optional calibration factor, but not laser delays, sheath pressure, software version or quality control.
  • Export and analysis can drop keywords, scales, negative values and gates; Gating-ML and MIFlowCyt cover what the file cannot hold.
  • In regulated use the file is a record kept under Part 11 or CLIA, and EuroFlow already compares laboratories on supplied files.

+ Part VI · Below the wavelength of light

Vesicles, followed to the limit.

Halve the diameter of a vesicle from 100 to 50 nanometers, and the light it scatters falls about fiftyfold. Most chapters so far have met extracellular vesicles, the guide's hard measurement, at the edge of what that ratio allows. Chapter 19 shows why several limits fail together as particles shrink below about 200 nanometers, and how a count can go wrong without any warning. Chapter 20 asks how many vesicles a sample holds and how large they are, and what calibration, reporting and comparison between laboratories have made of those questions. Between them they answer the second part of the central question: how small a particle a cytometer can see, and what it takes to know.

19 — Below 200 nm

What breaks below 200 nanometers.

+ The questionWhy do several limits fail together as particles shrink below about 200 nanometers, and how does a vesicle count go wrong without any sign of error?

Where most vesicles are

Reported concentrations of vesicles in plasma are of the order of ten billion per milliliter (Chapter 6), and most of the vesicles are smaller than nearly any cytometer can detect.

The international guidelines MISEV2023, published in 2024, define extracellular vesicles as particles that cells release, that cannot replicate on their own and that are enclosed by a lipid bilayer, the double layer of fat-like molecules that forms the lipid membrane of Chapter 1. The guidelines note that vesicles below 200 nanometers are often described as "small" and those above it as "large," and they add that the measured diameter depends on the method used to measure it. The word exosome is reserved for vesicles shown to come from a particular compartment inside the cell, and a cytometer cannot show that origin, so this guide speaks of vesicles.

Vesicle sizes are not spread evenly. Electron microscopes and sensitive cytometers both find that the number of vesicles in blood plasma rises steeply as the diameter falls. A 2014 study of urine vesicles fitted their size distribution with a power law, a curve in which the count rises by the same factor each time the diameter halves, and its authors chose that form because it was least affected by each method's smallest detectable size. Most vesicles, by number, are therefore at the small end, exactly where Chapter 4 showed scatter vanishing.

51 — Where most vesicles are
lower detection limits, one 2014 urine-vesicle study TEM ≈ 1 nm, off scale NTA 70–90 nm RPS 70–100 nm dedicated FC 150–190 nm conventional FC 270–600 nm 30 100 300 1,000 DIAMETER (nm, LOG) RELATIVE NUMBER (LOG) vesicles (schematic power law) most vesicles lie below it lipoproteins ≈ 10¹⁶ per mL vs vesicles ≈ 10¹⁰ per mL in plasma schematic distribution
ParticlesFocal detail
Plate 51 — Vesicle numbers rise steeply as diameter falls, so most vesicles are at the small end. In one comparison, a conventional cytometer detected vesicles only above 270 to 600 nanometers, a dedicated one above 150 to 190.

How many vesicles there are depends on what is counted. The authors of a 2019 review found that reported concentrations of vesicles in plasma spanned more than seven orders of magnitude, with a geometric mean of about 10¹⁰ per milliliter. Lipoproteins, the fat-carrying particles of Chapter 4, reach about 10¹⁶ per milliliter, a million times as many, so the review's authors called the vesicle "the one in a million." A cytometer measuring vesicles in plasma is looking for rare particles among far more numerous ones of similar size.

Four limits fail together

Four limits that are separate for cells converge for vesicles. Scatter falls roughly with the sixth power of diameter (Chapter 4), so a vesicle of 100 nanometers sends almost nothing to the detectors. A vesicle of 100 nanometers carries about a thousandth of the label of a 3-micrometer platelet with the same number of protein copies per unit area, so its fluorescence is close to the background (Chapters 5 and 8). And vesicles are so numerous and so small that many can sit in the beam at once (Chapter 6). An instrument built for cells meets all four limits at the same time.

As a result, the smallest detectable size depends on the instrument more than on anything else. The same 2014 study measured one sample of urine vesicles by several methods, two of them cytometers. Particle tracking records single particles on video as they drift at random in the liquid, and it works out the size of each from how fast it moves, because small particles move faster than large ones. Resistive pulse sensing applies the Coulter principle of Chapter 2 to a pore small enough for vesicles: each particle that passes through briefly raises the pore's electrical resistance.

The lower limits of detection in that study were about 70 to 90 nanometers for particle tracking, 70 to 100 for resistive pulse sensing, 150 to 190 for a cytometer built for small particles and 270 to 600 for a conventional cytometer. The conventional cytometer found about 300 times fewer vesicles than the methods that reached the smallest sizes. In a 2018 comparison of 46 instruments, 24 % could not detect polystyrene beads of 400 nanometers, which scatter far more than vesicles of that size.

52 — Four limits converge
ALL FOUR AT ONCE 50 100 200 500 1,000 DIAMETER (nm, LOG) schematic RELATIVE (LOG) background floor scatter ≈ d⁶ label ≈ surface, d² particles in the beam at once (high concentration) the first limit to fail
ParticlesFluorescenceScattered lightFocal detail
Plate 52 — Scatter, label, background and coincidence are separate limits for cells but converge for vesicles: below about 200 nanometers scatter and label sink toward the background while the number of particles in the beam at once rises.

Better instruments go further. The largest comparison between laboratories so far was published in 2025. Its authors included staff of the company that made the calibration beads used and a cofounder of a calibration company. In that study, the more sensitive half of the instruments reached vesicle diameters of about 113 to 133 nanometers and labels of the order of 10 to 100 molecules of equivalent soluble fluorochrome. When 18 to 19 of the 25 instruments were compared, the limit they all shared was about 240 nanometers (Chapter 20). Even the best cytometers see only the larger, brighter fraction of the vesicles in a sample. The lead author of the 2025 study stated that bias explicitly in a doctoral thesis.

Swarm detection

The fourth limit, many particles in the beam at once, produces the strangest failure. The 2012 study of Chapter 1 showed that when vesicles below the detection limit are present at high concentration, many of them can be illuminated at once and counted as a single event. Its authors named the effect swarm detection: "multiple vesicles are simultaneously illuminated by the laser beam and counted as a single event signal." No single vesicle crosses the threshold, but together they do.

The experiment that demonstrated swarm detection was simple. The authors mixed silica beads of 89 nanometers, too small to detect on their instrument, with silica beads of 610 nanometers at increasing ratios. At 100 small beads for each large one, the measured count stayed about the same. At 10,000 for each large one it rose by 40 %, and at 100,000 it rose by 350 %, although the number of large beads had not changed. The smallest single beads that instrument could detect were about 200 nanometers, and the smallest detectable single vesicle was estimated at 300 to 700 nanometers.

53 — Swarm detection
BEAM VOLUME threshold many below threshold, one event MEASURED ÷ TRUE COUNT 0 1 2 3 4 5 100 : 1 similar 10,000 : 1 +40 % 100,000 : 1 true count 89 nm BEADS PER 610 nm BEAD +350 % more events, wrong particles 2012 study: 89 nm and 610 nm silica beads
ParticlesExcitation lightReadoutFocal detail
Plate 53 — Mixed with large beads, invisible 89-nanometer beads left the count similar at 100 per large bead, but raised the count by 40 % at 10,000 and by 350 % at 100,000. Many sub-threshold particles in the beam together become one event.

Swarm detection is not a gain in sensitivity. Each swarm event reports the combined light of an unknown number of particles, so its scatter suggests a single larger particle. The count is then wrong in both directions: there are too many events, because particles that are individually invisible are counted, and too few particles, because each event stands for many. A later review described swarm detection as a special form of coincidence that can be reduced by dilution.

More events can mean fewer particles counted correctly

At high concentration, a cytometer can count swarms of invisible particles and so report more events than there are detectable particles, and each such event looks like one larger particle. Without a dilution series, a higher count from one sample than from another may reflect concentration rather than biology, and an apparent size distribution may be an artifact of swarm detection.

Dilution reveals it

Dilution is the test because single particles and swarms respond to it differently. When a sample of single, separately detected particles is diluted twofold, the event rate halves and the scatter and fluorescence of each event stay the same. When the events are swarms, dilution reduces the number of particles in the beam at any moment, so the combined signals shrink and many of them fall below the threshold. The event rate therefore falls faster than the dilution, and the median signal per event falls with it.

Reading a dilution series

Suppose a plasma sample gives 8,000 events per second at a dilution of 1 in 10. At 1 in 20, single particles would give 4,000 events per second, with the same median scatter. If the instrument instead records 2,000 events per second and the median scatter has dropped by half, at least half of the events at the first dilution were swarms. Single particles would still give half their number at 1 in 20, so no more than 4,000 of the 8,000 events can have been single particles. The series is repeated until further dilution halves the rate and leaves the medians unchanged, and counts are trusted only in that range. The values are illustrative, for this guide.

The same test protects cell counts at high event rates, where coincidence rather than swarming adds and merges events (Chapter 6), but for vesicles the test is not optional. The reporting framework for vesicle cytometry lists a serial dilution among its controls for this reason (Chapter 20).

Not everything is a vesicle

Even single, separately detected events are not all vesicles. Lipoproteins outnumber vesicles in plasma, and the authors of the 2019 review found that preparations of isolated vesicles contained at least ten times as many low-density lipoprotein particles as vesicles. The labeling reagents add particles of their own. The antibodies that carry dyes to their targets, and the dyes themselves, form aggregates of vesicle size that carry label and scatter light (Chapter 11). Cell fragments and protein complexes add more.

The controls of Chapter 11 separate vesicles from these other particles. Buffer run alone shows the instrument's own events, and buffer with the labeling reagents shows the aggregates. A detergent dissolves lipid membranes, so it removes vesicles while it leaves aggregates of antibody and dye behind. One completed report under the vesicle reporting framework recorded a fall of more than 90 % in labeled events after detergent. An event that survives detergent is not a vesicle, whatever its size and brightness.

Prove each event is one vesicle before counting

For every sample type, run a serial dilution and use only the range in which event rate is proportional to dilution and medians are constant. Include buffer-only, reagent-only and detergent controls in each run. Trigger on fluorescence where the label allows (Chapter 9). With every count, state the detection limits in calibrated scatter and fluorescence units (Chapter 17).

+ What this chapter established
  • Most vesicles by number are small, and plasma holds far more lipoproteins of similar size, so a vesicle count is a search for rare particles near every limit at once.
  • Scatter, label, background and coincidence limits converge below 200 nanometers; a conventional cytometer detected vesicles only above about 270 to 600 nanometers in one comparison.
  • Swarm detection counts many invisible vesicles as one event: adding 100,000 sub-threshold beads per real one raised counts by 350 %.
  • A dilution series in which rate falls with dilution and medians stay constant shows events are single, and detergent shows they are vesicles.
20 — Vesicles counted

How many vesicles, and how big.

+ The questionA vesicle count means something only with its size window, its brightness threshold and its volume. What do calibrated cytometers report today, how far do laboratories agree, and how do their numbers compare with other methods?

A count is a window

The question "how many vesicles are in this plasma?" has no single answer. Chapter 19 showed reported concentrations spanning more than seven orders of magnitude. Methods that count every particle above about 70 to 100 nanometers give values near 10¹⁰ per milliliter, and their counts include lipoproteins. A calibrated cytometer reports about 10⁷ per milliliter for each cell type, because it counts only vesicles that carry a marker of that cell type, measure between 150 and 1,000 nanometers and shine above a stated brightness. Both numbers can be right, because they count different things.

Every vesicle count therefore needs three limits stated with it. The first is the size window: the smallest and largest diameter included, in calibrated scatter, with the refractive index that the conversion assumed (Chapter 17). The second is the dimmest label included, in calibrated fluorescence units. The third is the analyzed volume, measured rather than assumed. Without these three limits, the count describes the instrument as much as the sample.

54 — A count is a window
all particles > 70–100 nm ≈ 10¹⁰ per mL, lipoproteins included conventional cytometer > about 300 nm calibrated small-particle cytometer 150–1,000 nm + label threshold ≈ 10⁷ per mL per cell type 30 100 300 1,000 DIAMETER (nm, LOG) NUMBER (LOG) schematic distribution the lower limit decides the count EVERY COUNT NEEDS size window calibrated scatter, index assumed brightness threshold calibrated units measured volume
ParticlesReadoutFocal detail
Plate 54 — Methods that count every particle above about 70 to 100 nanometers find about 10¹⁰ per milliliter, lipoproteins included; a calibrated cytometer counting labeled vesicles from 150 to 1,000 nanometers finds about 10⁷ per cell type. Both are right about different windows.
Why the window dominates the count

Suppose vesicle numbers rise steeply toward small sizes, so that each halving of the lower size limit multiplies the count by about eight. A method that counts from 75 nanometers would then find about eight times as many vesicles as one that counts from 150, and about sixty-four times as many as one that starts at 300, in the same sample. This steepness is an illustration chosen for this guide, and real distributions differ from sample to sample and are poorly known at the smallest sizes. The point holds for any distribution as steep as those Chapter 19 described: moving the lower limit changes the count more than most biological differences do.

Reporting what was measured

The community's answer is a reporting framework called MIFlowCyt-EV. A working group of the societies for vesicles, cytometry and thrombosis published it in 2020. It extends the MIFlowCyt standard of Chapter 18 with what vesicle measurements need. In its own words, it "does not prescribe specific protocols": it asks that whatever was done be reported in a form that others can compare. The international guidelines MISEV2023, published in 2024, point to it for flow cytometry.

The framework's items begin with the sample before analysis and its preparation, and they include the controls of Chapters 11 and 19: buffer, reagent, unstained, isotype, single-stained, procedural, serial dilution and detergent controls. They also cover the instrument's calibration: the trigger channel and threshold, the flow rate, and the calibration of fluorescence and scatter. Results are reported as a calibrated detection range, as a concentration in the starting material and as brightness, preferably in standard units. The framework also states that a gating strategy based on polystyrene beads alone is not a sound basis for standardization. Chapter 4 reached the same conclusion from the history of bead mixtures.

How far laboratories agree

Comparisons between laboratories show calibration closing a very wide gap. A 2023 review summarizes two workshops of the international thrombosis society, in 2009 and 2010: they used a bead mixture to set size gates, and the counts proved comparable only among instruments of the same type. In 2017 a workshop of 44 laboratories found that counts of platelet vesicles in its two samples varied by 37 and 28 % between laboratories. The maker of the workshop's beads supplied them and employed two of its authors.

In 2018 the same society sent samples to 33 participants with 46 instruments: with gates set by bead diameter, counts varied by 139 % between them, and with gates set in vesicle diameter, worked out from scatter models, they varied by 81 %. That figure is for a gate of 1,200 to 3,000 nanometers, which 31 of the 46 instruments could detect. The largest comparison so far was published in 2025, by authors who included staff of the company that made the calibration beads used and a cofounder of a calibration company. They calibrated flow rate, fluorescence and scatter on each of 25 cytometers in 18 laboratories. The spread of counts between laboratories fell from 67 % before calibration to 25 to 31 % after it. The study measured that spread as a median absolute deviation, which shows how far typical counts lie from the middle count.

55 — How far laboratories agree
SPREAD BETWEEN LABORATORIES (%) 0 50 100 150 standardized clinical cell intensities (Ch. 16) 2009–10 bead gates: comparable only within an instrument type sample 1 28 % sample 2 37 % bead gates 139 % vesicle gates 1,200–3,000 nm 81 % uncalibrated 67 % calibrated 2017 workshop 2018, 46 instruments 2025, 25 cytometers, 18 labs 25–31 % calibrated: comparable for the larger, brighter vesicles measures differ by study: CV or median absolute deviation
ReadoutFocal detail
Plate 55 — Calibration closed a wide gap. Bead gates gave 139 % variation between 46 instruments in 2018; vesicle-diameter gates 81 %; full calibration of 25 cytometers in 2025 cut the median absolute deviation from 67 % to 25–31 %.

That spread is of the same order as the variation of about 30 % that fully standardized clinical laboratories show in the brightness of cells (Chapter 16). The two figures are not directly comparable, because one describes counts and the other, a coefficient of variation, describes intensities. The 2025 figure also applies only to vesicles inside the gates that the compared instruments shared. When the more sensitive half of the instruments were compared, the shared gate began at about 113 to 133 nanometers. When 18 to 19 of the 25 were compared, it began at about 240 nanometers, with higher fluorescence thresholds. Calibration has made vesicle counts comparable between laboratories for the larger, brighter fraction of vesicles, not for vesicles as a whole.

Reference ranges

Comparable counts made reference ranges possible. A reference range is the span of values found in healthy people, against which a patient's value is read. The authors of the 2025 study measured plasma from 224 healthy donors on one calibrated instrument. They counted vesicles between 150 and 1,000 nanometers and above stated fluorescence thresholds, and they described the results as the first reference ranges of cell-type-specific vesicles in human plasma. The median concentrations were about 20 million per milliliter for vesicles from red cells, 18 million for vesicles from white cells and 34 million for vesicles from platelets.

In 2023 the same group had described a plasma vesicle test sample. It is a ready-to-use material that resembles the particles of plasma and stays stable for 12 months at −80 °C, so that laboratories can check their whole procedure on a shared sample. The missing piece is a reference material whose size and concentration are traceable. A European project set targets for one: sizes of 50 to 1,000 nanometers, refractive indices of 1.37 to 1.42 and concentrations of 10⁹ to 10¹² per milliliter, and its candidates range from hollow organosilica beads and liposomes to recombinant vesicles. As of October 2026 this guide found no diagnostic test based on vesicle cytometry cleared, granted or approved by the FDA; the measurement is a research tool on its way to becoming a clinical one.

Other methods see other vesicles

Comparisons with other methods belong here, because they too are comparisons of windows. The 2014 study of Chapter 19 measured one pooled sample of urine vesicles by five methods: electron microscopy, resistive pulse sensing, particle tracking and two cytometers, one of them built for small particles. Its authors wrote that each technique "gave a different size distribution and a different concentration for the same vesicle sample." The concentrations ranged from 10⁴ to 10¹² per milliliter, and the authors concluded that the differences were "primarily caused by differences between the minimum detectable vesicle sizes." The size distribution peaked at 45 nanometers by electron microscopy, 75 by resistive pulse sensing and 95 by particle tracking. For the last two, the peak lay just above the method's own lower limit.

56 — Other methods see other vesicles
TEM: peak 45 nm, limit ≈ 1 nm RPS: peak 75 nm, limit 70–100 NTA: peak 95 nm, limit 70–90 dedicated FC: limit 150–190 conventional FC: limit 270–600 the peak sits near its own limit 10 30 100 300 1,000 DIAMETER (nm, LOG) one pooled urine sample, 2014 study; distributions schematic dashed boxes: lower detection limits
ParticlesFocal detail
Plate 56 — Measured by five methods, one vesicle sample gave five size distributions and concentrations from 10⁴ to 10¹² per milliliter. Where a method's lower limit lay inside the vesicle range, its distribution peaked just above that limit: the differences are windows, not errors.

The authors judged the cytometer built for small particles the most accurate at sizing reference beads, but they expected it to be less accurate on vesicles, because the refractive index of vesicles varies. They named its strengths as speed and the ability to measure several fluorescent labels on each particle. Particle tracking, the method behind most high concentration estimates, counts lipoproteins and other particles along with vesicles. No method sees every vesicle: each sees those above its own threshold, and the cytometer is the one that can say which cell they came from.

Concentrations from different windows cannot be compared

A count from particle tracking, a count from a conventional cytometer and a count from a calibrated small-particle cytometer describe different subsets of the same sample. Comparing them compares methods, not samples. So does comparing a published value with a laboratory's own value without matching the size window, the label threshold and the volume calibration.

Report every vesicle count with its window

Follow MIFlowCyt-EV for every report. State the size window in calibrated scatter with the refractive index assumed, and the fluorescence threshold in calibrated units. Give the measured analyzed volume and the dilution range in which counts were proportional, and report the results of the buffer, reagent and detergent controls. Run a shared test sample where one exists, and compare counts with other laboratories or methods only within a matched window.

+ What this chapter established
  • A vesicle count is defined by its size window, brightness threshold and measured volume; without them it describes the instrument as much as the sample.
  • MIFlowCyt-EV asks for controls, trigger, flow rate and calibrations in standard units, and judges gates based on polystyrene beads alone unsound as a basis for standardization.
  • Calibration of flow rate, fluorescence and scatter cut the spread between laboratories from 67 % to 25 to 31 %, for the larger and brighter vesicles.
  • Reference ranges for plasma vesicles by cell type, which their authors described as the first, appeared in 2025, and other methods report different counts because they see different windows.

+ Part VII · Cytometry as a test

From a measurement to a medical result.

A research measurement has to convince its author; a clinical test has to be right for a patient who will never see the data. Part VII follows cytometry into the clinic through the guide's second case, leukemia immunophenotyping. Chapter 21 shows how patterns of markers become part of a diagnosis and what a report contains. Chapter 22 shows how a laboratory proves that an assay performs as claimed, down to the rarest cells it reports, and Chapter 23 how the instrument, its reagents and a laboratory's own panel are regulated in the United States, the European Union and India. The last part of the central question, when a count can be trusted as a test result, is answered here.

21 — Diagnosis

When a result becomes a diagnosis.

+ The questionA clinical laboratory turns a tube of blood or marrow into a sentence in a patient's record. How do patterns of markers point to a disease, what does a report contain, and what can the cytometer not decide on its own?

What clinical cytometry is asked

The US classification for flow cytometric leukemia and lymphoma panels lists the conditions they help to diagnose: acute and chronic leukemias, non-Hodgkin lymphomas, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms, in blood, bone marrow and lymph node. All of them are cancers or related disorders of blood cells and of the marrow cells that produce them. Beyond these, clinical laboratories use cytometry to count CD4 T cells in people with HIV and CD34 stem cells before transplantation. Laboratories also use cytometry to detect the missing surface proteins of paroxysmal nocturnal hemoglobinuria, to screen for inherited immune deficiencies and to look for leukemia left after treatment. Paroxysmal nocturnal hemoglobinuria is a rare disease in which blood cells lack a group of surface proteins and red cells break down.

In 2006 an international consensus meeting set out when diagnostic cytometry is indicated. A 2025 educational module from the College of American Pathologists restates the list for blood: abnormal cells seen under the microscope, an increase in lymphocytes that may be reactive or malignant, increased blasts, suspected relapse and several rarer situations. Blasts are the immature cells from which blood cells develop.

The module also states when cytometry is not indicated. Neutrophils are the most common white cells in blood. Normal mature neutrophils, red cells and platelets look the same whether or not they come from a clone, a population descended from a single cell, so an isolated rise in neutrophils, red cells or platelets is not a reason to order cytometry. Routine diagnostic panels characterize abnormal populations above about 1 % of cells. Detecting residual disease below 0.01 % is a separate, specialized test (Chapter 22).

A pattern, not a marker

No single marker identifies a leukemia. Blood cells develop along several branches, the lineages of Chapter 12. Normal blood and marrow contain cells at every stage of maturation in every lineage, and almost every marker found on leukemic cells is also found on some normal cell. What identifies a population is a combination: which markers it carries, how brightly, and in what pattern relative to its normal counterpart (Chapter 11).

The EuroFlow consortium of Chapter 10 built this idea into the design of its panels. Each eight-color tube combines backbone markers, which identify the main populations in the sample, with characterization markers, which describe them further. A panel of several tubes carries the backbone on the same dye in every tube. The population of interest then appears in the same place in each tube, and the tubes can be analyzed together (Chapter 16).

EuroFlow's entry point for suspected acute leukemia is a single tube, the acute leukemia orientation tube, and its one question is which lineage the leukemic cells belong to. The tube pairs markers found inside the cell, in its cytoplasm, with surface markers of immaturity and lineage. The internal markers are myeloperoxidase for the myeloid lineage, CD3 for T cells and CD79a for B cells, and the surface markers include CD34, CD45, CD19, CD7 and surface CD3. The myeloid lineage is the branch that produces red cells, platelets and the white cells other than lymphocytes.

The tube was refined over five design cycles on 385 acute leukemias and then tested prospectively on 483 further cases in eight laboratories. In the textbook reading, myeloperoxidase points to a myeloid leukemia, cytoplasmic CD3 with CD7 to a T-lineage one, and CD19 with cytoplasmic CD79a to a B-lineage one, while CD34 and dim CD45 mark the cells as immature. CD45 is carried by nearly all white cells, and immature ones carry less of it.

57 — Which lineage? The orientation tube
ONE TUBE, EIGHT MARKERS cyCD3 CD45 cyMPO cyCD79a CD34 CD19 CD7 smCD3 cy = inside the cell sm = on the surface IMMATURE? CD34, dim CD45 blasts: a large nucleus, a thin rim first decide immature, then lineage cyMPO → MYELOID → full classification panel cyCD3 (+CD7) → T-LINEAGE → full classification panel CD19 + cyCD79a → B-LINEAGE → full classification panel textbook reading; refined on 385 acute leukemias, tested on 483 cases in 8 laboratories
ParticlesReadoutFocal detail
Plate 57 — One eight-color tube asks one question: which lineage? Myeloperoxidase points to myeloid, cytoplasmic CD3 with CD7 to T, and CD19 with cytoplasmic CD79a to B, while CD34 and dim CD45 mark the cells as immature.

A worked case: chronic lymphocytic leukemia

Chronic lymphocytic leukemia shows how a pattern becomes a criterion. The 2018 international guidelines require at least 5 × 10⁹ clonal B lymphocytes per liter of blood, which is 5,000 per microliter, persisting for at least three months, and they require cytometry to show that the cells form a clone. The cells carry CD5, normally a T-cell marker, together with the B-cell markers CD19, CD20 and CD23. Their surface immunoglobulin, CD20 and CD79b are characteristically dim compared with normal B cells.

Surface immunoglobulin is the antibody that each B cell carries on its surface (Chapter 11). An antibody is a protein built from two heavy chains and two light chains, and cytometry shows clonality through the light chains of that surface antibody. Every B cell uses either a kappa or a lambda light chain, and a normal population contains both. A clone uses only one, because all its cells descend from one cell. A population of CD5-positive B cells that is all kappa or all lambda is therefore clonal, and the diagnosis rests on that measurement.

58 — A worked case: chronic lymphocytic leukemia
CD19 → CD5 ↑ schematic T CELLS CLL CELLS normal B cells NORMAL B CELLS: BOTH LAMBDA KAPPA CLONE: KAPPA ONLY LAMBDA KAPPA none one light chain: descended from one cell CRITERION (2018) ≥ 5 × 10⁹ clonal B cells per liter, ≥ 3 months
ReadoutFocal detail
Plate 58 — Chronic lymphocytic leukemia cells are B cells carrying CD5, and a clone uses only one light chain. Clonal B cells at 5 × 10⁹ per liter or more for at least three months meet the 2018 criterion.

The thresholds draw the boundaries of the diagnosis. The same clonal cells below 5 × 10⁹ per liter define monoclonal B lymphocytosis when the patient has no enlarged lymph nodes or organs, no low blood counts and no symptoms. With enlarged nodes, the same cells suggest small lymphocytic lymphoma, which a biopsy confirms. In 2018 a European harmonization project agreed on six required markers: CD19, CD5, CD20, CD23, kappa and lambda. The project also agreed on recommended markers for borderline cases, and it validated the approach retrospectively on 14,643 cases from 13 centers, with more than 97 % concordance with the diagnostic approaches then in use.

Counting cells in absolute numbers

Some clinical results are counts per microliter rather than percentages. In its 2003 guidelines for CD4 counts, the US Centers for Disease Control and Prevention favored single-platform methods, in which a known number of fluorescent counting beads is added to a measured volume of blood. The alternative, dual-platform methods, multiply a cytometry percentage by a count from a separate hematology analyzer, and so they compound the errors of both instruments.

A single-platform count

Suppose a tube receives 50,000 counting beads and 50 microliters of blood, so there are 1,000 beads for each microliter. After staining, the cytometer records 40,000 bead events and 20,000 CD4 T-cell events. Recording 40,000 of the 50,000 beads means that 40 microliters of blood were analyzed, so the count is 20,000 ÷ 40,000 × 1,000, or 500 CD4 T cells per microliter. The guidelines ask for at least 2,500 gated lymphocytes and accurate pipetting, because errors in the bead count and the blood volume pass straight into the result. The values are illustrative, for this guide.

The same principle counts CD34 stem cells. For that count, the US Pharmacopeia, which publishes official standards for medicines, sets a method that asks for at least 75,000 CD45-positive events and at least 100 CD34-positive cells. Because the cells and the beads are counted in the same run, the instrument's flow rate drops out of the result, and single-platform counting thereby solves, for cells, the volume problem that Chapter 17 found still open for vesicles.

A percentage of blasts depends on its denominator

Blasts can be reported as a percentage of all events, of CD45-positive cells, of nucleated cells or of a gated population. These percentages can differ widely in a marrow with many red-cell precursors or much debris. A report that does not state the denominator and the gating behind it cannot be compared with a microscope count or with the next report on the same patient.

The cytometer is one witness

A cytometry result is never a diagnosis on its own. The 2022 World Health Organization classification of myeloid neoplasms describes itself as predicated on integrating morphology, immunophenotype, and molecular and cytogenetic data. Morphology is the appearance of cells under the microscope, the immunophenotype is the pattern of markers that cytometry measures, and molecular and cytogenetic data describe the cells' genes and chromosomes. The classification also dropped the requirement of 20 % blasts for most acute myeloid leukemias that carry defining genetic abnormalities. A parallel International Consensus Classification, also of 2022, takes the same multiparameter approach. The US regulation for leukemia and lymphoma panels requires their labeling to say that results "should be interpreted by a pathologist or equivalent professional" together with other clinical and laboratory findings.

The 2013 recommendations of the international hematology and clinical cytometry societies describe the report itself. Interpretation is reserved for people who know malignant hematology, instrumentation, software and data analysis. Abnormal populations are quantified as percentages and described by their intensity, bright or dim, relative to their normal counterparts, and the findings are correlated with morphology. Counts such as lymphocyte subsets carry a comment that compares them with the reference range (Chapter 20). An Italian society's report format for acute leukemia lists 13 elements. They run from the specimen type and the sample quality, including viability, to the gating procedure, the blast phenotype and the panel to use later for residual disease.

59 — Reading a report
ILLUSTRATIVE REPORT: NOT A REAL PATIENT OR LABORATORY SPECIMEN peripheral blood, EDTA; received within 24 h QUALITY viability 96 % · cells acquired 100,000 per tube GATING CD45 vs side scatter; singlets; viable POPULATION CD5+ CD19+ B cells: 62 % of lymphocytes INTENSITY CD20 dim, surface immunoglobulin dim CLONALITY kappa restricted ABSOLUTE COUNT 12 × 10⁹ per liter (single-platform beads) denominator: lymphocytes (vs normal B cells) INTERPRETATION “Findings consistent with a clonal B-cell population with a CLL phenotype; correlate with morphology and clinical findings.” all values illustrative, for this guide Ch. 12 gates and denominators Ch. 11 controls Ch. 21 absolute count interpreter: pathologist or equivalent every percentage needs its denominator
Focal detail
Plate 59 — A clinical report is a chain of decisions made visible: specimen quality, gating, each population with its denominator and intensity relative to normal, absolute counts where relevant, and an interpretation by someone qualified to make it.
Write the intended use and the report together

For a panel developed for clinical use, state the intended use: the conditions, the specimen types, the population reported and its denominator. State also the limit of detection for an abnormal population and the interpretation statement that the labeling will carry. For a laboratory, fix a report template that names the specimen, the sample quality and viability, and the gating strategy. The template also gives each population with its denominator and its intensity relative to normal, absolute counts where relevant, and the interpreter's comment.

+ What this chapter established
  • Clinical cytometry helps diagnose leukemias, lymphomas and related neoplasms, counts CD4 and CD34 cells, and detects residual disease, but it is not indicated for isolated rises in mature blood cells.
  • Lineage is read from patterns: EuroFlow's orientation tube pairs internal lineage markers with surface markers, refined on 385 leukemias and tested on 483.
  • Chronic lymphocytic leukemia rests on CD5-positive B cells with a single light chain at 5 × 10⁹ per liter or more for at least three months.
  • Results are integrated with morphology and genetics by a qualified interpreter, and every reported percentage needs its denominator.
22 — Validation

Proving an assay does what it claims.

+ The questionAn instrument can be verified with beads, but a clinical result depends on cells that have no certified reference. How does a laboratory show that a flow assay is precise, sensitive and stable enough, and how many cells does a rare-event result need?

Validation without a reference cell

Most clinical tests are anchored to reference materials: a solution of known glucose, a serum of known hormone concentration. Cytometry has almost none for the quantities it reports. The international hematology and clinical cytometry societies published recommendations in five parts in 2013 (Chapter 21). The recommendations state the problem plainly: stable reference preparations "are unavailable for the cell-based measurements," and tracing a cell measurement back to a defined molecular quantity is not yet feasible. A laboratory must therefore prove its assay with patient samples, stabilized cells and careful design rather than with certified standards. That proof is validation, which shows that an assay serves its clinical or scientific purpose, just as verification shows that an instrument meets its specification (Chapter 15).

The Clinical and Laboratory Standards Institute, which writes standards for clinical laboratories, published the most complete guide to validation on 27 October 2021. It is H62, Validation of Assays Performed by Flow Cytometry, a first edition of 234 pages. Its governing idea is fit for purpose: "the level of validation should be tailored to the intended use of the data." The standard adds that this is "not an endorsement for inadequate validation." The institute noted that before H62 there were no official guidance documents for validating flow assays, and this guide found no FDA guidance specific to them.

In the United States the legal minimum is set by the CLIA regulations of Chapter 18. A laboratory using an unmodified cleared test verifies its accuracy, precision and reportable range, the span of results the test can report. It also confirms the reference intervals for its own patients. A reference interval is another name for the reference range of Chapter 20. For a test it developed or modified, the laboratory must establish accuracy, precision, analytical sensitivity and specificity, reportable range and reference intervals itself.

What kind of result

What has to be validated depends on what the assay reports. H62 and the 2013 recommendations sort flow assays into categories. A quantitative assay with true reference standards reports absolute values, which cytometry rarely achieves. A quasi-quantitative assay reports numbers that are proportional to the quantity but have no calibration standard, and a CD4 count is the usual example. A qualitative assay reports a category, such as the presence of an abnormal population with a given phenotype, and leukemia immunophenotyping belongs here. When the FDA authorized the first leukemia panels, it described them as qualitative assays.

60 — The validation menu depends on the assay
QUANTITATIVE rare in cytometry QUASI-QUANTITATIVE e.g., CD4 count QUALITATIVE e.g., leukemia phenotyping PARAMETER precision across range – linearity – limit of detection / quantitation reference intervals – agreement with diagnosis – – precision of the call – – smallest abnormal population detected – – specimen stability reagent stability and lots carryover the question a leukemia panel must answer CLSI H62 (2021): fit for purpose; ICSH/ICCS 2013
ReadoutFocal detail
Plate 60 — What a laboratory must show depends on what its assay reports. Counts need precision across their range, linearity and limits; a qualitative leukemia panel needs agreement with diagnosis and the smallest abnormal population it reliably detects. All need stability, carryover and lot checks.

The category decides the validation menu. A quantitative or quasi-quantitative assay needs precision across its range, linearity, limits of detection and quantitation, and reference intervals. A qualitative assay needs agreement with a reference diagnosis, precision of the call, and the smallest abnormal population it can reliably detect. For leukemia and lymphoma panels, the FDA sets special controls, requirements specific to that type of device (Chapter 23). They express that smallest population as limits of blank, detection and quantitation. The limit of blank is the highest result expected from a sample without the target. The limit of detection is the smallest amount that can be told apart from it, and the limit of quantitation the smallest that can be measured with acceptable precision and accuracy. Both kinds of assay need specimen and reagent stability, carryover and the effect of reagent lots.

Precision and agreement

Precision is measured with replicates, but each replicate is already the average of thousands of cells. The analytical part of the 2013 recommendations therefore limited replicates to no more than six, "since each 'measurement' actually is derived from measurements of tens of thousands of cells." A 2024 teaching workshop summarized the targets of the series' fifth part, on assay performance: a coefficient of variation below 10 % for most results and below 20 % for populations of about one in a thousand or rarer. The US special controls for leukemia and lymphoma panels go further for manufacturers, requiring precision on clinical samples at a minimum of three sites, at least two of them external, and reproducibility across at least three reagent lots.

Agreement is where the category matters most. The manufacturer of the first authorized leukemia panels ran the study behind them, and the FDA reviewed it. Two blinded experts read 279 specimens from four sites, and their readings were compared with each site's final diagnosis. Their sensitivity was 82 and 86 %, and their specificity 94 and 93 %. Sensitivity here is the share of patients with the disease whom a reader called positive, and specificity the share of patients without it whom a reader called negative.

In a later submission for a newer instrument, the same manufacturer reported 100 % agreement with its predicate instrument, the cleared instrument it was compared with, across 512 specimens stained with the manufacturer's later ten-color panels (Chapter 23). Both figures are correct, and they answer different questions. The first measures how often the panel's reading matches the patient's eventual diagnosis, and the second how often two instruments give the same reading.

61 — Two kinds of agreement
PANEL VS FINAL DIAGNOSIS FINAL DIAGNOSIS disease no disease PANEL READING positive negative true + false + false − true − SENSITIVITY 82 % · 86 % SPECIFICITY 94 % · 93 % two blinded experts 279 specimens, 4 sites ≠ different questions NEW INSTRUMENT VS PREDICATE INSTRUMENT PREDICATE INSTRUMENT positive negative NEW INSTRUMENT positive negative agree 0 0 agree 512 specimens 100 % AGREEMENT agreement with a machine, not with the patient manufacturer studies reviewed by the FDA
ReadoutFocal detail
Plate 61 — Agreement with a diagnosis and agreement between instruments answer different questions. The panel's readings matched final diagnosis with 82–86 % sensitivity and 93–94 % specificity; two instruments agreed on all 512 specimens.

Rare events and the limits of detection

Residual-disease testing pushes validation to its limit. The 2018 guidelines of Chapter 21 define undetectable disease in chronic lymphocytic leukemia as fewer than one leukemic cell in 10,000 leukocytes, or white blood cells. Myeloma is a cancer of plasma cells, the cells that make antibodies, and it grows in the bone marrow (Chapter 18). For myeloma, the EuroFlow consortium described next-generation flow in a 2017 study: two eight-color tubes, bulk lysis to acquire at least 10 million cells per sample, and automated gating against a database of normal marrows. Bulk lysis removes the red cells from a large volume of sample, which leaves many more white cells to measure.

The myeloma study defined the limit of detection as 20 abnormal plasma cells among at least 10⁷ events, 2 in a million or lower, and the lower limit of quantitation as 50, 5 in a million or lower. In 110 marrows from patients in deep response, 47 % were positive by the new method against 34 % by conventional eight-color cytometry.

The limits are counts, so they depend on how many cells were actually acquired. In the same study the median sample yielded 10.4 million cells, and 7 of 110 fell below 7 million. For B-cell precursor leukemia, a leukemia of immature B cells, a 2017 study compared flow cytometry with a PCR test, which copies and counts a DNA sequence found only in the leukemic cells. The study found flow cytometry at least as sensitive, reaching 1 in 100,000 "if sufficient cells are measured," which meant more than 4 million. In a 2022 analysis of acute myeloid leukemia, the target of 500,000 CD45-positive events was reached in 158 of 261 patients.

What a 20-event limit means

Counts of rare cells follow Poisson statistics (Chapter 12). If a sample truly contains enough abnormal cells to give 20 events on average, a single measurement shows 20 or more only about 53 % of the time. A 95 % chance of reaching 20 needs an expected count of about 28, and seeing at least one abnormal cell with 95 % probability needs an expected count of 3. The 20- and 50-event conventions are rules for how many events make a population, not statistical detection limits in the sense used for chemistry tests. The probabilities are derived for this guide.

62 — How many cells a residual-disease limit needs
10,000 100,000 1,000,000 10,000,000 100,000,000 1 in 1,000 1 in 10,000 1 in 100,000 1 in 1,000,000 CELLS NEEDED (LOG SCALE) TARGET FREQUENCY (LOG SCALE) 50 events (limit of quantitation) 20 events (limit of detection) acute myeloid leukemia target: 500,000 CD45+ events B-precursor leukemia: > 4,000,000 cells for 1 in 100,000 myeloma, next-generation flow: ≥ 10,000,000 cells (LOD 2 in a million) valid only if the sample reached 10 million cells expected 20 → sees ≥ 20 only 53 % of the time; 95 % needs about 28
ReadoutFocal detail
Plate 62 — Residual-disease limits are counts. Twenty abnormal cells at one in 100,000 need two million cells; at one in a million, twenty million. A sample that yields fewer cells has a correspondingly higher limit.

Regulators have taken note of residual disease as evidence. In a 2020 guidance on its use in drug development, the FDA asked that an assay detect at least tenfold below the clinical decision threshold. In April 2024 an FDA advisory committee voted 12 to 0 that residual disease could support accelerated approval of myeloma drugs, a route that approves a drug on an early measure likely to predict its benefit. In January 2026 the FDA issued a draft guidance that describes that early measure as the proportion of patients in complete response whose bone marrow is negative for residual disease by flow cytometry or sequencing, at a threshold of at least 1 in 100,000 cells. As of October 2026 this guide found no final version, and the only residual-disease device it found authorized in the United States was a sequencing test. Flow cytometric residual-disease assays run as laboratory-developed tests, which a laboratory designs and runs itself.

A validated limit applies only to samples that reach it

A residual-disease result reported as negative at 1 in 100,000 is negative at that level only if enough cells were acquired, the sample was fresh enough and the controls passed. A sample that yields a tenth of the target cells has a detection limit ten times higher, and a report that omits the number of cells analyzed hides that change.

Stability, lots and quality over time

A validated assay stays valid only within its tested conditions. Heparin and EDTA are anticoagulants, which keep blood from clotting. The 2013 recommendations on preanalytical issues, the handling of a sample before analysis, describe blood in heparin as optimally stable for 48 to 72 hours and in EDTA for up to 48 hours at room temperature. They note that some markers degrade faster with time than others: CD138 and CD16 more than CD45 or CD64. CD138 marks plasma cells, so in a myeloma residual-disease test the age of the marrow sample bears directly on the result. Stability is validated by testing at least five specimens of each type and anticoagulant over time, up to the oldest sample the laboratory will accept.

Reagent lots are a recurring change. Under the analytical recommendations, a new lot or any major hardware change calls for a full compensation procedure, and tandem dyes need values specific to each lot (Chapter 10). Over time, laboratories hold quality with daily instrument checks (Chapter 16), external quality assessment and accreditation. External quality assessment compares laboratories in the same way as the proficiency tests of Chapter 16, and the 2013 recommendations make it mandatory at least three times a year. Accreditation is to ISO 15189:2022, the international standard for medical laboratories. Under the arrangement among accreditation bodies, accreditation to the 2012 edition has not been recognized since the transition ended in December 2025. One UK scheme runs 11 accredited and 6 pilot programs for cytometry, from stem-cell counts to residual disease. List-mode files and analysis files are kept for at least two years (Chapter 18).

Build the validation plan from the intended use

State the assay category, then list the parameters it needs, each with acceptance criteria. They include precision with replicates and sites, agreement with a stated reference, and limits of detection and quantitation as event counts and cell numbers. They also include specimen and reagent stability, carryover, lot-to-lot reproducibility and reference intervals. Use H62 and the 2013 recommendations as the checklist. For rare-event assays, report the number of cells acquired and the resulting detection limit with every result.

+ What this chapter established
  • Cytometry lacks certified reference cells, so assays are validated with patient samples, stabilized cells and design; CLSI H62 of 2021 sets a fit-for-purpose approach.
  • The assay category, quantitative, quasi-quantitative or qualitative, decides what must be shown; agreement with a diagnosis differs from agreement between instruments.
  • Residual-disease limits are counts: 20 abnormal cells in 10⁷ for myeloma, which only samples that actually reach 10⁷ cells can claim.
  • Stability, reagent lots, external quality assessment and accreditation keep a validated assay valid over time.
23 — Regulation

From panel to authorized product.

+ The questionWhat must a cytometer, its reagents and a laboratory's own panel show before they may be used on patients in the US, the EU and India?

Three objects, three questions

The US Food and Drug Administration states that until June 2017 it had authorized no flow cytometry test to aid in detecting leukemias and lymphomas.

Clinical cytometry puts three kinds of object in front of regulators. The instrument measures light. The reagents decide what is measured: single antibodies or premixed panels, with the software and templates that come with them. And many laboratories build their own assays from single reagents, validate them themselves and report the results (Chapter 22). Each jurisdiction treats the three differently.

The evidence asked for is more uniform. The European regulation for diagnostic devices names three questions. Scientific validity: is the marker pattern associated with the condition? Analytical performance: does the complete system, instrument included, detect and measure the pattern correctly? Clinical performance: do its results correspond to the condition in the intended patients? The status of everything below is stated as of October 2026.

United States

In the United States the FDA classifies devices by risk and type, from class I, the lowest risk, to class III, the highest. The Clinical Laboratory Improvement Amendments, CLIA, regulate the laboratories that use the devices.

Instruments and most cleared reagents. Cytometers are cleared under the regulation for automated differential cell counters, 21 CFR 864.5220, and under a product code for flow cytometric reagents and accessories. The regulation's text covers devices using "a flow cytometric method utilizing monoclonal CD (cluster designation) markers." These are class II devices that need a premarket notification, a 510(k), in which the maker shows that a new device is substantially equivalent to one already on the market, called its predicate.

The clearances between 2013 and 2023 include analyzers from two manufacturers. The FDA cleared one of these analyzers on 3 July 2017 for in vitro diagnostic use on six fluorescence channels only, although its larger configurations have more. Another analyzer replaced the photomultipliers of its predicate with the avalanche photodiodes of Chapter 8, and the FDA cleared it on 22 November 2023 on the basis of a method comparison. This guide found only conventional instruments among the US clearances and no full-spectrum analyzer, although spectral analyzers have been approved for clinical use elsewhere, including China.

Leukemia and lymphoma panels. The first panels were authorized through the De Novo route, which the FDA uses for new devices of low to moderate risk that have no predicate. A request for five-color reagents was received on 3 October 2016 and granted on 29 June 2017, and the FDA called it the first authorization of a flow cytometry test to aid in detecting these blood cancers. The grant created a new regulation, 21 CFR 864.7010, codified on 27 December 2017. It was amended in December 2025, without change of substance, to refer to the new Quality Management System Regulation.

The regulation's special controls ask for the neoplasms validated, the number of events to collect, precision at three or more sites, reproducibility across three reagent lots, carryover, stability, and limits of blank, detection and quantitation. They also ask for "clear examples of all expected phenotypic patterns and gating strategies." A ten-color successor, cleared by 510(k) in March 2019, carries CD45 and CD34 on the same dyes in all four of its tubes. It is the backbone design of Chapter 21 in a commercial product.

Single reagents and laboratory tests. A single antibody sold for laboratories to build their own tests is an analyte-specific reagent, class I and exempt by default. It may be sold only to manufacturers, high-complexity laboratories and non-diagnostic users, and without performance claims. A laboratory that reports a test built from such reagents must state: "This test was developed and its performance characteristics determined by (Laboratory Name). It has not been cleared or approved by the U.S. Food and Drug Administration." The FDA's 2007 guidance states that reagents bundled as a preconfigured mixture are not analyte-specific reagents, so a premixed clinical cocktail needs its own FDA authorization, by 510(k) or, for a new type, De Novo. Reagents labeled for research use only may not be promoted for diagnosis.

Laboratory-developed tests. In 2024 the FDA issued a rule bringing such tests under device regulation. A federal court vacated the rule on 31 March 2025, and the agency removed its language from the regulations on 19 September 2025. Flow cytometry tests developed in laboratories therefore remain under CLIA, as high-complexity tests that must establish their own analytical performance; CLIA does not review their clinical validity. As Chapter 22 noted, this guide found no flow cytometric residual-disease assay authorized by the FDA; the one authorized residual-disease device it found is a sequencing test, granted in September 2018.

63 — Three objects, three jurisdictions
US EU (IVDR) INDIA (MDR 2017) INSTRUMENT CLASS II 21 CFR 864.5220 510(k) CLASS A Rule 5 self-declared CLASS A “flow cytometry analyser” REAGENT PANEL CLASS II 21 CFR 864.7010 De Novo 2017, then 510(k) class C by analogy Rules 3(h), 3(k) notified body probably class C not listed LAB'S OWN ASSAY LDT UNDER CLIA single antibodies as ASRs (class I) IN-HOUSE DEVICE Art. 5(5) EN ISO 15189 no pathway found no route like an LDT or an in-house device status as of October 2026
ReadoutFocal detail
Plate 63 — The same three objects are classed differently in each jurisdiction: the instrument is class II in the US and class A in the EU and India; a leukemia panel has a dedicated US regulation, is class C by analogy in the EU and probably class C in India; a laboratory's own panel has a route in the US and the EU but not clearly in India.

European Union

The In Vitro Diagnostic Medical Devices Regulation, the IVDR, has applied since 26 May 2022. It sorts devices into classes A to D, from the lowest risk to the highest, by rules in its Annex VIII. The class decides whether the manufacturer self-declares conformity or a notified body assesses it. A notified body is an independent organization that an EU country designates to assess devices against the regulation.

Instruments. Rule 5 places instruments that the manufacturer specifically intends for diagnostic procedures in class A, while the reagents they run are classed in their own right. A cytometer sold for use with antibody reagents therefore falls in class A by this reading of the rule, and the manufacturer of a non-sterile class A device declares its conformity itself.

Reagents. The Medical Device Coordination Group, which brings together the device authorities of the EU countries, publishes guidance on the classification rules for in vitro diagnostic devices. Its September 2026 revision of that guidance gave no flow cytometry example. It does place CD4 T-cell counting in people with HIV in class C, under the rule for managing life-threatening disease, and it places FISH panels for lymphoma, myeloma and leukemia in class C under the rule for cancer diagnosis. FISH tests use fluorescent DNA probes that bind to chosen sites on the chromosomes and so reveal changes in them. Leukemia immunophenotyping panels are therefore class C by close analogy rather than by a named example.

Transition. Reagents of this kind were generally self-certified under the directive that the IVDR replaced, and they now need a notified body for the first time. A legacy device is one whose conformity was declared under the old directive before the IVDR applied. A 2024 regulation amending the IVDR's transition rules lets a legacy class C device stay on the market until 31 December 2028, but only on conditions. Its manufacturer must have had an IVDR quality management system in place by 26 May 2025, applied to a notified body by 26 May 2026 and signed an agreement by 26 September 2026, and the device must not have changed significantly. All three dates have passed, so a legacy panel that missed any of them cannot rely on the extension.

In-house devices. A hospital laboratory that assembles a panel from research-use reagents and uses it for diagnosis makes an in-house device under Article 5(5). The coordination group's 2023 guidance confirmed that this applies to research-use components. The laboratory must work under an appropriate quality system, comply with EN ISO 15189 or national provisions and publish a declaration. From 26 May 2028 it must also justify why no equivalent CE-marked device, one that carries the EU mark of conformity, meets its patients' needs. In December 2025 the European Commission proposed dropping that condition, and as of October 2026 the proposal was still at committee stage in the European Parliament.

64 — IVDR dates that matter for cytometry
2022 2023 2024 2025 2026 2027 2028 2029 Oct 2026 26 MAY 2026 class C: application to notified body 26 SEP 2026 class C: written agreement passed: legacy panels that missed it cannot rely on the extension 31 DEC 2028 legacy class C may stay on the market until 26 MAY 2022 IVDR applies 26 MAY 2024 in-house conditions (b, c, e–i) apply 26 MAY 2028 in-house: no-equivalent- device condition (d) Dec 2025 proposal would drop (d): at committee stage, Oct 2026
ReadoutFocal detail
Plate 64 — For legacy class C reagents, the deadlines to apply to a notified body and sign an agreement passed in 2026. For in-house panels, the no-equivalent-device condition applies from 26 May 2028 unless the 2025 simplification proposal is adopted first.

India

India's Medical Devices Rules, 2017, have been in force since 1 January 2018, and they classify diagnostic devices into classes A to D. The Central Drugs Standard Control Organisation, India's national regulator for drugs and devices, publishes the classification of device types. Its list, updated on 25 October 2023, names the "Flow cytometry analyser" as class A, beside hematology and blood-cell-count analyzers. The list describes that analyzer as intended to count, examine or sort cells or microscopic particles in a clinical specimen.

Neither that list nor the 2017 list names a flow cytometry reagent. The 2017 list mostly places tumor-marker tests in class C, so by analogy leukemia panels are probably class C, but this guide could not confirm it. Since February 2026, a manufacturer or importer of a device that is not on either list can apply through the regulator's online system for medical devices to have it classified. Licensing has been mandatory for classes A and B since 1 October 2022 and for classes C and D since 1 October 2023. The state authority issues manufacturing licenses for classes A and B, and the central authority for classes C and D. New devices in classes B to D need a performance evaluation on three batches by an accredited or government-recognized laboratory. Products for research use that are not intended for diagnosis fall outside the rules. This guide found no Indian pathway corresponding to CLIA's laboratory-developed tests or the IVDR's in-house devices.

One evidence core, three presentations

The three systems classify the same objects differently. The instrument is class A in the EU and India and class II with premarket notification in the United States. A leukemia panel is class II under a dedicated regulation in the United States, class C by analogy in the EU and probably class C in India. A laboratory's own panel is a CLIA test in the United States, an in-house device in the EU and an unaddressed case in India.

The evidence underneath barely changes. Intended use, precision across sites and lots, analytical sensitivity as events and cells, agreement with diagnosis, stability, carryover and an interpretation statement answer all three regulators, and the laboratory guidance of Chapter 22 supplies the study designs. A manufacturer's file and a laboratory's validation therefore look alike. A developer can build the evidence once, organized by the system's requirements, and present it in three ways.

65 — One evidence core
US EU INDIA EVIDENCE intended use neoplasms named drives the class drives the class precision (sites, lots) ≥ 3 sites (≥ 2 external), ≥ 3 lots Annex I precision 3 batches analytical sensitivity (events, cells) LoB, LoD, LoQ, events to collect LoD, LoQ, cut-off per protocol agreement / clinical performance method comparison or clinical validity clinical performance performance evaluation stability, carryover, anticoagulants required Annex I not specified interpretation statement pathologist or equivalent labeling – lab's own test CLIA, high complexity Art. 5(5) + ISO 15189 no route found study designs: CLSI H62, ICSH/ICCS 2013 one core, three presentations
Focal detail
Plate 65 — The regulators classify differently but ask for nearly the same evidence: intended use, precision across sites and lots, analytical sensitivity in events and cells, agreement, stability and carryover, and an interpretation statement. Built once, it can be presented three ways.
Research use only is a label, not a lesser approval

A reagent labeled for research use only carries no claim of clinical performance. When a laboratory uses it to diagnose, the responsibility moves to the laboratory. In the United States the test becomes a laboratory-developed test under CLIA and in the EU an in-house device under Article 5(5), while in India the rules give no clear route. In none of the three does the label make clinical use lawful by itself.

Classify every object in every market, and track the dates

For a cytometer, a reagent panel or a laboratory's own assay, write the intended use once. Determine its class in each target market against current regulations and guidance, and record the route, the assessor and the evidence required. Keep a dated register of the deadlines that apply, including the EU's 26 May 2028 condition for in-house devices, and recheck it whenever guidance is revised.

+ What this chapter established
  • In the US, cytometers and cleared reagents other than leukemia panels are class II under 21 CFR 864.5220, leukemia panels fall under 21 CFR 864.7010 since a 2017 De Novo, and laboratory-developed tests remain under CLIA.
  • In the EU, instruments are class A and leukemia panels class C by analogy; legacy class C panels may stay until 31 December 2028 only if they met conditions due by 26 September 2026, and in-house panels face a no-equivalent-device test from 26 May 2028 unless a pending proposal drops it.
  • In India, the flow cytometry analyzer is class A, reagent classes are not listed, and new class B to D devices need a three-batch performance evaluation.
  • One evidence core of intended use, precision, sensitivity, agreement, stability and interpretation answers all three regulators.

+ Part VIII · Beyond the analyzer

The same principles, stretched.

The analyzer measures each particle once and lets it go. This last chapter looks at instruments that do more with the same principles: sorters that keep chosen cells alive, imaging cytometers that take a picture of each one, mass cytometers that count metal ions instead of photons, compact counters built for clinics without a laboratory, and algorithms that read the data in place of people. It asks what each gains and gives up, and sets out what remains unsolved.

24 — Beyond

Sorting, imaging, mass and compact cytometers.

+ The questionThe analyzer measures and discards. What changes when a cytometer must also sort cells, photograph them, weigh their labels, fit in a clinic, or be read by an algorithm?

Sorting: a decision before the drop breaks

A droplet sorter measures each cell as an analyzer does and decides whether to keep it before the cell reaches the point where the stream breaks into drops. Then it acts on the stream. A vibrating crystal shakes the jet that leaves the nozzle, and the jet breaks into drops at a regular rate. A teaching guide on sorting gives the optimum spacing of the drops as about 4.5 times the jet's diameter. With a 70-micrometer nozzle at 60 pounds per square inch, most sorters produce 90,000 to 100,000 drops a second and accept up to about 70,000 cells a second. When a wanted cell reaches the point where drops form, the sorter charges its drop, and an electric field deflects that drop into a tube. The drop delay is the time the cell takes to travel from the laser to that point, and it must be set exactly, because if it is wrong, the charged drop is not the one carrying the cell.

66 — A droplet sorter
vibrating crystal 70 µm nozzle, 60 psi: 90,000–100,000 drops/s LASER break-off point ≈ 4.5 × jet diameter − + + sorted waste DROP DELAY wrong delay: the charged drop is empty PURITY MASK ABORT an unwanted cell in the drop window: purity at the cost of yield
ParticlesFluidExcitation lightFocal detail
Plate 66 — A sorter measures each cell, decides, and charges the drop that will carry it when the jet breaks up. With a 70-micrometer nozzle at 60 pounds per square inch, 90,000 to 100,000 drops form each second; the drop delay must be exact.

Cells arrive at random (Chapter 6), so some drops hold two. The sorter therefore applies a mask, a rule for which drops to keep. A purity mask aborts a sort when an unwanted cell falls too close to a wanted one, which gives purity at the cost of yield, the share of wanted cells recovered, while an enrichment mode keeps every candidate drop and accepts impurity. The arithmetic of random arrival decides how fast a sort can run.

How often a drop holds two cells

At 30,000 cells a second and 93,000 drops a second, each drop holds on average 0.32 cells. By Poisson statistics, about 72 % of drops are empty, 23 % hold one cell and 4 % hold two or more. At 70,000 cells and 100,000 drops a second, the average rises to 0.70 and the share with two or more to about 16 %. The teaching guide on sorting tabulates the consequence for a target that makes up a fifth of the cells. With a one-drop envelope, which sorts a single drop for each wanted cell, at 93,000 drops a second, the table shows 96 % of wanted cells sorted at 5,000 cells a second and 77 % at 30,000. The loss at 30,000 is far larger than the 4 % of crowded drops, because what matters is whether a wanted cell shares its drop with an unwanted one: at an average of 0.26 unwanted cells per drop, that happens about 23 % of the time. The occupancy figures are derived for this guide.

Sorting also changes the cells. In a 2018 study of astrocytes, support cells of the brain, nearly half of the metabolic features measured in the sorted cells changed by at least 1.5-fold. The sorted cells also showed a 50 % rise in reactive oxygen species, chemically reactive forms of oxygen that build up when cells are stressed. A 2020 study of human blood cells, by contrast, found no significant differences in viability and proliferation between sort conditions. What an experiment measures after the sort decides whether sorting harms it. Sorters also make aerosols from samples that may be infectious, which is why biosafety rules built on the international cytometry society's 2014 standard require aerosol management and regular containment testing.

Pictures and ions

An imaging flow cytometer records a picture of each cell as it flows. A 2007 review by staff of its first manufacturer describes it as combining the statistical power of flow cytometry with the spatial resolution of microscopy. The cost is speed. One manufacturer states 5,000 objects a second at 20-fold magnification, 2,000 at 40-fold and 1,200 at 60-fold, against tens of thousands for an analyzer.

Image-activated sorting joined imaging to sorting, so that the decision to keep a cell rests on its picture. A 2018 system imaged cells, classified them with deep learning and sorted about 100 cells a second, and its 2020 successor sorted about 2,000 cells a second, with a sensitivity near 50 molecules of equivalent soluble fluorochrome. In 2022 a manufacturer's developers and an academic group reported an instrument that sorted on fluorescence images at up to about 15,000 events a second.

67 — Information per event against speed
100 1,000 10,000 100,000 INFORMATION PER EVENT ↑ parameters + image parameters EVENTS PER SECOND (LOG SCALE) schematic placement; manufacturer and study figures 60×: 1,200/s 40×: 2,000/s 20×: 5,000/s IMAGING 100/s (2018) 2,000/s (2020) ~15,000/s (2022, manufacturer) IMAGE-ACTIVATED SORTING closing the gap mass cytometry: ≤ 1,000/s, 34 parameters, no scatter, 30–50 % of cells recorded counts ions, not photons spectral: up to 35,000–40,000/s analyzer: tens of thousands/s
ReadoutFocal detail
Plate 67 — Beyond the analyzer, every gain in information per event is paid for in speed: imaging falls from 5,000 objects a second at 20-fold to 1,200 at 60-fold, and mass cytometry measured 34 parameters at up to about 1,000 cells a second without scatter.

Mass cytometry replaces dyes with metal isotopes. Each antibody carries a different metal, and each cell is vaporized in an argon plasma, a gas so hot that its atoms lose electrons and become ions. A time-of-flight mass spectrometer then counts the metal ions, telling the metals apart by the time their ions take to fly a fixed distance, which depends on their mass.

In a 2011 study whose authors included staff of the instrument's maker, the mass cytometer measured 34 parameters per cell at up to 1,000 cells a second, without forward or side scatter. A 2015 primer reported that only about 30 % of the cells introduced were recorded, rising to 50 % in a later model. In mass cytometry the number in the file is a count of ions rather than of photons. The distinction that Chapter 1 drew between particle, signal and number still holds in its general form, because the number still measures a signal, not a particle.

Compact counters and the clinic

Some of cytometry's most important clinical uses are simple counts in places without a laboratory. By 2012 the World Health Organization had prequalified a point-of-care CD4 analyzer, one used beside the patient rather than in a laboratory, and in 2014 it prequalified a second. Prequalification is the organization's assessment of a product's quality, safety and performance, which guides purchases by health programs. The maker of the first analyzer states that it reports results in under twenty minutes.

A 2015 meta-analysis of that analyzer pooled 22 studies and 11,803 paired measurements. It found that the analyzer read on average 23 cells per microliter below the laboratory reference, at a median reference count of 383 cells per microliter. Of the patients whose laboratory count was below 350 cells per microliter, it placed 93 % below that threshold too. In 2020 the organization prequalified a CD4 test that is a strip read by eye, which reports only whether the count is above or below 200 cells per microliter.

Point-of-care CD4 testing is a clinical role rather than an instrument class. The strip is not a cytometer at all, and neither analyzer is a flow cytometer, although the organization lists the first under that heading. Each analyzer labels cells with fluorescent antibodies in a disposable cartridge and counts them in camera images. The organization's public report on the first describes static image analysis, and the US clearance of the second describes an imaging cytometer whose sample stays still while it is imaged.

At the other extreme, dedicated small-particle analyzers are built for extracellular vesicles, the guide's hard measurement. By its maker's figures, one such instrument detects biological particles best between 40 and 200 nanometers, the range that Chapter 19 found beyond conventional cytometers. Claims of this kind need the calibration and controls of Chapters 17 and 20 before their counts can be compared.

Algorithms as readers

Software increasingly does the reading. In a 2026 study, one clinical laboratory described a pipeline for residual chronic lymphocytic leukemia that cleaned the data, clustered events, mapped them and classified them with a neural network. The pipeline agreed closely with expert review in 227 research samples and 192 validation samples. It detected every case at or above 0.01 % and cut analysis time from 9.0 to 0.9 minutes per case.

The study did not state a regulatory status. In October 2026 this guide found no flow cytometry analysis software on the FDA's list of AI-enabled devices, though the list was only partly searchable. Other methods go further. Ghost cytometry classifies cells from structured light, a fixed pattern of illumination that each cell crosses, without forming an image, at more than 10,000 cells a second. It was published in 2018 by a group whose members founded a company to commercialize it.

An algorithm depends on every step that comes before it. It reads data that have been compensated, transformed and gated, from an instrument run at its settings (Chapters 10 to 13). The algorithm is therefore part of the system to be specified, validated and regulated, not an independent judge (Chapters 22 and 23).

What remains unsolved

Several problems run through every instrument in this chapter. Reference materials with values traceable to physical units remain scarce for cells and for vesicles, so most results are standardized rather than calibrated (Chapter 17). Sensitivity below 100 nanometers remains out of reach for nearly all cytometers, and most vesicles, by number, are smaller than nearly any cytometer can detect (Chapter 19). The file still cannot hold several settings that decide whether its numbers are valid (Chapter 18). And the comparability of intensities between laboratories stops at a variation of about 30 %, even under full standardization (Chapter 16).

The instrument described at Los Alamos in 1969 sorted the flashes of one stain into a histogram, and the ratio of its two peaks came out at 1.97 against an expected 2.00. That check was simple, because DNA doubles exactly and one stain reported it. The cytometers of this guide are asked harder things. Patterns of light from labeled proteins tell one kind of cell from another. Physics sets how small a particle can be seen, at roughly 100 to 250 nanometers for well-calibrated instruments today. Whether a count can be trusted as a test result depends on the whole system: how it is specified, calibrated, controlled, validated and recorded. Most of the work still open lies there.

A new instrument class is a new measurement

A sorter, an imaging cytometer, a mass cytometer and a compact counter each measure differently from the analyzer they resemble. Their limits of detection, their precision and the populations they report must be established on their own, not carried over from the analyzer whose results they are compared with.

Choose the instrument by what the result must be

Before choosing an instrument other than an analyzer, name what the result needs: living cells for further work, morphology, more parameters than fluorescence allows, a count without a laboratory, or faster reading. Each instrument class gains one of these and gives up speed, recovery, scatter or breadth. Write the intended use down first, because it decides between them.

+ What this chapter established
  • Droplet sorters run at 90,000 to 100,000 drops a second with a 70-micrometer nozzle, trading purity against yield, and sorting alters metabolism more than viability.
  • Imaging cytometers trade speed for pictures, and mass cytometers count metal ions for more parameters at lower rates and without scatter.
  • Point-of-care CD4 counting is a clinical role filled by compact analyzers and even strips, while small-particle analyzers target the vesicle range.
  • Algorithms can read data faster than experts but inherit every upstream setting; reference materials, sub-100-nanometer sensitivity, the file and comparability remain unsolved.
§ Lessons

Lessons.

Thirteen rules distilled from the chapters, for people who design, verify, buy, regulate or write about flow cytometers and the tests run on them. Each names the chapter whose mechanism it rests on.

  1. Treat every number as a measurement of light, not of a particle. An event is a pulse that crossed a threshold: it may be one cell, two cells, debris or a swarm of vesicles. A particle that stayed below the threshold leaves no record at all (Chapters 1, 6, 9 and 19).
  2. Specify detection channel by channel, as detection efficiency Q and background B. In the published example of Chapter 8, background, not detector efficiency, set the dimmest resolvable signal. Single sensitivity figures on datasheets cannot be compared between manufacturers (Chapters 8 and 15).
  3. Never read forward scatter as size, or bead size as vesicle size. Scatter depends on refractive index and collection angle as much as on diameter; a 100-nanometer polystyrene bead scatters like a vesicle of about 175 nanometers (Chapters 4, 15 and 17).
  4. Fix the flow rate, the trigger and the threshold, and record them. A faster run widens the core and raises coincidence. The threshold decides which particles exist in the data (Chapters 6 and 9).
  5. Expect compensation to restore averages, never precision. Spillover spreading grows with the square root of the spilled light. Dim markers therefore belong in detectors that bright dyes on the same cells do not spread into (Chapters 10 and 14).
  6. Set each positive boundary on a control that contains everything except the specific binding. Fluorescence-minus-one controls and cells known to lack the marker do that. Unstained and isotype samples do not (Chapter 11).
  7. Keep the original file, and record what it cannot hold. Transforms, gates, matrices, denominators, laser delays and software versions decide what a number means. The standard file keeps only some of them (Chapters 12, 13 and 18).
  8. Count donors as replicates, and count enough events of the population reported. A million events from one sample are one observation. A rare population's precision depends on its own events: one hundred events give about 10 % (Chapters 12 and 22).
  9. Own the interfaces, and check them in every run. Failures in stream speed, laser delays, sample preparation and settings arise at the boundaries between subsystems. They look like biology rather than like errors (Chapters 7, 13 and 16).
  10. Standardize to make instruments alike; calibrate to make numbers mean something. Shared targets made beads agree within 5.5 % and cells within about 30 %. Calibrated units carry the assumptions of their models (Chapters 16 and 17).
  11. Prove that each vesicle event is one particle, and a vesicle. A dilution series, buffer and reagent controls and a detergent step come before any count, and every count needs its size window, brightness threshold and measured volume (Chapters 19 and 20).
  12. Validate for the intended use, and report the cells acquired with every rare-event result. A limit of 20 abnormal cells in ten million applies only to a sample that reached ten million cells (Chapters 21 and 22).
  13. Assemble the evidence once, then map it to each jurisdiction. The instrument, the reagents and a laboratory's own panel are classed differently in the US, the EU and India. A research-use label never makes clinical use lawful by itself (Chapter 23).
§ Glossary

Glossary.

Terms are defined as they are used in this guide.

510(k)
A US premarket notification showing that a device is substantially equivalent to a legally marketed device; a cleared 510(k) allows marketing.
Abort (electronic)
An event discarded by the electronics because a second pulse arrived while the first was still being processed.
Analog-to-digital converter
The circuit that samples a detector's voltage many millions of times a second and turns it into numbers.
Analyte-specific reagent
In the US, a single reagent such as an antibody sold for laboratories to build their own tests, without claims of performance.
Antibodies bound per cell
A calibrated unit giving the number of labeled antibodies bound to a cell, based on a biological standard such as CD4 on T cells.
Antigen density
The number of copies of a protein on a cell, which sets how many antibodies, and how much dye, a cell can carry.
Area, height and width
The three numbers taken from each pulse: the integrated signal, its peak and its duration.
Autofluorescence
The faint fluorescence of unlabeled cells, from molecules such as flavins inside them.
Avalanche photodiode
A semiconductor detector with high efficiency in the red and near-infrared and modest internal gain.
Backbone markers
Markers placed on the same dyes in every tube of a panel so that the population of interest lands in the same place in each tube.
Bandpass filter
A filter that passes a stated band of wavelengths; 530/30 passes 515 to 545 nanometers.
Calibration
Relating an instrument's arbitrary units to physical units, such as molecules, square nanometers or volume, through a reference material and a model.
Carryover
The fraction of one sample that appears in the next sample run on the same instrument.
CD (cluster of differentiation)
The international numbering of cell-surface proteins recognized by antibodies, such as CD4 or CD19.
CLIA
The US Clinical Laboratory Improvement Amendments, which regulate clinical laboratories, including the tests they develop themselves.
Clonality
Descent of a population of cells from one cell; for B cells, shown by a single light chain, kappa or lambda.
Clustering
Grouping events by similarity with an algorithm instead of hand-drawn gates.
Coefficient of variation (CV)
The standard deviation of a population divided by its mean, as a percentage; a robust CV uses percentiles instead.
Coincidence
Two or more particles in the laser beam within one processing window, recorded as one event or aborted.
Compensation
Subtracting each dye's spillover from the other detectors, using values measured on single-stain controls.
Control
A sample, or a population within a sample, that supplies the comparison on which a positive boundary is set.
Core stream
The thin thread of sample at the center of the sheath flow that carries particles in single file through the beam.
De Novo
The US route for a new type of low-to-moderate-risk device with no predicate; a granted request creates a new classification.
Dichroic mirror
A mirror that reflects light on one side of a stated wavelength and transmits the rest, dividing collected light by color.
Dimmest resolvable signal
The smallest signal whose population still separates from the negatives by two standard deviations each; 4 × (1 ÷ Q + background spread).
Doublet
Two cells passing together and recorded as one event; often removed by comparing pulse area with height.
Drop delay
In a sorter, the time between a cell crossing the laser and its arrival at the point where the jet breaks into drops.
Dynamic range
The span from the dimmest to the brightest signal measured within a stated deviation from linearity.
ERF
Equivalent reference fluorophore: the number of molecules of a stated reference dye in solution giving the same signal as one bead.
Event
A pulse that crossed the threshold and was recorded as one row in the data file.
Extracellular vesicle
A particle released from cells, delimited by a lipid bilayer, that cannot replicate on its own; most are smaller than 200 nanometers.
Fc receptor
A protein on some white cells that holds antibodies by their constant tail, causing binding unrelated to the target.
FCS
Flow Cytometry Standard, the file format for cytometry data; version 3.1 stores keywords and list-mode data and requires the data to be stored uncompensated.
Fit for purpose
Validation tailored to the intended use of the data, as set out in CLSI H62.
Flow cell
The quartz cuvette in which the laser meets the stream in most analyzers.
Fluorescence-minus-one (FMO) control
A sample stained with every antibody of a panel except one, used to set that marker's positive boundary.
Forward scatter
Light scattered by a particle at small angles around the laser's direction.
Full-spectrum (spectral) cytometer
An instrument that records each particle's emission across many detectors and separates dyes by unmixing.
Gate
A boundary drawn on a plot that selects events for the next step of analysis.
Gating hierarchy
The sequence of gates, from time and doublets through viability and lineage to subsets, behind every reported percentage.
Gating-ML
A standard for describing gates and transforms exactly, outside the FCS file.
Hydrodynamic focusing
Narrowing the sample into a thin core inside a faster sheath flow so that particles cross the beam one at a time.
Imaging flow cytometer
An instrument that records a picture of each cell as it flows.
In-house device
In the EU, a test made and used within a health institution under Article 5(5) of the IVDR.
Interface
A boundary between two parts of a system, with parameters both sides must agree on.
Interrogation point
The fixed point at which the laser crosses the stream and each particle is measured.
Intrinsic brightness
A dye's molar absorption coefficient multiplied by its quantum yield.
Isotype control
An antibody of the same class and dye as the test antibody but against an absent target; rarely a good match for its background.
IVDR
Regulation (EU) 2017/746 on in vitro diagnostic medical devices, applicable since 26 May 2022.
Jet-in-air
A sorter design in which the laser meets the free stream after it leaves the nozzle.
Laboratory-developed test
A test made and used within one laboratory; in the US regulated under CLIA.
Laser delay
The interval the electronics wait between a particle's pulse at one laser and its pulse at the next.
Limit of detection
The smallest amount an assay detects with stated reliability; in rare-event cytometry set by convention as 20 events in the final gate, a cluster-size rule rather than a statistical limit.
Linearity
The proportionality of an instrument's output to its input over a stated range.
List mode
Data stored as one row per event and one column per parameter.
Logicle
A display transform that is linear near zero and logarithmic at high values, so compensated data near and below zero can be shown.
Lower limit of quantitation
The smallest amount measured with acceptable precision; in rare-event cytometry often set as 50 events.
Mass cytometry
Cytometry in which antibodies carry metal isotopes that are counted by a mass spectrometer after the cell is vaporized.
MESF
Molecules of equivalent soluble fluorochrome: the number of free dye molecules in solution giving the same fluorescence as a particle.
Mie theory
The physics of light scattering by spheres of any size, used to relate scatter to diameter and refractive index.
MIFlowCyt
The minimum information standard for reporting a flow cytometry experiment, published in 2008.
MIFlowCyt-EV
The extension of MIFlowCyt for vesicle measurements, published in 2020.
Molar absorption coefficient
How strongly a molecule absorbs light of a given wavelength; also called the extinction coefficient.
Numerical aperture
A measure of the width of the cone of light a lens accepts, which sets the fraction of emitted light collected.
Photomultiplier tube
A detector in which one photoelectron is multiplied about ten million times by a chain of electrodes.
Pseudoreplication
Treating measurements that are not independent, such as events from one sample, as replicates.
Pulse
The rise and fall of a detector's signal as a particle crosses the beam.
Q and B
A channel's detection efficiency, in photoelectrons per unit of dye, and its background; together they set the dimmest resolvable signal.
Qualitative, quasi-quantitative and quantitative assays
Assays that report a category, a number without a calibration standard, or an absolute value traceable to standards.
Quantum yield
The fraction of absorbed photons that a molecule emits as fluorescence.
Reference material
A material whose value is known with a stated uncertainty, used for calibration.
Refractive index
How much a material slows light compared with a vacuum; scatter depends on the contrast between particle and medium.
Residual disease (MRD)
Leukemic or myeloma cells remaining after treatment, measured by flow cytometry at frequencies down to about 2 in a million.
Sheath
The clean fluid that surrounds and narrows the sample stream.
Side scatter
Light scattered by a particle at wide angles, collected by the same lens as fluorescence.
Signature
The pattern of one dye's light across all the detectors of a spectral instrument.
Silicon photomultiplier
An array of tiny photodiodes, each firing on a single photon, with high gain.
Single-platform count
An absolute count made in one tube on one instrument relative to a known number of counting beads.
Single-stain control
A sample stained with one dye of a panel, used to measure that dye's spillover or spectral signature.
Spillover
The fraction of a dye's signal in its own detector that appears in another dye's detector.
Spillover spreading
The widening of compensated populations caused by the counting noise of spilled light.
Stain index
The difference between positive and negative medians divided by twice the spread of the negatives.
Standardization
Making instruments read the same reference material alike, without assigning physical units.
Stokes shift
The difference between the wavelengths at which a dye absorbs and emits most strongly.
Swarm detection
Many particles below the detection limit, illuminated together, recorded as one event.
Tandem dye
Two dyes joined so that the first passes its energy to the second, which emits at a longer wavelength.
Target values
Bead intensities that every instrument in a standardized network is adjusted to reach.
Threshold
The level a chosen detector's signal must exceed for the electronics to record an event.
Titration
Staining with a series of antibody amounts to find the one that best separates positive from negative cells.
Trigger
The detector whose signal is compared with the threshold to decide that a particle has arrived.
Unmixing
Finding the amount of each dye whose combined signatures best fit a particle's readings across many detectors.
Validation
Showing that an assay serves its intended use, with precision, sensitivity, agreement and stability established.
Verification
Showing that an instrument or design meets its specification.
Viability dye
A dye excluded by intact membranes that marks dead cells so they can be removed from analysis.
§ Sources

Sources.

Sources are listed by the chapter in which they are first used. Figures from manufacturers, and from studies written by manufacturers' staff, are identified as such in the text. Regulatory status and standards editions are as of October 2026.

  1. Opening — Van Dilla M.A., Trujillo T.T., Mullaney P.F., Coulter J.R. Cell microfluorometry: a method for rapid fluorescence measurement. Science 163, 1213–1214 (1969). doi:10.1126/science.163.3872.1213 (the opening story: stream, laser, pulse length, analyzer rate, the 1.97 peak ratio, the 594-cell comparison and "a minimum of optics")
  2. Ch. 1 — Wikipedia. Flow cytometry (History section), accessed 6 Oct 2026 (web page; secondary). en.wikipedia.org/wiki/Flow_cytometry
  3. Ch. 1 — BD Biosciences. BD FACSCanto II technical specifications, X23-1091801EUROPE (2011). Manufacturer.
  4. Ch. 1 — Spidlen J., Moore W., Parks D., et al. Data File Standard for Flow Cytometry, Version FCS 3.1 — Normative Reference. ISAC (2008–2009); and Data file standard for flow cytometry, version FCS 3.1. Cytometry A 77, 97–100 (2010). doi:10.1002/cyto.a.20825
  5. Ch. 1 — Lee J.A., Spidlen J., Boyce K., et al. MIFlowCyt: the minimum information about a flow cytometry experiment. Cytometry A 73A, 926–930 (2008). doi:10.1002/cyto.a.20623; and MIFlowCyt 1.0 standard document, ISAC Recommendation (21 Feb 2008).
  6. Ch. 1 — Arnold L.W., Lannigan J. Practical issues in high-speed cell sorting. Curr Protoc Cytom 51, 1.24.1–1.24.30 (2010). doi:10.1002/0471142956.cy0124s51
  7. Ch. 1 — flowWorkspaceData (Bioconductor experiment data package): FlowJo workspaces with FCS files of CytoTrol freeze-dried control cells, including CytoTrol_1; gate counts, transform and software comparisons rerun in R 4.6.1 (1 Sep 2026).
  8. Ch. 1 — van der Pol E., van Gemert M.J.C., Sturk A., Nieuwland R., van Leeuwen T.G. Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost 10, 919–930 (2012). doi:10.1111/j.1538-7836.2012.04683.x
  9. Ch. 1 — Welsh J.A., Goberdhan D.C.I., O'Driscoll L., et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles 13, e12404 (2024). doi:10.1002/jev2.12404; definitions as reproduced in ISEV, MISEV2023 slide set (web document). isev.org
  10. Ch. 2 — Coulter W.H. Means for counting particles suspended in a fluid. US Patent 2,656,508 (filed 27 Aug 1949; granted 20 Oct 1953).
  11. Ch. 2 — Picot J., Guerin C.L., Le Van Kim C., Boulanger C.M. Flow cytometry: retrospective, fundamentals and recent instrumentation. Cytotechnology 64, 109–130 (2012). doi:10.1007/s10616-011-9415-0
  12. Ch. 2 — Crosland-Taylor P.J. A device for counting small particles suspended in a fluid through a tube. Nature 171, 37–38 (1953). doi:10.1038/171037b0 (abstract read; the sheath-flow passage is quoted in Purdue University Cytometry Laboratories lecture slides, EE520; Van Dilla et al. 1969 credit their laminar flow chamber to this design)
  13. Ch. 2 — Kamentsky L.A., Melamed M.R., Derman H. Spectrophotometer: new instrument for ultrarapid cell analysis. Science 150, 630–631 (1965).
  14. Ch. 2 — Fulwyler M.J. Electronic separation of biological cells by volume. Science 150, 910–911 (1965). doi:10.1126/science.150.3698.910
  15. Ch. 2 — Sweet R.G. High frequency recording with electrostatically deflected ink jets. Rev Sci Instrum 36, 131–136 (1965). doi:10.1063/1.1719502
  16. Ch. 2 — Dittrich W., Göhde W. Automatisches Meß- und Zählgerät für die Teilchen einer Dispersion. German patent DE1815352 (priority 18 Dec 1968; published 14 Jan 1971); and Impulsfluorometrie bei Einzelzellen in Suspensionen. Z Naturforsch (1969).
  17. Ch. 2 — Van Dilla M.A., Trujillo T.T., Mullaney P.F., Coulter J.R. Cell microfluorometry: a method for rapid fluorescence measurement. Science 163, 1213–1214 (1969). doi:10.1126/science.163.3872.1213 (Los Alamos Scientific Laboratory; argon-ion laser at 488 nm)
  18. Ch. 2 — Hulett H.R., Bonner W.A., Barrett J., Herzenberg L.A. Cell sorting: automated separation of mammalian cells as a function of intracellular fluorescence. Science 166, 747–749 (1969).
  19. Ch. 2 — Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975). doi:10.1038/256495a0
  20. Ch. 2 — Bonner W.A., Hulett H.R., Sweet R.G., Herzenberg L.A. Fluorescence activated cell sorting. Rev Sci Instrum 43, 404–409 (1972). doi:10.1063/1.1685647
  21. Ch. 2 — Herzenberg L.A., Parks D., Sahaf B., et al. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem 48, 1819–1827 (2002).
  22. Ch. 2 — Perfetto S.P., Chattopadhyay P.K., Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 4, 648–655 (2004). doi:10.1038/nri1416
  23. Ch. 2 — Park L.M., Lannigan J., Jaimes M.C. OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood. Cytometry A 97, 1044–1051 (2020). doi:10.1002/cyto.a.24213 (two of three authors at Cytek Biosciences) [authors include manufacturer staff]
  24. Ch. 2 — Konecny A.J., Mage P.L., Tyznik A.J., Prlic M., Mair F. OMIP-102: 50-color phenotyping of the human immune system with in-depth assessment of T cells and dendritic cells. Cytometry A 105, 430–436 (2024). doi:10.1002/cyto.a.24841 (developed on a Sony ID7000 and a BD FACSDiscover S8; two authors are BD Biosciences employees, and BD supplied 11 antibodies) [authors include manufacturer staff]
  25. Ch. 2 — Nolan J.P. The evolution of spectral flow cytometry. Cytometry A 101, 812–817 (2022). doi:10.1002/cyto.a.24566 (read as reprinted in Wiley, Spectral Flow Cytometry Article Collection, 2024)
  26. Ch. 2 — Sony Biotechnology. Press release: launch of the SP6800 Spectral Analyzer, 17 May 2013; and announcement of a spectral analyzer, 19 June 2012. Manufacturer.
  27. Ch. 3 — IUPAC Gold Book. Stokes shift (S06031), from Glossary of terms used in photochemistry, Pure Appl Chem 68, 2223 (1996), p. 2278; and Kasha rule (K03370) (web pages). goldbook.iupac.org
  28. Ch. 3 — Brouwer A.M. Standards for photoluminescence quantum yield measurements in solution (IUPAC Technical Report). Pure Appl Chem 83, 2213–2228 (2011).
  29. Ch. 3 — Shaner N.C., Steinbach P.A., Tsien R.Y. A guide to choosing fluorescent proteins. Nat Methods 2, 905–909 (2005).
  30. Ch. 3 — Oi V.T., Glazer A.N., Stryer L. Fluorescent phycobiliprotein conjugates for analyses of cells and molecules. J Cell Biol 93, 981–986 (1982). doi:10.1083/jcb.93.3.981 (Table 1: absorption coefficients and quantum yields; the allophycocyanin value is per 33,000-dalton unit)
  31. Ch. 3 — Thermo Fisher Scientific. Molecular Probes Handbook, Table 6.2: Spectral data for B-PE, R-PE and APC (web page). Manufacturer.
  32. Ch. 3 — Maecker H., Trotter J. Selecting reagents for multicolor flow cytometry with BD LSR II and BD FACSCanto systems. Nat Methods application note (Dec 2008). Manufacturer.
  33. Ch. 3 — Cossarizza A., Chang H.-D., Radbruch A., et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol 51, 2708–3145 (2021). doi:10.1002/eji.202170126
  34. Ch. 3 — Doornbos R.M.P., de Grooth B.G., Greve J. Experimental and model investigations of bleaching and saturation of fluorescence in flow cytometry. Cytometry 29, 204–214 (1997).
  35. Ch. 4 — Tzur A., Moore J.K., Jorgensen P., Shapiro H.M., Kirschner M.W. Optimizing optical flow cytometry for cell volume-based sorting and analysis. PLoS One 6, e16053 (2011). doi:10.1371/journal.pone.0016053
  36. Ch. 4 — van der Pol E., Sturk A., van Leeuwen T., et al. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. J Thromb Haemost 16, 1236–1245 (2018). doi:10.1111/jth.14009
  37. Ch. 4 — Liu P.Y., et al. Cell refractive index for cell biology and disease diagnosis: past, present and future. Lab Chip 16, 634–644 (2016). doi:10.1039/C5LC01445J
  38. Ch. 4 — de Rond L., et al. Refractive index to evaluate staining specificity of extracellular vesicles by flow cytometry. J Extracell Vesicles 8, 1643671 (2019).
  39. Ch. 4 — Johnsen K.B., Gudbergsson J.M., Andresen T.L., Simonsen J.B. What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer. Biochim Biophys Acta Rev Cancer 1871, 109–116 (2019). doi:10.1016/j.bbcan.2018.11.006
  40. Ch. 4 — van der Pol E., Hoekstra A.G., Sturk A., et al. Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost 8, 2596–2607 (2010). doi:10.1111/j.1538-7836.2010.04074.x
  41. Ch. 4 — van der Pol E., Coumans F.A.W., Grootemaat A.E., et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 12, 1182–1192 (2014). doi:10.1111/jth.12602
  42. Ch. 4 — de Rond L., van der Pol E., Bloemen P.R., et al. A systematic approach to improve scatter sensitivity of a flow cytometer for detection of extracellular vesicles. Cytometry A 97A, 582–591 (2020). doi:10.1002/cyto.a.23974
  43. Ch. 4 — Welsh J.A., van der Pol E., Arkesteijn G.J.A., et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J Extracell Vesicles 9, 1713526 (2020). doi:10.1080/20013078.2020.1713526 (working group of ISEV, ISAC and ISTH; Table 1 and the light-scatter calibration section read)
  44. Ch. 5 — Tian L., Nelson A.R., Lowe T., et al. Standardization of flow cytometric detection of antigen expression. Cytometry B (2024). doi:10.1002/cyto.b.22155
  45. Ch. 5 — Chattopadhyay P.K., Gaylord B., Palmer A., et al. Brilliant Violet fluorophores: a new class of ultrabright fluorescent compounds for immunofluorescence experiments. Cytometry A 81A, 456–466 (2012). doi:10.1002/cyto.a.22043 (two authors employed by Sirigen, which developed the dyes, and one by BioLegend, which sells conjugates) [authors include manufacturer staff]
  46. Ch. 5 — BioLegend. Tandem dyes (technical web page). Manufacturer.
  47. Ch. 5 — Maecker H.T., Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 69A, 1037–1042 (2006). doi:10.1002/cyto.a.20333 (BD Biosciences) [authors include manufacturer staff]
  48. Ch. 5 — Ferrer-Font L., Pellefigues C., Mayer J.U., et al. Panel design and optimization for high-dimensional immunophenotyping assays using spectral flow cytometry. Curr Protoc Cytom 92, e70 (2020). doi:10.1002/cpcy.70 (read as bioRxiv preprint 784884; Cytek Biosciences co-author) [authors include manufacturer staff]
  49. Ch. 5 — Thermo Fisher Scientific. Eliminate dead cells for increased accuracy. BioProbes 64 (April 2011). Manufacturer.
  50. Ch. 5 — Thermo Fisher Scientific. Molecular Probes Handbook, Technical Note 7.1: Antibody structure and classification (web page; the basic antibody unit about 150,000 daltons), seen 15 Oct 2026. Manufacturer.
  51. Ch. 5 — Bettin B.A., Li B., Falkena K., et al. Calibration of flow cytometers enables reproducible measurements of extracellular vesicle concentrations and reference range establishment. J Extracell Vesicles 14, e70189 (2025). doi:10.1002/jev2.70189 (two authors at BD Biosciences, the maker of the MESF beads used; the senior author a cofounder of Exometry B.V., a calibration company) [authors include manufacturer staff]
  52. Ch. 6 — BD Biosciences. BD FACSCalibur technical specifications. Manufacturer.
  53. Ch. 6 — Parks D.R., Moore W.A., Brinkman R.R., et al. Methodology for evaluating and comparing flow cytometers: a multisite study of 23 instruments. Cytometry A 93, 1087–1091 (2018). doi:10.1002/cyto.a.23605 [authors include manufacturer and software-company staff]
  54. Ch. 6 — Kaduchak G., Goddard G., et al. Ultrasonic analyte concentration and application in flow cytometry. US Patent 7,340,957 B2 (priority 29 Jul 2004; Los Alamos National Laboratory, assignee now Triad National Security).
  55. Ch. 6 — Goddard G., Martin J.C., Graves S.W., Kaduchak G. Ultrasonic particle-concentration for sheathless focusing of particles for analysis in a flow cytometer. Cytometry A 69A, 66–74 (2006).
  56. Ch. 6 — Applied Biosystems. Applied Biosystems debuts industry's first acoustic flow cytometer (press release, 7 Dec 2009). Manufacturer.
  57. Ch. 6 — Thermo Fisher Scientific. The Attune NxT acoustic focusing cytometer, BioProbes 71; and Hornstein J., Attune blog (31 Oct 2012). Manufacturer.
  58. Ch. 7 — Telford W. Near infrared lasers in flow cytometry. Methods (2015). PMID 25814439
  59. Ch. 7 — BD Biosciences. BD FACSymphony A5 SE User's Guide. Manufacturer.
  60. Ch. 7 — Beckman Coulter. CytoFLEX LX specification sheet FLOW-2429SPEC03.17 (2017). Manufacturer.
  61. Ch. 7 — Cytek Biosciences. Cytek Aurora brochure N9-20001. Manufacturer.
  62. Ch. 7 — BD Biosciences. CS&T webinar (April 2008). Manufacturer.
  63. Ch. 7 — Whitehead Institute flow cytometry core. Flow post-it: laser delays (core facility note, Jan 2022; author unlisted). wi.mit.edu
  64. Ch. 8 — Hamamatsu Photonics. R3896/R12896 photomultiplier tube datasheet (Feb 2014). Manufacturer.
  65. Ch. 8 — Schiffman A., Finan E. APD vs PMT and beyond: flow cytometry light detectors. Thermo Fisher Scientific blog (30 Sep 2025). Manufacturer.
  66. Ch. 8 — Ladd B. SiPM vs PMT: a photon finish. University of Chicago Cytometry and Antibody Technology facility blog (22 Nov 2021).
  67. Ch. 8 — Parks D.R., Roederer M., Moore W.A. A new “Logicle” display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. Cytometry A 69A, 541–551 (2006).
  68. Ch. 8 — BD Biosciences. Qr and Br, Application Note 23-10516-01 (June 2012). Manufacturer.
  69. Ch. 8 — Welsh J.A., Arkesteijn G.J.A., Bremer M., et al. A compendium of single extracellular vesicle flow cytometry. J Extracell Vesicles 12, e12299 (2023). doi:10.1002/jev2.12299
  70. Ch. 8 — Hoffman R.A., Wang L., Bigos M., Nolan J.P. NIST/ISAC standardization study: variability in assignment of intensity values to fluorescence standard beads and in cross calibration of standard beads to hard dyed beads. Cytometry A 81A, 785–796 (2012). doi:10.1002/cyto.a.22086
  71. Ch. 9 — BD Biosciences. Window extension, Technical Bulletin 23-11552-00 (Feb 2010). Manufacturer.
  72. Ch. 9 — Arraud N., Gounou C., Turpin D., Brisson A. Fluorescence triggering: a general strategy for enumerating and phenotyping extracellular vesicles by flow cytometry. Cytometry A 89, 184–195 (2016). doi:10.1002/cyto.a.22669
  73. Ch. 9 — exRNA consortium (ERCC). Completed MIFlowCyt-EV report, ERCC mAb database (17 Oct 2022) (web document). exrna.org
  74. Ch. 9 — Sony. ID7000 technical specifications. Manufacturer.
  75. Ch. 9 — Beckman Coulter. System for high dynamic range analysis in flow cytometry. US Patent 7,590,500 B2 (filed 28 Feb 2005). Manufacturer.
  76. Ch. 10 — Roederer M. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry 45, 194–205 (2001). doi:10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
  77. Ch. 10 — Shapiro H.M. Compensation: an introduction. Boston Users' Group for Cytometry (slides, 10 Sep 2003).
  78. Ch. 10 — Nguyen R., Perfetto S., Mahnke Y.D., Chattopadhyay P., Roederer M. Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design. Cytometry A 83A, 306–315 (2013). doi:10.1002/cyto.a.22251
  79. Ch. 10 — Bhowmick D., van Diepen F., Pfauth A., Tissier R., Ratliff M.L. A gain and dynamic range independent index to quantify spillover spread to aid panel design in flow cytometry. Sci Rep (2021). doi:10.1038/s41598-021-99831-7
  80. Ch. 10 — Novo D. A comparison of spectral unmixing to conventional compensation for the calculation of fluorochrome abundances from flow cytometric data. Cytometry A 101, 885–891 (2022). doi:10.1002/cyto.a.24669 [author founded an analysis-software company]
  81. Ch. 10 — Mage P.L., Konecny A.J., Mair F. Measurement and prediction of unmixing-dependent spreading due to collinearity in spectral flow cytometry. Cytometry A 109, 436–455 (2026). doi:10.1002/cyto.a.70044 [first author is manufacturer staff]
  82. Ch. 10 — Novo D., Grégori G., Rajwa B. Generalized unmixing model for multispectral flow cytometry utilizing nonsquare compensation matrices. Cytometry A 83A, 508–520 (2013). doi:10.1002/cyto.a.22272 [first author founded an analysis-software company]
  83. Ch. 10 — Kalina T., Flores-Montero J., van der Velden V.H.J., et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26, 1986–2010 (2012). doi:10.1038/leu.2012.122
  84. Ch. 11 — Hulspas R., O'Gorman M., Wood B., Gratama J.-W., Sutherland R. Considerations for the control of background fluorescence in clinical flow cytometry. Cytometry B 76, 355–364 (2009). doi:10.1002/cyto.b.20485
  85. Ch. 11 — Keeney M., Gratama J.W., Chin-Yee I.H., Sutherland D.R. Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry—time to let go! Cytometry 34, 280–283 (1998).
  86. Ch. 11 — Barnett D., Louzao R., Gambell P., et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part IV – postanalytic considerations. Cytometry B 84B, 309–314 (2013). doi:10.1002/cyto.b.21107
  87. Ch. 11 — Hallek M., Cheson B.D., Catovsky D., et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745–2760 (2018).
  88. Ch. 12 — diffcyt (Bioconductor package). transformData documentation (web page), citing Bendall S.C., et al., Science (2011), Suppl. Fig. S2. rdrr.io/bioc/diffcyt
  89. Ch. 12 — Finak G., Perez J.-M., Weng A., Gottardo R. Optimizing transformations for automated, high throughput analysis of flow cytometry data. BMC Bioinformatics 11, 546 (2010).
  90. Ch. 12 — Maecker H.T., Rinfret A., D'Souza P., et al. Standardization of cytokine flow cytometry assays. BMC Immunol 6, 13 (2005). doi:10.1186/1471-2172-6-13 (first and corresponding author and two others at BD Biosciences, which supplied the reagents) [authors include manufacturer staff]
  91. Ch. 12 — Finak G., Langweiler M., Jaimes M., et al. Standardizing flow cytometry immunophenotyping analysis from the Human ImmunoPhenotyping Consortium. Sci Rep 6, 20686 (2016). [authors include manufacturer staff]
  92. Ch. 12 — Aghaeepour N., Finak G., FlowCAP Consortium, DREAM Consortium, et al. Critical assessment of automated flow cytometry data analysis techniques. Nat Methods 10, 228–238 (2013). doi:10.1038/nmeth.2365
  93. Ch. 12 — Weber L.M., Robinson M.D. Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytometry A 89, 1084–1096 (2016). doi:10.1002/cyto.a.23030
  94. Ch. 12 — Van Gassen S., Callebaut B., Van Helden M.J., et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636–645 (2015). doi:10.1002/cyto.a.22625
  95. Ch. 12 — Kobak D., Berens P. The art of using t-SNE for single-cell transcriptomics. Nat Commun 10, 5416 (2019). doi:10.1038/s41467-019-13056-x
  96. Ch. 12 — Chari T., Pachter L. The specious art of single-cell genomics. PLoS Comput Biol 19, e1011288 (2023). doi:10.1371/journal.pcbi.1011288
  97. Ch. 12 — Hurlbert S.H. Pseudoreplication and the design of ecological field experiments. Ecol Monogr 54, 187–211 (1984).
  98. Ch. 13 — Monaco G., Chen H., Poidinger M., et al. flowAI: automatic and interactive anomaly discerning tools for flow cytometry data. Bioinformatics 32, 2473–2480 (2016). doi:10.1093/bioinformatics/btw191, PMID 27153628; and Monaco G., flowAI vignette, Bioconductor (3 Aug 2016).
  99. Ch. 14 — Wade C.G., Rhyne R.H. Jr., Woodruff W.H., Bloch D.P., Bartholomew J.C. Spectra of cells in flow cytometry using a vidicon detector. J Histochem Cytochem 27, 1049–1052 (1979). doi:10.1177/27.6.110874
  100. Ch. 14 — Grégori G., Patsekin V., Rajwa B., et al. Hyperspectral cytometry at the single-cell level using a 32-channel photodetector. Cytometry A 81A, 35–44 (2012). doi:10.1002/cyto.a.21120
  101. Ch. 14 — Daemen S., Adelaar T.I., Barlampas P., et al. Managing autofluorescence in spectral flow cytometry for macrophage identification in the liver. Eur J Immunol 56, e70217 (2026). doi:10.1002/eji.70217
  102. Ch. 14 — Jaimes M., Zhang Z., Zhou J., et al. Methods of forming multi-color fluorescence-based flow cytometry panel. US Patent Application US 2022/0082488 A1 (published 17 Mar 2022), granted as US 12,209,948 B2 (28 Jan 2025); assignee Cytek Biosciences. Manufacturer.
  103. Ch. 14 — Lucas, André, Snyder. All the colors, none of the drama: a practical primer on spectral flow cytometry in clinical settings. College of American Pathologists member article (2026; not peer-reviewed). cap.org
  104. Ch. 14 — Beckman Coulter Life Sciences. Unlocking insights: the vital role of unmixing algorithms in spectral flow cytometry (application note, undated). Manufacturer.
  105. Ch. 14 — Kalina T., Flores-Montero J., Lecrevisse Q., et al. Quality assessment program for EuroFlow protocols: summary results of four-year (2010–2013) quality assurance rounds. Cytometry A 87, 145–156 (2015). doi:10.1002/cyto.a.22581
  106. Ch. 14 — Brestoff J.R. Full spectrum flow cytometry in the clinical laboratory. Int J Lab Hematol 45 (Suppl 2), 44–49 (2023). doi:10.1111/ijlh.14098
  107. Ch. 14 — FDA. 510(k) database records K130373 (Navios Flow Cytometer System, decision 18 Sep 2013), K141468 (BD FACSCanto II, 27 Feb 2015) and K162897 (Navios EX, 23 Jun 2017).
  108. Ch. 14 — FDA. 510(k) K170974: BD FACSLyric, FACSuite Clinical, Multitest assays (decision 3 Jul 2017) and 510(k) summary (performance data submitted by the manufacturer).
  109. Ch. 14 — FDA. 510(k) K232600: DxFLEX Flow Cytometer; ClearLLab 10C Panels (decision 22 Nov 2023) and 510(k) summary (performance data submitted by the manufacturer).
  110. Ch. 15 — BD Biosciences. CS&T webinar (June 2012). Manufacturer.
  111. Ch. 15 — BD Biosciences. BD FACSDiscover A8 cell analyzer technical specifications, BD-133318 v6.0. Manufacturer.
  112. Ch. 15 — Thermo Fisher Scientific. Accurate carryover measurements, Attune NxT (application note COL02200 0716, July 2016). Manufacturer.
  113. Ch. 15 — Perfetto S.P., Ambrozak D., Nguyen R., Chattopadhyay P., Roederer M. Quality assurance for polychromatic flow cytometry. Nat Protoc 1, 1522–1530 (2006). doi:10.1038/nprot.2006.250
  114. Ch. 15 — Perfetto S.P., Ambrozak D., Nguyen R., Chattopadhyay P.K., Roederer M. Quality assurance for polychromatic flow cytometry using a suite of calibration beads. Nat Protoc 7, 2067–2079 (2012). doi:10.1038/nprot.2012.126
  115. Ch. 15 — IEC 61010-1:2010 (Ed. 3.0) with AMD1:2016 (IEC Webstore); IEC 61010-1/AMD2 ED3 project status, IEC project 107234 (as of Sept 2026); and SIQ, IEC 61010-1 Amendment 2: upcoming changes to safety requirements (3 Apr 2025).
  116. Ch. 15 — IEC 61010-2-101:2018 (Ed. 3.0). Particular requirements for in vitro diagnostic (IVD) medical equipment (IEC Webstore).
  117. Ch. 15 — IEC 61326-1:2020 (Ed. 3.0) and IEC 61326-2-6:2025 (Ed. 4.0, replacing the 2020 edition, withdrawn 18 Jun 2025). Electrical equipment for measurement, control and laboratory use — EMC requirements (IEC Webstore).
  118. Ch. 15 — IEC 60825-1:2014 (Ed. 3.0). Safety of laser products (IEC Webstore); Ed. 4 status from a third-party standards tracker (genorma.com).
  119. Ch. 15 — FDA. Laser products — conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56). Federal Register (8 May 2019), FR Doc. 2019-09381; reissued as final guidance on 21 Feb 2023 (FDA guidance page, seen 15 Oct 2026). fda.gov/media/110120/download
  120. Ch. 16 — Yuan J. Methods for optimizing PMT voltages. SickKids-UHN flow cytometry facility (2010).
  121. Ch. 16 — Glier H., et al. Standardization of 8-color flow cytometry across different flow cytometer instruments: a feasibility study in clinical laboratories in Switzerland. J Immunol Methods 475, 112348 (2019). doi:10.1016/j.jim.2017.07.013
  122. Ch. 17 — Bettin B.A., Varga Z., Nieuwland R., van der Pol E. Standardization of extracellular vesicle concentration measurements by flow cytometry: the past, present, and future. J Thromb Haemost 21, 2032–2044 (2023). doi:10.1016/j.jtha.2023.04.042
  123. Ch. 17 — NIST. Certificate of Analysis, Standard Reference Material 1932, Fluorescein Solution (issued 1 Dec 2022). tsapps.nist.gov/srmext/certificates/1932.pdf
  124. Ch. 17 — Wang L., Gaigalas A.K. Development of multicolor flow cytometry calibration standards: assignment of equivalent reference fluorophores (ERF) unit. J Res Natl Inst Stand Technol 116, 671 (2011). doi:10.6028/jres.116.012
  125. Ch. 17 — Wang L., DeRose P., Gaigalas A.K. Assignment of the number of equivalent reference fluorophores to dyed microspheres. J Res Natl Inst Stand Technol 121, 269 (2016). doi:10.6028/jres.121.012
  126. Ch. 17 — Wang L., Gaigalas A., Marti G., Abbasi F., Hoffman R. Toward quantitative fluorescence measurements with multicolor flow cytometry. Cytometry A 73A, 279–288 (2008). doi:10.1002/cyto.a.20507
  127. Ch. 17 — Wang L., Gaigalas A.K., DeRose P.C. A model for the binding of fluorescently labeled anti-human CD4 monoclonal antibodies to CD4 receptors on human lymphocytes. J Res Natl Inst Stand Technol 123, 123022 (2018). doi:10.6028/jres.123.022
  128. Ch. 17 — Welsh J.A., Horak P., Wilkinson J.S., et al. FCMPASS software aids extracellular vesicle light scatter standardization. Cytometry A 97, 569–581 (2020). doi:10.1002/cyto.a.23782
  129. Ch. 18 — Spidlen J., Moore W., Parks D., et al. Data file standard for flow cytometry, version FCS 3.2. Cytometry A 99, 100–102 (2021). doi:10.1002/cyto.a.24225
  130. Ch. 18 — Spidlen J., Moore W., ISAC Data Standards Task Force, Brinkman R.R. ISAC's Gating-ML 2.0 data exchange standard for gating description. Cytometry A 87, 683–687 (2015). doi:10.1002/cyto.a.22690; and flowCore reference manual (Bioconductor), Gating-ML 2.0 transformation classes.
  131. Ch. 18 — ISAC. Data standards (web page, accessed 6 Oct 2026). isac-net.org/data-standards
  132. Ch. 18 — FlowRepository. Quick start guide, with notice of temporary suspension of new experiment creation (web page, accessed 6 Oct 2026). flowrepository.org
  133. Ch. 18 — 21 CFR Part 11 (eCFR, current as of 2 Oct 2026).
  134. Ch. 18 — 42 CFR 493.1105 (eCFR, current as of 2 Oct 2026).
  135. Ch. 18 — EuroFlow. External Quality Assessment Program (web page). euroflow.org/qa
  136. Ch. 19 — Bettin B.A. From beads to bedside: standardizing extracellular vesicle concentration measurements. PhD thesis, University of Amsterdam (2024). dare.uva.nl
  137. Ch. 20 — Bettin B.A., Varga Z., Nieuwland R., van der Pol E. Standardization of extracellular vesicle concentration measurements by flow cytometry: the past, present, and future. J Thromb Haemost 21, 2032–2044 (2023). doi:10.1016/j.jtha.2023.04.042 (source of the 2009–2010 workshop history)
  138. Ch. 20 — Cointe S., Judicone C., Robert S., et al. Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. J Thromb Haemost 15, 187–193 (2017). doi:10.1111/jth.13514 (two authors employed by BioCytex, which supplied the beads) [authors include manufacturer staff]
  139. Ch. 20 — Welsh J.A., van der Pol E., Arkesteijn G.J.A., et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J Extracell Vesicles 9, 1713526 (2020). doi:10.1080/20013078.2020.1713526
  140. Ch. 20 — Bettin B.A., van der Pol E., Nieuwland R. Plasma extracellular vesicle test sample to standardize flow cytometry measurements. Res Pract Thromb Haemost 7, 100181 (2023). doi:10.1016/j.rpth.2023.100181
  141. Ch. 20 — Welsh J.A., van der Pol E., Bettin B.A., et al. Towards defining reference materials for measuring extracellular vesicle refractive index, epitope abundance, size and concentration. J Extracell Vesicles 9, 1816641 (2020). doi:10.1080/20013078.2020.1816641
  142. Ch. 21 — FDA. Product classification database, product code PWD (21 CFR 864.7010). accessdata.fda.gov
  143. Ch. 21 — Borowitz M.J., et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B 78, 211–230 (2010).
  144. Ch. 21 — van Dongen J.J.M., et al. EuroFlow-based flowcytometric diagnostic screening and classification of primary immunodeficiencies of the lymphoid system. Front Immunol 10, 1271 (2019). doi:10.3389/fimmu.2019.01271
  145. Ch. 21 — Davis B.H., Holden J.T., Bene M.C., et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B 72 (Suppl 1), S5–S13 (2007).
  146. Ch. 21 — Nakashima M.O., Kelley J.T. Peripheral blood flow cytometry testing (educational module), v1.0. College of American Pathologists (27 Aug 2025).
  147. Ch. 21 — van Dongen J.J.M., Lhermitte L., Böttcher S., et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26, 1908–1975 (2012). doi:10.1038/leu.2012.120
  148. Ch. 21 — Rawstron A.C., et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an ERIC & ESCCA harmonisation project. Cytometry B 94, 121–128 (2018). doi:10.1002/cyto.b.21595
  149. Ch. 21 — Mandy F.F., Nicholson J.K.A., McDougal J.S. Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. MMWR 52 (RR-2), 1–14 (2003).
  150. Ch. 21 — USP General Chapter <127> Flow cytometric enumeration of CD34+ cells (USP 40).
  151. Ch. 21 — Khoury J.D., et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36, 1703–1719 (2022). doi:10.1038/s41375-022-01613-1
  152. Ch. 21 — Arber D.A., et al. International Consensus Classification of myeloid neoplasms and acute leukemias. Blood 140, 1200–1228 (2022). doi:10.1182/blood.2022015850
  153. Ch. 21 — 21 CFR 864.7010, Flow cytometric test system for hematopoietic neoplasms (eCFR; 82 FR 61165, 27 Dec 2017; amended 90 FR 55981, 4 Dec 2025).
  154. Ch. 21 — Del Vecchio L., Brando B., Lanza F., et al. Recommended reporting format for flow cytometry diagnosis of acute leukemia. Haematologica 89, 594–598 (2004).
  155. Ch. 22 — Davis B.H., Wood B., Oldaker T., Barnett D. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part I – rationale and aims. Cytometry B 84B, 282–285 (2013). doi:10.1002/cyto.b.21104
  156. Ch. 22 — CLSI. H62: Validation of assays performed by flow cytometry, 1st ed. (H62Ed1E, 27 Oct 2021); product page and sample pages.
  157. Ch. 22 — 42 CFR 493.1253, Establishment and verification of performance specifications (eCFR).
  158. Ch. 22 — Tanqri S., Vall H., Kaplan D., et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part III – analytical issues. Cytometry B 84B, 291–308 (2013). doi:10.1002/cyto.b.21106
  159. Ch. 22 — Litwin V., Salkowitz-Bokal J., Steele P. Flow cytometry: new considerations for validating laboratory-developed tests. Clinical Laboratory News (1 Dec 2013).
  160. Ch. 22 — FDA. Evaluation of automatic class III designation for ClearLLab Reagents: decision summary, DEN160047; and De Novo database entry DEN160047 (received 3 Oct 2016; granted 29 Jun 2017) (performance data submitted by the manufacturer).
  161. Ch. 22 — Wood B., Jevremovic D., Béné M.C., et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part V – assay performance criteria. Cytometry B 84, 315–323 (2013). doi:10.1002/cyto.b.21108 (abstract only)
  162. Ch. 22 — Gothot A. Quality assurance in flow cytometry (workshop slides, UCLL, 9 Feb 2024), summarizing ICSH/ICCS 2013 and CLSI H62.
  163. Ch. 22 — Flores-Montero J., Sanoja-Flores L., Paiva B., et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094–2103 (2017). doi:10.1038/leu.2017.29
  164. Ch. 22 — Theunissen P., Mejstrikova E., Sedek L., et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129, 347–357 (2017). doi:10.1182/blood-2016-07-726307
  165. Ch. 22 — Buccisano F., Palmieri R., Piciocchi A., et al. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. Haematologica 107, 2823–2833 (2022). doi:10.3324/haematol.2021.279777
  166. Ch. 22 — FDA. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment (final guidance, January 2020; docket FDA-2018-D-3090). fda.gov/media/134605/download
  167. Ch. 22 — FDA. Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval (draft guidance, January 2026; docket FDA-2025-D-2616; notice of availability 91 FR 2537, 21 Jan 2026). fda.gov/media/190647/download
  168. Ch. 22 — OncLive. FDA's ODAC recognizes MRD as an accepted end point for accelerated approval in multiple myeloma (12 Apr 2024).
  169. Ch. 22 — FDA. De Novo database entry DEN170080, clonoSEQ (granted 28 Sep 2018; 21 CFR 866.6100).
  170. Ch. 22 — Davis B.H., Dasgupta A., Kussick S., Han J.Y., Estrellado A. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS – part II – preanalytical issues. Cytometry B 84B, 286–290 (2013). doi:10.1002/cyto.b.21105
  171. Ch. 22 — ILAC. ISO 15189:2022 for medical labs published (news, 8 Dec 2022). ilac.org
  172. Ch. 22 — UK NEQAS for Leucocyte Immunophenotyping. EQA/PT programmes (web page, accessed 6 Oct 2026). ukneqasli.co.uk
  173. Ch. 23 — Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), consolidated version of 10 Jan 2025, Art. 5(5), Art. 56 and Annex XIII. EUR-Lex 02017R0746-20250110
  174. Ch. 23 — 21 CFR 864.5220, Automated differential cell counter (eCFR; 67 FR 1607, 14 Jan 2002).
  175. Ch. 23 — FDA. Product classification database, product code OYE, Flow cytometric reagents and accessories. accessdata.fda.gov
  176. Ch. 23 — FDA. FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas (news release, 29 Jun 2017).
  177. Ch. 23 — FDA. Medical Devices; Quality Management System Regulation Technical Amendments. 90 FR 55981 (4 Dec 2025), FR Doc. 2025-21955; effective 2 Feb 2026.
  178. Ch. 23 — FDA. 510(k) K183592: ClearLLab 10C Panels, Navios, Navios EX (decision 21 Mar 2019) and 510(k) summary (performance data submitted by the manufacturer).
  179. Ch. 23 — 21 CFR 864.4020, Analyte specific reagents (eCFR; 62 FR 62260, 21 Nov 1997).
  180. Ch. 23 — 21 CFR 809.30, Restrictions on the sale, distribution and use of analyte specific reagents (eCFR; 62 FR 62259, 21 Nov 1997).
  181. Ch. 23 — FDA. Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions (final guidance, 14 Sep 2007; docket FDA-2006-D-0357).
  182. Ch. 23 — FDA. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only (final guidance, November 2013; docket FDA-2011-D-0305).
  183. Ch. 23 — FDA. Medical Devices; Laboratory Developed Tests. Final rule, 89 FR 37286 (6 May 2024); American Clinical Laboratory Association v. FDA, No. 4:24-CV-479-SDJ (E.D. Tex., 31 Mar 2025), consolidated with AMP v. FDA; and Medical Devices; Laboratory Developed Tests; Implementation of Vacatur. Final rule, 90 FR 45134 (19 Sep 2025).
  184. Ch. 23 — 42 CFR 493.17, Test categorization (eCFR).
  185. Ch. 23 — MDCG 2020-16 rev.5. Guidance on classification rules for in vitro diagnostic medical devices under Regulation (EU) 2017/746 (September 2026).
  186. Ch. 23 — Regulation (EU) 2024/1860 of 13 Jun 2024 amending Regulations (EU) 2017/745 and (EU) 2017/746 (OJ 9 Jul 2024).
  187. Ch. 23 — MDCG 2023-1. Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 (January 2023).
  188. Ch. 23 — Regulation (EU) 2022/112 of 25 Jan 2022 amending Regulation (EU) 2017/746 (OJ 28 Jan 2022).
  189. Ch. 23 — European Commission. COM(2025) 1023 final (16 Dec 2025); European Parliament Legislative Observatory, procedure 2025/0404(COD) (accessed 6 Oct 2026).
  190. Ch. 23 — Government of India. Medical Devices Rules, 2017, G.S.R. 78(E) (31 Jan 2017).
  191. Ch. 23 — CDSCO. List of in-vitro diagnostic medical devices under Medical Devices Rules, 2017, File IVD/Misc/196/2020 (updated 25 Oct 2023).
  192. Ch. 23 — DCG(I). Classification of medical devices and in vitro diagnostic medical devices under the provisions of the Medical Devices Rules, 2017 (1 Nov 2017).
  193. Ch. 23 — Lok Sabha. Unstarred Question No. 1669 (16 Dec 2022).
  194. Ch. 23 — CDSCO. In-vitro diagnostic (IVD) medical devices: frequently asked questions, CDSCO/IVD/FAQ/03/2022.
  195. Ch. 23 — CDSCO. Provision for risk classification of in-vitro diagnostic medical devices on the CDSCO online system for medical devices (public notice, 6 Feb 2026; scanned image, text not read); and Addendum No. 02 to FAQ CDSCO/IVD/FAQ/04/2022, question 17 (13 Mar 2026).
  196. Ch. 24 — Llufrio E.M., Wang L., Naser F.J., Patti G.J. Sorting cells alters their redox state and cellular metabolome. Redox Biol 16, 381–387 (2018). doi:10.1016/j.redox.2018.03.004
  197. Ch. 24 — Pfister G., Toor S.M., Sasidharan Nair V., Elkord E. An evaluation of sorter induced cell stress (SICS) on peripheral blood mononuclear cells (PBMCs) after different sort conditions — are your sorted cells getting SICS? J Immunol Methods 487, 112902 (2020). doi:10.1016/j.jim.2020.112902
  198. Ch. 24 — Holmes K.L., Fontes B., Hogarth P.J., et al. International Society for the Advancement of Cytometry cell sorter biosafety standards. Cytometry A 85, 434–453 (2014). doi:10.1002/cyto.a.22454
  199. Ch. 24 — NIH Division of Occupational Health and Safety. NIH Manual Chapter 3038: Installation and Operation of Cell Sorters (26 Sep 2017). policymanual.nih.gov/3038
  200. Ch. 24 — Stanford Environmental Health & Safety. Cell Sorting (FACS) Guidance (web document). ehs.stanford.edu
  201. Ch. 24 — Basiji D.A., Ortyn W.E., Liang L., Venkatachalam V., Morrissey P. Cellular image analysis and imaging by flow cytometry. Clin Lab Med 27, 653–670 (2007). doi:10.1016/j.cll.2007.05.008 [authors are manufacturer staff, Amnis]
  202. Ch. 24 — Cytek Biosciences. Amnis ImageStreamX Mk II (product page). Manufacturer.
  203. Ch. 24 — Nitta N., Sugimura T., Isozaki A., et al. Intelligent image-activated cell sorting. Cell 175, 266–276.e13 (2018). doi:10.1016/j.cell.2018.08.028; and Kyoto University press release (5 Sep 2018).
  204. Ch. 24 — Isozaki A., Mikami H., Tezuka H., et al. Intelligent image-activated cell sorting 2.0. Lab Chip 20, 2263–2273 (2020). doi:10.1039/d0lc00080a
  205. Ch. 24 — Schraivogel D., Kuhn T.M., Rauscher B., et al. High-speed fluorescence image-enabled cell sorting. Science 375, 315–320 (2022). doi:10.1126/science.abj3013 (developed at BD with EMBL) [authors include manufacturer staff]
  206. Ch. 24 — Bendall S.C., Simonds E.F., Qiu P., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332, 687–696 (2011). [authors include manufacturer staff]
  207. Ch. 24 — Immune monitoring technology primer: flow and mass cytometry. J Immunother Cancer 3, 44 (2015). doi:10.1186/s40425-015-0085-x (authors not confirmed)
  208. Ch. 24 — Alere Inc. Pima CD4 Test receives WHO prequalification (press release, Dec 2011). Manufacturer.
  209. Ch. 24 — WHO Prequalification of In Vitro Diagnostics. Pima CD4 Test, product 0099-032-00: product page (prequalified 25 November 2011; assay format listed as flow cytometry) and public report PQDx 0099-032-00 v6.0 (9 May 2022; static image analysis with an on-board camera; gives the listing date as 20 November 2012). extranet.who.int/prequal
  210. Ch. 24 — BD. WHO issues prequalification of BD FACSPresto near-patient CD4 counter system (press release, 23 Sep 2014). Manufacturer. Listing confirmed by WHO, Prequalification public report PQDx 0197-045-00, BD FACSPresto Near-Patient CD4 Counter System, v4.0 (August 2023): listed September 2014.
  211. Ch. 24 — FDA. 510(k) K150815, BD FACSPresto System and CD4/Hb Cartridge: decision summary (substantially equivalent, 17 Dec 2015; product code PMG). accessdata.fda.gov
  212. Ch. 24 — Manabe Y.C., Wang Y., Elbireer A., Auerbach B., Castelnuovo B. Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS One 7, e34319 (2012). doi:10.1371/journal.pone.0034319
  213. Ch. 24 — Scott L.E., Campbell J., Westerman L., et al. A meta-analysis of the performance of the Pima CD4 for point of care testing. BMC Med 13, 168 (2015). doi:10.1186/s12916-015-0396-2
  214. Ch. 24 — WHO Prequalification of In Vitro Diagnostics. Public report: VISITECT CD4 Advanced Disease, PQDx 0384-077-00, v5.0.
  215. Ch. 24 — Imperial College London, Hammersmith flow cytometry facility. NanoFCM Flow NanoAnalyzer (equipment page restating the manufacturer's figures). Manufacturer figures.
  216. Ch. 24 — Chiu A., et al. Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia. Leukemia 40, 1516–1526 (2026). doi:10.1038/s41375-026-02986-3
  217. Ch. 24 — FDA. Artificial Intelligence-Enabled Medical Devices (web page, accessed 6 Oct 2026).
  218. Ch. 24 — Ota S., Horisaki R., Kawamura Y., et al. Ghost cytometry. Science 360, 1246–1251 (2018). doi:10.1126/science.aan0096 (competing interests: three authors are founders and shareholders of ThinkCyte, which develops the method).
§ PDF edition

Take the PDF with you.

Reading online needs no sign-up. For the PDF edition, laid out for print and offline reading, tell us where to send it and we will email you.

We use your details to send the guide, and to tell you about new guides only if you tick the box. See the privacy policy.

Created with Claude (Anthropic).
Educational reference material, not engineering, regulatory or clinical advice. Product and company names referenced are the property of their respective owners.